# Intra-articular corticosteroid for knee osteoarthritis (Review)

Jüni P, Hari R, Rutjes AWS, Fischer R, Silletta MG, Reichenbach S, da Costa BR



This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2015, Issue 10

http://www.thecochranelibrary.com

# WILEY

## TABLE OF CONTENTS

HEADER		1
ABSTRACT		1
PLAIN LANGUAGE SUMMARY		2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON		5
BACKGROUND		7
OBJECTIVES		7
METHODS		7
RESULTS		10
Figure 1		11
Figure 2		13
Figure 3		14
Figure 4		15
Figure 5		16
Figure 6		17
Figure 7		18
Figure 8		19
Figure 9		20
Figure 10		20
Figure 11		20
Figure 12		21
Figure 13		21
DISCUSSION		22
AUTHORS' CONCLUSIONS		23
ACKNOWLEDGEMENTS		23
REFERENCES		23
CHARACTERISTICS OF STUDIES		31
DATA AND ANALYSES		70
Analysis 1.1. Comparison 1 Pain, Outcome 1 Pain - Main.		72
Analysis 1.2. Comparison 1 Pain, Outcome 2 Pain - Timepoints.		73
Analysis 2.1. Comparison 2 Function, Outcome 1 Function - Main.		76
Analysis 2.2. Comparison 2 Function, Outcome 2 Function - Timepoints.		77
Analysis 3.1. Comparison 3 Quality of life, Outcome 1 Quality of life - Main		79
Analysis 4.1. Comparison 4 Number of participants experiencing any adverse event, Outcome 1 Num		\$
experiencing any adverse event - Main.		80
Analysis 5.1. Comparison 5 Number of participants who withdraw because of adverse events, Outco		
participants who with draw because of adverse events -Main.		81
Analysis 6.1. Comparison 6 Number of participants experiencing any serious adverse event, Outcom	ie 1 Number of	
participants experiencing any serious adverse event - Main.		82
Analysis 7.1. Comparison 7 Joint space narrowing, Outcome 1 Joint space narrowing - Main.		83
ADDITIONAL TABLES		83
APPENDICES		89
WHAT'S NEW		95
HISTORY		96
CONTRIBUTIONS OF AUTHORS		96
DECLARATIONS OF INTEREST		96
SOURCES OF SUPPORT		96
DIFFERENCES BETWEEN PROTOCOL AND REVIEW		97
INDEX TERMS		97

Intra-articular corticosteroid for knee osteoarthritis (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. i

## [Intervention Review]

# Intra-articular corticosteroid for knee osteoarthritis

Peter Jüni<sup>1</sup>, Roman Hari<sup>1</sup>, Anne WS Rutjes<sup>2,3</sup>, Roland Fischer<sup>4</sup>, Maria G Silletta<sup>2</sup>, Stephan Reichenbach<sup>5</sup>, Bruno R da Costa<sup>1</sup>

<sup>1</sup>Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland. <sup>2</sup>Centre for Systematic Reviews, Fondazione "Università G. D'Annunzio", Chieti, Italy. <sup>3</sup>Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland. <sup>4</sup>Department of General Internal Medicine, Inselspital Bern, Bern, Switzerland. <sup>5</sup>Department for Rheumatology, Clinical Immunology, and Allergology, University Hospital, Bern, Switzerland

Contact address: Bruno R da Costa, Institute of Primary Health Care (BIHAM), University of Bern, Gesellschaftsstrasse 49, Bern, 3012, Switzerland. bruno.dacosta@biham.unibe.ch.

**Editorial group:** Cochrane Musculoskeletal Group. **Publication status and date:** Edited (no change to conclusions), published in Issue 11, 2015. **Review content assessed as up-to-date:** 3 February 2015.

**Citation:** Jüni P, Hari R, Rutjes AWS, Fischer R, Silletta MG, Reichenbach S, da Costa BR. Intra-articular corticosteroid for knee os-teoarthritis. *Cochrane Database of Systematic Reviews* 2015, Issue 10. Art. No.: CD005328. DOI: 10.1002/14651858.CD005328.pub3.

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

#### Background

Knee osteoarthritis is a leading cause of chronic pain, disability, and decreased quality of life. Despite the long-standing use of intraarticular corticosteroids, there is an ongoing debate about their benefits and safety. This is an update of a Cochrane review first published in 2005.

## Objectives

To determine the benefits and harms of intra-articular corticosteroids compared with sham or no intervention in people with knee osteoarthritis in terms of pain, physical function, quality of life, and safety.

## Search methods

We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE (from inception to 3 February 2015), checked trial registers, conference proceedings, reference lists, and contacted authors.

## Selection criteria

We included randomised or quasi-randomised controlled trials that compared intra-articular corticosteroids with sham injection or no treatment in people with knee osteoarthritis. We applied no language restrictions.

## Data collection and analysis

We calculated standardised mean differences (SMDs) and 95% confidence intervals (CI) for pain, function, quality of life, joint space narrowing, and risk ratios (RRs) for safety outcomes. We combined trials using an inverse-variance random-effects meta-analysis.

## Main results

We identified 27 trials (13 new studies) with 1767 participants in this update. We graded the quality of the evidence as 'low' for all outcomes because treatment effect estimates were inconsistent with great variation across trials, pooled estimates were imprecise and did not rule out relevant or irrelevant clinical effects, and because most trials had a high or unclear risk of bias. Intra-articular corticosteroids appeared to be more beneficial in pain reduction than control interventions (SMD -0.40, 95% CI -0.58 to -0.22), which corresponds to a difference in pain scores of 1.0 cm on a 10-cm visual analogue scale between corticosteroids and sham injection and translates

into a number needed to treat for an additional beneficial outcome (NNTB) of 8 (95% CI 6 to 13). An I<sup>2</sup> statistic of 68% indicated considerable between-trial heterogeneity. A visual inspection of the funnel plot suggested some asymmetry (asymmetry coefficient - 1.21, 95%CI -3.58 to 1.17). When stratifying results according to length of follow-up, benefits were moderate at 1 to 2 weeks after end of treatment (SMD -0.48, 95% CI -0.70 to -0.27), small to moderate at 4 to 6 weeks (SMD -0.41, 95% CI -0.61 to -0.21), small at 13 weeks (SMD -0.22, 95% CI -0.44 to 0.00), and no evidence of an effect at 26 weeks (SMD -0.07, 95% CI -0.25 to 0.11). An I<sup>2</sup> statistic of  $\geq$  63% indicated a moderate to large degree of between-trial heterogeneity up to 13 weeks after end of treatment (P for heterogeneity≤0.001), and an I<sup>2</sup> of 0% indicated low heterogeneity at 26 weeks (P=0.43). There was evidence of lower treatment effects in trials that randomised on average at least 50 participants per group (P=0.05) or at least 100 participants per group (P=0.013), in trials that used concomittant viscosupplementation (P=0.08), and in trials that used concomittant joint lavage (P≤0.001).

Corticosteroids appeared to be more effective in function improvement than control interventions (SMD -0.33, 95% CI -0.56 to -0.09), which corresponds to a difference in functions scores of -0.7 units on standardised Western Ontario and McMaster Universities Arthritis Index (WOMAC) disability scale ranging from 0 to 10 and translates into a NNTB of 10 (95% CI 7 to 33). An I<sup>2</sup> statistic of 69% indicated a moderate to large degree of between-trial heterogeneity. A visual inspection of the funnel plot suggested asymmetry (asymmetry coefficient -4.07, 95% CI -8.08 to -0.05). When stratifying results according to length of follow-up, benefits were small to moderate at 1 to 2 weeks after end of treatment (SMD -0.43, 95% CI -0.72 to -0.14), small to moderate at 4 to 6 weeks (SMD -0.36, 95% CI -0.63 to -0.09), and no evidence of an effect at 13 weeks (SMD -0.13, 95% CI -0.37 to 0.10) or at 26 weeks (SMD 0.06, 95% CI -0.16 to 0.28). An I<sup>2</sup> statistic of  $\geq 62\%$  indicated a moderate to large degree of between-trial heterogeneity at 26 weeks (P=0.52). We found evidence of lower treatment effects in trials that randomised on average at least 50 participants per group (P=0.023), in unpublished trials (P= 0.023), in trials that used non-intervention controls (P=0.031), and in trials that used concomitant viscosupplementation (P=0.06).

Participants on corticosteroids were 11% less likely to experience adverse events, but confidence intervals included the null effect (RR 0.89, 95% CI 0.64 to 1.23,  $I^2$ =0%). Participants on corticosteroids were 67% less likely to withdraw because of adverse events, but confidence intervals were wide and included the null effect (RR 0.33, 95% CI 0.05 to 2.07,  $I^2$ =0%). Participants on corticosteroids were 27% less likely to experience any serious adverse event, but confidence intervals were wide and included the null effect (RR 0.63, 95% CI 0.15 to 2.67,  $I^2$ =0%).

We found no evidence of an effect of corticosteroids on quality of life compared to control (SMD -0.01, 95% CI -0.30 to 0.28,  $I^2$  = 0%). There was also no evidence of an effect of corticosteroids on joint space narrowing compared to control interventions (SMD - 0.02, 95% CI -0.49 to 0.46).

## Authors' conclusions

Whether there are clinically important benefits of intra-articular corticosteroids after one to six weeks remains unclear in view of the overall quality of the evidence, considerable heterogeneity between trials, and evidence of small-study effects. A single trial included in this review described adequate measures to minimise biases and did not find any benefit of intra-articular corticosteroids.

In this update of the systematic review and meta-analysis, we found most of the identified trials that compared intra-articular corticosteroids with sham or non-intervention control small and hampered by low methodological quality. An analysis of multiple time points suggested that effects decrease over time, and our analysis provided no evidence that an effect remains six months after a corticosteroid injection.

## PLAIN LANGUAGE SUMMARY

## Joint corticosteroid injection for knee osteoarthritis

## **Review question**

We searched the literature until 3 February 2015 for studies of the effects on pain, function, quality of life, and safety of intra-articular (injected into the joint) corticosteroids compared with sham injection or no treatment in people with knee osteoarthritis.

## Background

Osteoarthritis is a disease associated with a breakdown of cartilage of the joints, such as the knee. When the joint loses cartilage, the body responds by growing bone abnormally, which can result in the bone becoming misshapen and the joint painful and unstable. This can affect physical function and the ability to use the joint.

Although osteoarthritis is generally thought to be of degenerative rather than inflammatory origin, an inflammatory component may be present at times. Intra-articular corticosteroids are potent anti-inflammatory agents injected inside the knee joint.

#### Study characteristics

After searching for all relevant studies to 3 February 2015, we found 27 randomised controlled trials with a total of 1767 participants, of a duration ranging from two weeks to one year.

## Key results

Pain

• People who received intra-articular corticosteroids rated improvement in their pain to be about 3 on a scale of 0 (no pain) to 10 (extreme pain) after 1 month.

• People who received a placebo rated improvement in their pain to be about 2 on a scale of 0 (no pain) to 10 (extreme pain) after 1 month.

Another way of saying this is:

• 44 people out of 100 who receive intra-articular corticosteroids respond to treatment (44%).

• 31 people out of 100 who receive a placebo respond to treatment (31%).

• 13 more people respond to treatment with intra-articular corticosteroids than with placebo (difference of 13%).

Note that these numbers may considerably overestimate the true benefit due to the low quality of the evidence.

#### Physical function

• People who received intra-articular corticosteroids rated improvement in their physical function to be about 2 on a scale of 0 (no disability) to 10 (extreme disability) after 1 month.

• People who received a placebo rated improvement in their physical function to be about 1 on a scale of 0 (no disability) to 10 (extreme disability) after 1 month.

Another way of saying this is:

- 36 people out of 100 who received intra-articular corticosteroids respond to treatment (36%).
- 26 people out of 100 who received a placebo respond to treatment (26%).
- 10 more people respond to treatment with intra-articular corticosteroids than with placebo (difference of 10%).

Note that these numbers may considerably overestimate the true benefit due to the low quality of the evidence.

#### Side effects

- 13 people out of 100 who used intra-articular corticosteroids experienced side effects (13%).
- 15 people out of 100 who used a placebo experienced side effects (15%).
- 2 more people experienced side effects with placebo than with intra-articular corticosteroids (difference of 2%).

## Dropouts because of side effects

• 6 people out of 1000 who used intra-articular corticosteroids dropped out because of side effects (0.6%).

- 17 people out of 1000 who used a placebo dropped out because of side effects (1.7%).
- 11 more people dropped out because of side effects with placebo than with intra-articular corticosteroids (difference of 1.1%).

Side effects resulting in hospitalisation, persistent disability, or death

• 3 people out of 1000 who used intra-articular corticosteroids experienced side effects resulting in hospitalisation, persistent disability, or death (0.3%).

• 4 people out of 1000 who used a placebo experienced side effects resulting in hospitalisation, persistent disability, or death(0.4%).

• 1 more person experienced side effects resulting in hospitalisation, persistent disability, or death with placebo than with intra-articular corticosteroids (difference of 0.1%).

Based on the evidence, intra-articular corticosteroids may cause a moderate improvement in pain and a small improvement in physical function, but the quality of the evidence is low and results are inconclusive. Intra-articular corticosteroids appear to cause as many side effects as a placebo. However, we do not have precise and reliable information about side effects.

## Quality of evidence

We graded the quality of the evidence as low for all of our findings, which means that we have little confidence in these results. This was because results were generally highly discordant across studies and mainly based on small studies of low quality.

# SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [Explanation]

# Intra-articular corticosteroid compared with sham injection for osteoarthritis of the knee

Patient or population: participants with osteoarthritis of the knee Settings: various orthopaedic or rheumatology clinics Intervention: intra-articular corticosteroid Comparison: sham injection

Outcomes	Illustrative comparative r	isks* (95% CI)	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk	_			
	Sham injection	Intra-articular corticos- teroid				
Pain intensity Various pain scales. (median follow-up: 12 weeks)	-1.8 cm change on 10- cm VAS <sup>1</sup> 29% improvement	-2.8 cm change (Δ -1.0 cm, -1.5 to -0.6) 2 46% improvement (Δ 17%, 10% to 25%) <sup>3</sup>	SMD -0.40 (-0.58 to -0. 22) Predictive interval (-1.20 to 0.40)	1749 (26)	⊕⊕⊖⊖ low <sup>9</sup>	NNTB 8 (95% CI 6 to 13) 4
<b>Function</b> Various function scales. (median follow-up: 12 weeks)	-1.2 units on WOMAC (range 0 to 10) <sup>1</sup> 21% improvement	-1.9 units on WOMAC $(\Delta -0.7, -1.2 \text{ to } -0.2)^5$ 34% improvement $(\Delta 13\%, 4\% \text{ to } 22\%)^6$	SMD -0.33 (-0.56 to -0. 09) Predictive interval (-1.19 to 0.54)	1014 (15)	⊕⊕⊖⊖ low <sup>9</sup>	NNTB 10 (95% CI 7 to 33) 7
Number of participants experiencing any ad- verse event (median follow-up: 17 weeks)	150 per 1000 participant- years <sup>8</sup>	134 per 1000 participant- years (96 to 185)	RR 0.89 (0.64 to 1.23)	84 (2)	⊕⊕⊖⊖ low <sup>10</sup>	Little evidence of harmful effect (NNTB not statisti- cally significant)

who withdraw because of adverse events (median follow-up: 25 weeks)	17 per 1000 participant- years <sup>8</sup>	6 per 1000 participant- years (1 to 35)	RR 0.33 (0.05 to 2.07)	204 (2)	⊕⊕⊖⊖ low <sup>10</sup>	Little evidence of harmfu effect (NNTB not statisti- cally significant)
Number of participants experiencing any seri- ous adverse event (median follow-up: 26 weeks)	4 per 1000 participant- years <sup>8</sup>	3 per 1000 participant- years (1 to 11)	RR 0.63 (0.15 to 2.67)	331 (5)	⊕⊕⊖ low <sup>10</sup>	Little evidence of harmfu effect (NNTB not statisti- cally significant)
CI: confidence interval; NN Ontario and McMaster Uni GRADE Working Group gr	versities Arthritis Index	for an additional beneficial	outcome; RR: risk ratio; S	MD: standardised mean d	ifference; VAS: visual ana	logue scale; WOMAC: Westerr
Moderate quality: Further	research is likely to have an arch is very likely to have an	n important impact on our o important impact on our c	confidence in the estimate			
<b>/ery low quality:</b> We are Median reduction as obs SMDs were back-transfo	erved across placebo group prmed onto a 10-cm visual	ps in large osteoarthritis tri analogue scale (VAS) on t	ne basis of a typical poole	d standard deviation (SD)	of 2.5 cm in large trials th	hat assessed pain using a VAS
Very low quality: We are Median reduction as obs SMDs were back-transfo and expressed as change Percentage of improvem Absolute response risks SMDs were back-transfo SD of 2.1 in trials that ass Percentage of improvem Absolute response risks	erved across placebo group ormed onto a 10-cm visual based on an assumed stand ent was calculated based o for pain in the control group rmed onto a standardised V essed function using WOM/	os in large osteoarthritis tria analogue scale (VAS) on ti dardised reduction of 0.72 n median observed pain at os were assumed 31% (se Vestern Ontario and McMas AC disability scores and ex n median observed WOMA roups were assumed 26%	ne basis of a typical poole SD units in the control gro baseline across control g e methods section) ther Universities Arthritis In pressed as change based C function scores at base (see methods section).	d standard deviation (SD) up. oups of large osteoarthriti dex (WOMAC) disability so on an assumed standardis ine across control groups	s trials of 6.1 cm on 10-c ore ranging from 0 to 10 ed reduction of 0.58 SD i	m VAS (Nüesch 2009). on the basis of a typical poole

## BACKGROUND

## **Description of the condition**

Knee osteoarthritis is a leading cause of chronic disability in the United States (Felson 2000; Felson 2000a). It results from a multitude of both local and systemic factors. Progression of the disease leads to cartilage degeneration and thinning of the joint surface with subsequent joint pain and stiffness (Brandt 1996).

## **Description of the intervention**

Intra-articular corticosteroid therapy has been used in knee osteoarthritis for over 50 years. The first clinical trial of intra-articular corticosteroids in knee osteoarthritis was performed in 1958 by Miller and colleagues (Miller 1958). Corticosteroids are available in both crystalline and non-crystalline forms. The crystalline triamcinolone and the non-crystalline prednisolone and methylprednisolone are used most frequently. Although this review is restricted to osteoarthritis of the knee joint, intra-articular corticosteroids have also been evaluated in osteoarthritis of various other joints (McColl 2000; Rozental 2000).

## How the intervention might work

Although osteoarthritis is generally thought to be of degenerative rather than inflammatory origin, there is evidence that an inflammatory component may be present in at least some phases of the disease (Creamer 1997). Corticosteroids are known as potent antiinflammatory agents that act through a variety of mechanisms on different cellular levels.

### Why it is important to do this review

The 2012 American College of Rheumatology (ACR) guidelines recommend the participation in exercise programs as well as weight loss (for overweight patients) as first-line treatments for symptomatic knee osteoarthritis. There is no strong recommendation for any pharmacological treatment other than over-the-counter paracetamol or nonsteroidal anti-inflammatory drugs. However, for people unresponsive to the basic treatment, there is a conditional, weak recommendation for the use of intra-articular corticosteroids (Hochberg 2012). Despite the long-standing use of intra-articular corticosteroids, there is an ongoing debate about their effectiveness and safety. Concerns have been expressed that intraarticular corticosteroids might mask the pain, enabling patients to prematurely mobilise and hereby promoting further destruction of the joint (Brandt 2001)

## OBJECTIVES

To determine the benefits and harms of intra-articular corticosteroids compared with sham or no intervention in people with knee osteoarthritis in terms of pain, physical function, quality of life, and safety.

## METHODS

## Criteria for considering studies for this review

#### Types of studies

Randomised or quasi-randomised controlled trials with a control group receiving sham or no intervention.

## **Types of participants**

At least 75% of participants with clinically or radiologically confirmed osteoarthritis of the knee. We did not consider trials that included exclusively people with inflammatory arthritis, such as rheumatoid arthritis.

#### **Types of interventions**

The experimental intervention of interest is any type of intraarticular corticosteroid. The control interventions of interest are sham intra-articular corticosteroid and no intervention.

#### Types of outcome measures

## **Primary outcomes**

The main outcomes were pain and function, as currently recommended for osteoarthritis trials (Altman 1996; Pham 2004), reported within four and six weeks after end of treatment. If data on more than one pain scale were provided for a trial, we referred to a previously described hierarchy of pain-related outcomes (Jüni 2006; Reichenbach 2007), and extracted data on the pain scale that was highest on this list:

- 1. global pain;
- 2. pain on walking;

3. Western Ontario and McMaster Universities Arthritis Index (WOMAC) osteoarthritis index pain subscore;

- 4. composite pain scores other than WOMAC;
- 5. pain on activities other than walking;
- 6. rest pain or pain during the night;
- 7. WOMAC global algofunctional score;
- 8. Lequesne osteoarthritis index global score;
- 9. other algofunctional scale;

10. participant's global assessment;

11. physician's global assessment.

If data on more than one function scale were provided for a trial, we extracted data according to the hierarchy:

- 1. global disability score;
- 2. walking disability;
- 3. WOMAC disability subscore;
- 4. composite disability scores other than WOMAC;
- 5. disability other than walking;
- 6. WOMAC global scale;
- 7. Lequesne osteoarthritis index global score;
- 8. other algofunctional scale;
- 9. participant's global assessment;
- 10. physician's global assessment

#### Secondary outcomes

Secondary outcomes were pain and function assessed at 1 to 2, 4 to 6, 13, and 26 weeks after end of treatment, quality of life assessed at 1 to 2, 4 to 6, 13, and 26 weeks, and the following safety outcomes: joint space narrowing assessed at 1 to 2, 4 to 6, 13, and 26 weeks; the number of participants who experienced any adverse event; withdrew because of adverse events; and experienced any serious adverse events. We defined serious adverse events as events resulting in hospitalisation, prolongation of hospitalisation, persistent or significant disability, congenital abnormality or birth defect of offspring, life-threatening events, or death.

## Search methods for identification of studies

#### **Electronic searches**

Please see Bellamy 2006 for information on electronic searches applied in the previous version of this review. Here, we developed a new search strategy using the electronic databases the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 1, 2015; mrw.interscience.wiley.com/cochrane/), MEDLINE, and EMBASE (Ovid SP platform). We did a top-up search in PubMed to capture citations not yet indexed in MEDLINE. We used a combination of text words and controlled terms (MeSH or MeSH-like terms), including truncated variations of preparation names and brand names combined with terms related to osteoarthritis. We applied a validated methodological filter for controlled clinical trials (Dickersin 1994; Lefebvre 2008). We have displayed the specific search algorithms in Appendix 1 and Appendix 2. We performed the searches from inception to 3 February 2015.

#### Searching other resources

We manually searched the proceedings of the European League Against Rheumatism at http://www.abstracts2view.com/eular/ sessionindex.php, the American College of Rheumatology at http://acrannualmeeting.org/abstracts/abstract-archives/ (we no longer have access to Osteoarthritis Research Society International); used Science Citation Index to retrieve reports citing relevant articles; contacted content experts and trialists; and screened reference lists of all obtained articles. We also retrieved and screened systematic reviews published since January 2004 that evaluated the effects and safety of corticosteroid injections for knee osteoarthritis (Abdulla 2013; Arroll 2004; Avouac 2010; Bannuru 2015; Bellamy 2006; Bjordal 2007; Cheng 2012; Garg 2014; Godwin 2004; Hepper 2009; Hirsch 2013; Maricar 2013). Finally, we searched the following clinical trial registries: ClinicalTrials.gov, metaRegister of Controlled Trials (http://www.controlledtrials.com/), Australian New Zealand Clinical Trials Registry ( http://www.anzctr.org.au/TrialSearch.aspx), and UMIN Clinical Trials Registry (http://www.umin.ac.jp/ctr)) to identify ongoing trials. We performed the last update of the search on 26 March 2015.

#### Data collection and analysis

We used a generic protocol with instructions for data extraction, quality assessment, and statistical analyses, which we also used in our previous Cochrane reviews (da Costa 2012; da Costa 2014; Reichenbach 2010; Rutjes 2009; Rutjes 2009a; Rutjes 2010).

#### Selection of studies

Please see Bellamy 2006 for information on the selection of studies in the original review. In this review update, two out of three review authors independently evaluated all titles and abstracts for eligibility (MGS, MdN and AR). We resolved disagreements by discussion. We applied no language restrictions. If multiple reports described the same trial, we considered all.

## Data extraction and management

Please see Bellamy 2006 for information on data extraction and management in the original review. In this review update, two out of three review authors (BDC, RF, RH) extracted trial information independently and in duplicate using a standardised, piloted extraction form accompanied by a codebook. We resolved disagreements by discussion. We extracted characteristics of the experimental intervention (ultrasound-guided injection, use of local anesthetic, crystalline preparation, and prednisolone equivalance), the type of control used, dosage, frequency, duration of treatment, participant characteristics, types of measures used and pain-, function-, and quality of life-related outcomes, trial design, trial size, duration of follow-up, type and source of financial support, and publication status. When necessary, we approximated means and measures of dispersion from figures in the reports. For cross-over trials, we extracted data from the first period only. Whenever possible, we used results from an intention-to-treat analysis.

#### Assessment of risk of bias in included studies

Two out of three review authors (BDC, RF, RH) assessed randomisation, blinding, and adequacy of analyses independently and in duplicate (Jüni 2001). We resolved disagreements by consensus. We assessed two components of randomisation: generation of allocation sequences and concealment of allocation. We considered generation of sequences to be adequate if it resulted in an unpredictable allocation schedule; mechanisms considered adequate included random-number tables, computer-generated random numbers, minimisation, coin tossing, shuffling cards, and drawing lots. We considered trials using an unpredictable allocation sequence to be randomised and trials using potentially predictable allocation mechanisms, such as alternation or the allocation of participants according to date of birth to be quasi-randomised. We considered concealment of allocation to be adequate if participants and investigators responsible for participant selection were unable to suspect before allocation which treatment was next. Methods considered adequate included central randomisation; pharmacy-controlled randomisation using identical, prenumbered containers; and sequentially numbered, sealed, opaque envelopes. We considered blinding of participants to be adequate if a sham injection was used with a syringe that was identical in appearance to the control intervention, or an attempt was made to hide the participant's view of the injected knee by placing screens, for example. We considered blinding of therapists to be adequate if a credible blinding attempt was described, such as the use of independently prepared, opaque syringes. We considered analyses to be performed according to the intention-to-treat principle if all randomised participants were included in the analysis. We further assessed the reporting of primary outcomes, sample size calculations, and funding source. Finally, we used GRADE to describe the quality of the overall body of evidence (Guyatt 2008; Higgins 2011), defined as the extent of confidence into the estimates of treatment benefits and harms.

#### Measures of treatment effect

We summarised continuous outcomes using standardised mean differences (SMD) with 95% confidence intervals (CI), with the differences in mean change from baseline values across treatment groups divided by the pooled standard deviation (SD). If differences in mean change were unavailable, we used differences in mean values at the end of the treatment (da Costa 2013). If some of the required data were unavailable, we used approximations, as previously described (Reichenbach 2007). An SMD of -0.20 SD units can be considered a small difference between the experimental and control groups, an SMD of -0.50 a moderate difference, and -0.80 a large difference (Cohen 1988; Jüni 2006). SMDs can also be interpreted in terms of the percent of overlap of the experimental group's scores with scores of the control group. An SMD of -0.20 indicates an overlap in the distribution of pain or function scores in about 85% of cases, an SMD of -0.50 in about 67%, and

an SMD of -0.80 in about 53% of cases (Cohen 1988; Jüni 2006). On the basis of a median pooled SD of 2.5 cm, found in largescale osteoarthritis trials that assessed pain using a 10-cm visual analogue scale (VAS) (Nüesch 2009), SMDs of -0.20 correspond to approximate differences in pain scores between experimental and control groups of 0.5 cm on a 10-cm VAS, -0.50 of 1.25 cm, and -0.80 of 2 cm. We back transformed SMDs for function to a standardised WOMAC disability score (Bellamy 1995), ranging from 0 to 10 on the basis of a median pooled SD of 2.1 units observed in large-scale osteoarthritis trials (Nüesch 2009). We expressed binary outcomes as risk ratios (RR) with 95% CI.

## Data synthesis

We used a standard inverse-variance random-effects meta-analysis to combine the trials (DerSimonian 1986). We quantified heterogeneity between trials using the I<sup>2</sup> statistic (Higgins 2003), which describes the percentage of variation across trials that is attributable to heterogeneity rather than to chance. I<sup>2</sup> values of 25% may be interpreted as low, 50% as moderate, and 75% as high betweentrial heterogeneity (da Costa 2014a), although interpretation of I<sup>2</sup> depends on the size and number of trials included (Rucker 2008). Each trial contributed once to our main effectiveness analyses with the effect estimate closer to our primary time point of interest at four to six weeks. We investigated the association between trial size and treatment effects in contour-enhanced funnel plots (Peters 2008), plotting effect sizes on the vertical axis against their standard errors on the horizontal axis (Sterne 2001; Sterne 2011; Thompson 1999), accompanied by a regression test for asymmetry (Egger 1997). We then performed stratified analyses of the primary outcomes, pain and function, accompanied by interaction tests according to the following trial characteristics: concealment of allocation (adequate versus inadequate or unclear), blinding of participants (adequate versus inadequate or unclear), blinding of therapists (adequate versus inadequate or unclear), type of control (placebo versus no intervention), analysis in accordance with the intention-to-treat principle (yes versus no or unclear), trial size, funding (funding independent of industry versus industry or unclear source of funding), publication type (full journal article versus other type or unpublished material), ultrasound-guidance of injections (yes versus no or unclear), use of local anaesthetic (yes versus no or unclear), use of crystalline preparation (yes versus no or unclear), prednisolone equivalence dose ( $\geq$  50 mg versus < 50 mg), use of intra-articular viscosupplementation as co-intervention (yes versus no or unclear), and use of joint lavage as cointervention (yes versus no or unclear). We prespecified a cutoff of 100 allocated participants per trial arm to distinguish between small and large trials. A sample size of 2 x 100 participants will yield more than 80% power to detect a small to moderate SMD of -0.40 at a two-sided P value of 0.05, which corresponds to a difference of 1 cm on a 10-cm VAS between the experimental and control intervention (Nüesch 2010). Since only one large trial was available, we also used a less stringent cutoff of 50 participants

Intra-articular corticosteroid for knee osteoarthritis (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

per arm as previously described (Nüesch 2013). Two arms with 50 participants each will yield more than 80% power to detect a moderate to large SMD of -0.60. We calculated prednisolone equivalence doses, with prednisolone 10 mg considered equivalent to betametasone 1.6 mg, cortivazol 0.8 mg, dexamethasone 1.6 mg, hydrocortisone 40 mg, methylprednisolone 8 mg, and triamcinolone 8 mg. Interaction tests were based on z scores of the difference in effect sizes between strata divided by the corresponding standard error.

We converted SMDs of pain intensity and function to number needed to treat for an additional beneficial outcome on pain or function as compared with placebo (NNTB), and number needed to treat for an additional harmful outcome (NNTH) (da Costa 2012a). We defined treatment response as a 50% improvement in scores (Clegg 2006; Dworkin 2008; Dworkin 2009). With a median standardised pain intensity at baseline of 2.4 SD units, observed in large osteoarthritis trials (Nüesch 2009), this corresponds to a mean decrease in scores of 1.2 SD units. Based on the median standardised decrease in pain scores of 0.72 SD units (Nüesch 2009), we calculated that a median of 31% of participants in the placebo group would achieve an improvement of pain scores of 50% or more. We used this percentage as the control group response rate to calculate NNTBs for pain. Based on the median standardised WOMAC function score at baseline of 2.7 SD units and the median standardised decrease in function scores of 0.58 SD units (Nüesch 2009), 26% of participants in the placebo group would achieve a reduction in function of 50% or more. Again, we used this percentage as the control group response rate to calculate NNTBs for function. We used the median risks of 150 patients with adverse events per 1000 patient-years, four patients with serious adverse events per 1000 patient-years and 17 dropouts due to adverse events per 1000 patient-years as observed in placebo groups in large osteoarthritis trials to calculate NNTHs for safety outcomes (Nüesch 2009). All P values were two-sided. We performed analyses using Review Manager 5.3 (RevMan 2014), and STATA version 14.0 (StataCorp, College Station, Texas).


## RESULTS

## **Description of studies**

### **Results of the search**

We identified 2324 potentially relevant references through our electronic searches and 20 additional references through other sources (Figure 1). We excluded 1769 references after screening titles and abstracts and retrieved 154 potentially relevant references for full-text assessment. We included 33 reports on 27 RCTs in the review.

## Figure 1. Study flow chart. \*records with the exact same bibliographic information of another alreadyscreened record.



## **Included studies**

Twenty-six trials reported effectiveness data. We included all 26 trials in the analysis of pain outcomes, 15 trials in the analysis of function outcomes (Beyaz 2012; Campos 2013; Castro 2007; Chao 2010; Di Sante 2012; Gaffney 1995; Henriksen 2015; Lyons 2005; Petrella 2015; Popov 1989; Ravaud 1999; Raynauld 2003; Smith 2003; Yavuz 2012; Young 2001), and two trials in the analysis of quality-of-life outcomes (Gaffney 1995; Henriksen 2015). Of the 26 included trials, 19 compared corticosteroid injection to

sham injection (Beyaz 2012; Cederlof 1966; Chao 2010; Dieppe 1980; Friedman 1980; Gaffney 1995; Henriksen 2015; Jones 1996; NCT00414427; Lyons 2005; Miller 1958; Popov 1989; Ravaud 1999; Raynauld 2003; Schue 2011; Smith 2003; Yavuz 2012; Young 2001; Zhilyayev 2012), and 7 compared corticosteroid injection to no treatment (Campos 2013; Castro 2007; Di Sante 2012; Fri<sup>-</sup> as 2004; Grecomoro 1992; Ozturk 2006; Petrella 2015).

Triamcinolone was used in 15 trials (Beyaz 2012; Campos 2013; Castro 2007; Chao 2010; Dieppe 1980; Fri as 2004; Friedman

1980; Gaffney 1995; NCT00414427; Ozturk 2006; Petrella 2015; Popov 1989; Raynauld 2003; Yavuz 2012; Zhilyayev 2012), methylprednisolone in seven trials (Di Sante 2012; Henriksen 2015; Lyons 2005; Schue 2011; Smith 2003; Yavuz 2012; Young 2001), hydrocortisone in two trials (Miller 1958; Popov 1989), prednisolone in two trials (Cederlof 1966; Jones 1996), dexamethasonephosphate in one trial (Grecomoro 1992), betametazone disodium phosphate in one trial (Yavuz 2012), and cortivazol in one trial (Ravaud 1999). Four trials used viscosupplementation as a concomitant treatment (Campos 2013; Grecomoro 1992; Ozturk 2006; Petrella 2015), and four trials used lavage as a concomitant treatment (Castro 2007; Fri as 2004; Ravaud 1999; Smith 2003). Two trials used ultrasound to assure intra-articular delivery of corticosteroid preparation (Di Sante 2012; Henriksen 2015). The median prednisolone equivalence dose across all trials was 50 mg, and the median number of corticosteroid injections was one. Trials randomised a median of 76 participants (range 16 to 205 participants).

One additional trial investigating hydrocortisone only reported safety data, on number of participants experiencing any adverse event (Wright 1960).

#### **Excluded studies**


The Characteristics of excluded studies table displays the reasons

for excluding trials in this systematic review. Typical reasons were wrong study design, use of active control interventions, more than 25% of participants with rheumatoid arthritis in the sample, or the use of cross-over designs without providing sufficient information on the first phase.

#### **Risk of bias in included studies**

Figure 2 summarises the methodological characteristics and sources of funding of included trials. Two trials (7%) reported both adequate sequence generation and adequate allocation concealment (Henriksen 2015; Smith 2003), and six trials reported only adequate sequence generation (Campos 2013; Cederlof 1966; Di Sante 2012; Ozturk 2006; Petrella 2015; Raynauld 2003). In the remaining 18 trials, low quality of reporting hampered any judgement regarding sequence generation and concealment of allocation. Six trials reported the use of indistinguishable interventions to blind participants, and three trials reported the use of indistinguishable interventions to blind therapists. Nine and five trials conducted analysis of pain and function outcomes according to the intention-to-treat principle, respectively. Eleven trials received financial support from a nonprofit organisation, and no trial was explicitly supported by a commercial organisation. Twenty-three trials used parallel-group randomisation, and two were cross-over trials (Dieppe 1980; Jones 1996).

# Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.



For the effectiveness outcomes pain and function, we classified the quality of the evidence as low in view of the high risk of bias in the included trials and the high heterogeneity between trials (Summary of findings for the main comparison) (Guyatt 2008). For adverse event, dropouts due to adverse events, and serious adverse event outcomes, we classified the quality of the evidence as low because of the small number of trials reporting the outcomes and the small number of overall events, which resulted in imprecise estimates, and because we considered 50% or more of these trials to be at high risk of bias (Summary of findings for the main comparison) (Guyatt 2008).

## **Effects of interventions**

See: Summary of findings for the main comparison

#### **Primary outcomes**

Knee pain

Figure 3 presents results of the overall analysis of knee pain reported closest to four to six weeks after end of treatment. Corticosteroids were more effective in pain reduction than control interventions (SMD -0.40, 95% CI -0.58 to -0.22), which corresponds to a difference in pain scores of 1.0 cm on a 10-cm VAS between corticosteroids and sham injection. This corresponds to a difference in improvement of 17% (95% CI 10% to 25%) between corticosteroids and sham injection (Summary of findings for the main comparison), which translates into a NNTB to cause one additional treatment response on pain of 8 (95% CI 6 to 13) (Summary of findings for the main comparison). An I<sup>2</sup> statistic of 68% indicated a moderate to large degree of between-trial heterogeneity (P for heterogeneity < 0.001). A visual inspection of the funnel plot suggested some asymmetry (asymmetry coefficient -1.21, 95% CI -3.58 to 1.17), but the corresponding regression test for asymmetry indicated no evidence for asymmetry (P = 0.30) (Figure 4).

Figure 3. Forest plot of comparison: | Pain, outcome: |.| Pain - Main.

			A Corticosteroid	Control		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Std. Mean Difference	SE	Tota			IV, Random, 95% Cl	IV, Random, 95% Cl
Beyaz 2012	-0.68667	0.291396	26	i 25	3.8%	-0.69 [-1.26, -0.12]	
Campos 2013	-0.4102612	0.1991779	52	. 51	4.8%	-0.41 [-0.80, -0.02]	
Castro 2007	0.153865	0.25452	32	: 30	4.2%	0.15 [-0.34, 0.65]	
Cederlof 1966	0.343675	0.443639	26	i 25	2.6%	0.34 [-0.53, 1.21]	
Chao 2010	-0.8324666	0.2550403	34	33	4.2%	-0.83 [-1.33, -0.33]	
Di Sante 2012	-1.269434	0.3481429	20	20	3.3%	-1.27 [-1.95, -0.59]	
Dieppe 1980	-0.8378893	0.4273436	12	! 12	2.7%	-0.84 [-1.68, -0.00]	
Friedman 1980	-0.06448	0.343092	17	' 17	3.3%	-0.06 [-0.74, 0.61]	
Frías 2004	0	0.1396861	103	103	5.4%	0.00 [-0.27, 0.27]	
Gaffney 1995	-0.0516039	0.2182551	42	42	4.6%	-0.05 [-0.48, 0.38]	
Grecomoro 1992	0.2	0.3170589	20	20	3.6%	0.20 [-0.42, 0.82]	
Henriksen 2015	-0.0392837	0.2000197	50	50	4.8%	-0.04 [-0.43, 0.35]	
Jones 1996	-0.9257629	0.2721303	30	) 30	4.0%	-0.93 [-1.46, -0.39]	
Lyons 2005	-0.566251	0.4570631	10	10	2.5%	-0.57 [-1.46, 0.33]	
Miller 1958	-0.2151739	0.3313255	37	36	3.4%	-0.22 [-0.86, 0.43]	
NCT00414427	-0.8803853	0.2562751	33	34	4.2%	-0.88 [-1.38, -0.38]	
Ozturk 2006	-0.1368758	0.2921525	23	24	3.8%	-0.14 [-0.71, 0.44]	
Petrella 2015	-0.0355	0.2463161	34	32	4.3%	-0.04 [-0.52, 0.45]	
Popov 1989	-1.088324	0.4184004	19	11	2.7%	-1.09 [-1.91, -0.27]	
Ravaud 1999	-0.4619007	0.2061198	49	49	4.7%	-0.46 [-0.87, -0.06]	
Raynauld 2003	0.1177483	0.2464029	33	33	4.3%	0.12 [-0.37, 0.60]	
Schue 2011	-0.207736	0.6144019	6	i 5	1.7%	-0.21 [-1.41, 1.00]	
Smith 2003	-0.3261666	0.2395615	38	33	4.4%	-0.33 [-0.80, 0.14]	
Yavuz 2012	-1.53523	0.234898	90	) 30	4.4%	-1.54 [-2.00, -1.07]	
Young 2001	-0.3845994	0.3154607	21	20	3.6%	-0.38 [-1.00, 0.23]	
Zhilyayev 2012	-0.4685471	0.1873348	67	52	4.9%	-0.47 [-0.84, -0.10]	
Total (95% CI)			922	827	100.0%	-0.40 [-0.58, -0.22]	◆
Heterogeneity: Tau <sup>2</sup> =	= 0.14; Chi <sup>2</sup> = 78.14, df =	25 (P < 0.000	01); I² = 68%				
Test for overall effect	Z = 4.29 (P < 0.0001)						-2 -1 U 1 2 Favours corticosteroid Favours control

Figure 4. Contour-enhanced funnel plot for effects on knee pain. Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs




Figure 5 presents results stratified according to length of followup. Benefits were moderate at 1 to 2 weeks after end of treatment (SMD -0.48, 95% CI -0.70 to -0.27), small to moderate at 4 to 6 weeks (SMD -0.41, 95% CI -0.61 to -0.21), small at 13 weeks (SMD -0.22, 95% CI -0.44 to 0.00), and no effect at 26 weeks (SMD -0.07, 95% CI -0.25 to 0.11). An I<sup>2</sup> statistic of  $\geq$  63% indicated a moderate to large degree of between-trial heterogeneity up to 13 weeks after end of treatment (P for heterogeneity  $\leq$ 0.001), and an I<sup>2</sup> of 0% indicated low heterogeneity at 26 weeks (P = 0.43).

Mean Difference         SE           -0.83381         0.295388           -0.81381         0.295388           -0.81387         0.356857           -0.27         0.317743           -0.4608         0.3478           -0.4608         0.3478           -0.4608         0.3478           -0.4608         0.3478           -0.4608         0.24951           -0.4709         0.24951           -0.4018         0.20002           -0.4018         0.240823           -1.0832         0.4184           -0.670337         0.23553           -0.1244         0.613101           -0.21561         0.23655           -1.509         0.234594           -0.42288         0.188871           ChP = 40.31, df = 15 (P = 0.0004); P           33 (P < 0.0001)         0.343675           -0.41026         0.234594           -0.41026         0.244630           0.153685         0.25452           0.343675         0.443639           -0.05448         0.343092           -0.057699         0.2721303           -0.057699         0.2721303           -0.05625         0.4436763	Total 25 26 20 20 12 2 0 1 2 20 34 49 5 38 90 67 566 = 63% 25 52 26 34 20 17 103 34 20 30 10 37 33 23 34 49 5 8 90	255 522 5225 200 2225 200 222 200 322 323 300 322 475 333 300 255 511 300 255 333 200 255 333 200 360 314 320 300 314 320 310 316 314 320 317 317 317 317 317 317 317 317 317 317	6.1% 6.1% 5.7% 4.2% 5.7% 4.2% 5.7% 4.3% 7.6% 7.6% 7.8% 7.8% 7.2% 7.3% 8.43% 7.2% 7.3% 8.43% 7.2% 7.3% 8.43% 7.2% 7.3% 8.43% 7.2% 7.2% 7.3% 8.43% 7.2% 7.3% 8.43% 7.2% 7.2% 7.2% 7.2% 7.2% 7.2% 7.2% 7.2	V, Random, 95% CI -0.83 [-1.41, -0.25] -0.62 [-1.01, -0.25] -0.34 [-1.04, 0.36] -0.27 [-0.89, 0.35] -0.24 [-1.48, 0.00] -0.46 [-1.48, 0.00] -0.46 [-1.48, 0.00] -0.46 [-1.44, 0.23] -0.46 [-0.43, 0.35] -0.40 [-0.89, 0.09] -1.09 [-1.91, -0.27] -0.67 [-1.08, 0.26] -0.12 [-1.33, 1.08] -0.22 [-0.68, 0.48] -0.22 [-0.68, 0.48] -0.22 [-0.68, 0.48] -0.48 [-0.70, 0.27] -0.48 [-0.70, 0.27] -0.48 [-0.70, 0.27] -0.48 [-0.70, 0.27] -0.68 [-1.26, -0.12] -0.41 [-0.80, 0.06] 0.34 [-0.53, 1.21] -0.83 [-1.33, 0.33] -1.27 [-1.95, 0.56] -0.06 [-0.74, 0.61] -0.08 [-1.46, 0.33] -0.27 [-1.46, 0.33] -0.27 [-1.46, 0.34] -0.88 [-1.38, 0.38] -0.34 [-0.71, 0.44] -0.44 [-0.71, 0.44] -0.45 [-0.71, 0.44] -0.44 [-	N, Random, 95% Cl
$\begin{array}{c} -0.61535 & 0.200793 \\ -0.3873 & 0.356867 \\ -0.27 & 0.317743 \\ -0.83789 & 0.427344 \\ -0.4608 & 0.3478 \\ -0.28951 & 0.21951 \\ 0.21951 & 0.21951 \\ -0.03928 & 0.20002 \\ -0.0018 & 0.248933 \\ -1.08832 & 0.4184 \\ -0.6703337 & 0.21953 \\ -0.1244 & 0.613101 \\ -0.21581 & 0.238655 \\ -1.509 & 0.234594 \\ -0.42298 & 0.186871 \\ ChF = 40.31, df = 15 (P = 0.0004); P \\ 33 (P < 0.0001) \\ \hline \\ \hline \\ -0.640106 & 0.199178 \\ -0.343655 & 0.24524 \\ 0.343675 & 0.43639 \\ -0.343675 & 0.43639 \\ -0.3324660 & 0.2391396 \\ -0.0575697 & 0.2182642 \\ 0.0343675 & 0.43639 \\ -0.0575697 & 0.2182642 \\ 0.0343675 & 0.43639 \\ -0.0575697 & 0.2182642 \\ 0.0343675 & 0.43639 \\ -0.0575697 & 0.2182642 \\ 0.0343675 & 0.43639 \\ -0.057699 & 0.2721303 \\ -0.05625 & 0.457053 \\ -0.256275 & 0.2721303 \\ -0.256275 & 0.2721303 \\ -0.256275 & 0.2721303 \\ -0.256275 & 0.2721303 \\ -0.256275 & 0.2721303 \\ -0.256275 & 0.2721303 \\ -0.256275 & 0.2721303 \\ -0.256275 & 0.22153 \\ -0.33617 & 0.239562 \\ -0.326170 & 0.239562 \\ -0.326170 & 0.239562 \\ -0.326170 & 0.239562 \\ -0.326170 & 0.239562 \\ -0.32617 & 0.239562$	52 26 20 12 42 50 50 50 50 50 50 50 50 50 50 50 50 50	52 25 20 20 20 20 20 20 20 20 20 20 20 20 20	80% 51% 42% 57% 42% 57% 80% 7.6% 80% 7.0% 7.0% 7.0% 7.2% 7.3% 4.2% 4.9% 4.9% 4.9% 4.5% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0%	$\begin{array}{c} -0.62 \ [+\ 0.1, -0.22 \]\\ -0.34 \ [+\ 1.04 \ 0.36 \]\\ -0.27 \ [+\ 0.89 \], 0.35 \]\\ -0.48 \ [+\ 1.48 \], -0.00 \]\\ -0.46 \ [+\ 1.44 \], 0.22 \]\\ -0.29 \ [+\ 0.27 \], 0.04 \]\\ -0.47 \], 0.45 \]\\ -0.40 \ [+\ 0.43 \], 0.35 \]\\ -0.40 \ [+\ 0.43 \], 0.35 \]\\ -0.40 \ [+\ 0.43 \], 0.35 \]\\ -0.40 \ [+\ 0.43 \], 0.35 \]\\ -0.40 \ [+\ 0.43 \], 0.35 \]\\ -0.42 \ [+\ 0.47 \], 0.42 \]\\ -0.42 \ [+\ 0.79 \], -0.66 \]\\ -0.42 \ [+\ 0.79 \], -0.66 \]\\ -0.42 \ [+\ 0.79 \], -0.66 \]\\ -0.48 \ [+\ 0.79 \], -0.66 \]\\ -0.48 \ [+\ 0.79 \], -0.66 \]\\ -0.48 \ [+\ 0.79 \], -0.66 \]\\ -0.48 \ [+\ 0.79 \], -0.66 \]\\ -0.48 \ [+\ 0.79 \], -0.66 \]\\ -0.48 \ [+\ 0.79 \], -0.66 \]\\ -0.46 \ [+\ 0.46 \], 0.37 \]\\ -0.36 \]\ -0.36$	
-0.33873 0.366857 -0.27 0.317743 -0.4608 0.427344 -0.4608 0.3478 -0.29951 0.21951 0.4 0.319539 -0.03928 0.20002 -0.40018 0.248823 -1.08332 0.2103553 -0.1244 0.613101 -0.21641 0.238655 -1.509 0.234594 -0.42298 0.186871 -0.42298 0.186871 -0.42298 0.186871 -0.42298 0.186871 -0.41026 0.254524 0.343675 0.443639 -0.343675 0.443639 -0.343675 0.443639 -0.343675 0.443639 -0.343675 0.443639 -0.343675 0.443639 -0.343675 0.443639 -0.343675 0.443639 -0.343675 0.443639 -0.343675 0.443639 -0.057569 0.2721303 -0.56625 0.457063 -0.2557629 0.2721303 -0.56625 0.457063 -0.21517 0.331226 -0.38080 0.292153 -0.32617 0.331226 -0.32617 0.2246316 -0.4614007 0.2261188 -0.226118	26 20 12 17 42 50 50 50 67 566 = 63% = 63% = 63% = 63%	25 200 500 500 500 500 500 500 500 500 5	$\begin{array}{c} 5.1\%\\ 5.7\%\\ 4.2\%\\ 5.3\%\\ 5.7\%\\ 8.0\%\\ 5.7\%\\ 8.0\%\\ 7.0\%\\ 4.3\%\\ 7.2\%\\ 8.2\%\\ 8.2\%\\ 8.0\%\\ 5.7\%\\ 8.2\%$	$\begin{array}{c} -0.34 \ [+1.04, 0.36] \\ -0.27 \ [+0.89, 0.35] \\ -0.27 \ [+0.89, 0.35] \\ -0.27 \ [+0.89, 0.36] \\ -0.46 \ [+1.40, 0.22] \\ -0.28 \ [+0.27, 0.14] \\ -0.40 \ [+0.23, 1.03] \\ -0.40 \ [+0.43, 0.35] \\ -0.40 \ [+0.43, 0.35] \\ -0.40 \ [+0.89, 0.09] \\ -1.09 \ [+1.91, -0.27] \\ -0.67 \ [+1.98, 0.26] \\ -0.12 \ [+1.33, 1.08] \\ -0.42 \ [+0.70, -0.27] \\ -0.48 \ [+0.70, -0.27] \\ -0.48 \ [+0.70, -0.27] \\ -0.48 \ [+0.37, 0.03] \\ -0.34 \ [+0.33, -0.33] \\ -1.77 \ [+1.95, -0.59] \\ -0.06 \ [+0.24, 0.82] \\ -0.36 \ [+1.36, -0.39] \\ -0.26 \ [+0.44, 0.39] \\ -0.27 \ [+1.46, -0.39] \\ -0.27 \ [+1.46, -0.39] \\ -0.26 \ [+1.46, -0.39] \\ -0.26 \ [+1.46, -0.39] \\ -0.26 \ [+1.46, -0.39] \\ -0.46 \ [+0.37, -0.44] \\ -0.44 \ [+0.57, 0.44] \\ -0.44 \ [+0.57, 0.44] \\ -0.44 \ [+0.57, 0.44] \\ -0.44 \ [+0.47, -0.44] \\ -0.44 \ [+0.47, -0.44] \\ -0.44 \ [+0.47, -0.44] \\ -0.44 \ [+0.47, -0.44] \\ -0.44 \ [+0.47, -0.44] \\ -0.44 \ [+0.47, -0.44] \\ -0.44 \ [+0.47, -0.44] \\ -0.44 \ [+0.47, -0.44] \\ -0.44 \ [+0.47, -0.44] \\ -0.44 \ [+0.47, -0.44] \\ -0.44 \ [+0.47, -0.44] \\ -0.44 \ [+0.41, 1.00] \\ -0.21 \ [+1.41, 1.00] \\$	
-0.27 0.317743 -0.83789 0.427344 -0.4608 0.3478 -0.28951 0.21951 0.4 0.319539 -0.03928 0.20002 -0.40018 0.24823 -1.08832 0.4184 -0.6703337 0.2103553 -0.1244 0.613101 -0.21581 0.238655 -1.509 0.234594 -0.42298 0.186871 ChF = 4.031, df = 15 (P = 0.0004); P -0.688667 0.291396 -0.41026 0.199178 0.153865 0.25452 0.343675 0.443639 -0.432667 0.219396 -0.41026 0.199178 0.153865 0.25452 0.343675 0.443639 -0.632466 0.2356403 -1.269434 0.343129 -0.06448 0.343092 0.0336861 -0.0575697 0.2182842 0.033466 0.256103 -0.0575697 0.2182842 0.0336661 -0.057569 0.2721303 -0.05625 0.4457063 -0.256705 -0.13688 0.292153 -0.0356 0.226175 -0.33617 0.331326 -0.03561 0.226176 -0.32617 0.331326 -0.266176 0.331326	20 12 17 42 20 50 50 50 50 50 56 56 56 56 56 52 26 56 22 56 26 32 26 34 20 17 10 34 20 10 34 20 10 34 20 20 34 20 56 56 56 56 56 56 56 56 56 56 56 56 56	20 12 17 42 20 50 50 52 51 30 52 52 51 30 52 52 51 30 32 52 51 30 32 52 51 30 32 53 33 32 25 51 30 30 32 42 49 50 32 40 50 50 50 50 50 50 50 50 50 50 50 50 50	$\begin{array}{c} 5.7\%\\ 4.2\%\\ 5.3\%\\ 5.3\%\\ 7.6\%\\ 8.0\%\\ 4.3\%\\ 7.2\%\\ 8.0\%\\ 4.3\%\\ 125\%\\ 8.2\%$	$\begin{array}{c} -0.27 \ [+0.89, 0.36] \\ -0.27 \ [+0.89, -0.00] \\ -0.46 \ [+1.14, 0.22] \\ -0.29 \ [+0.77, 0.14] \\ 0.40 \ [+0.23, 1.03] \\ -0.40 \ [+0.43, 0.35] \\ -0.40 \ [+0.48, 0.09] \\ -1.09 \ [+1.91, -0.27] \\ -0.67 \ [+1.08, -0.26] \\ -0.12 \ [+1.33, 1.08] \\ -0.22 \ [+0.68, 0.26] \\ -0.12 \ [+1.33, 1.08] \\ -0.22 \ [+0.68, 0.26] \\ -0.42 \ [+0.79, -0.06] \\ -0.42 \ [+0.79, -0.06] \\ -0.48 \ [+0.70, -0.27] \\ -0.48 \ [+0.70, -0.27] \\ -0.48 \ [+0.70, -0.27] \\ -0.48 \ [+0.70, -0.27] \\ -0.48 \ [+0.70, -0.27] \\ -0.69 \ [+1.26, -0.12] \\ -0.34 \ [+0.50, -0.50] \\ -0.06 \ [+0.74, 0.61] \\ -0.34 \ [+0.50, -0.50] \\ -0.06 \ [+0.74, 0.61] \\ -0.06 \ [+0.74, 0.61] \\ -0.06 \ [+0.74, 0.61] \\ -0.08 \ [+1.38, -0.38] \\ -0.14 \ [+0.71, 0.44] \\ -0.04 \ [+0.52, 0.45] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.57, -0.06] \\ -0.46 \ [+0.47, -0.06] \\ -0.46 \ [+0.41, -0.00] \\ -0.41 \ [+1.41, -0.01] \\ -0.41 $	
-0.83769 0.427344 -0.4608 0.3478 -0.28951 0.21951 0.4 0.319539 -0.3928 0.20002 -0.40018 0.248623 -1.08832 0.4184 -0.1244 0.613101 -0.21561 0.238655 -1.509 0.234594 -0.42298 0.186871 -0.42298 0.186871 -0.42298 0.186871 -0.42298 0.186871 -0.42298 0.186871 -0.41026 0.199178 -0.41026 0.294594 -0.44026 0.255452 0.334575 0.443639 -0.33665 0.255452 0.334575 0.43692 -0.328661 0.256452 0.334575 0.43692 -0.328665 0.255452 0.334575 0.43692 -0.328665 0.255452 0.334565 0.45703 -0.328652 0.457053 -0.21517 0.331326 -0.38080 0.2292153 -0.0356 0.2265175 -0.33680 0.2292153 -0.0355 0.429188 -0.21517 0.331326 -0.32617 0.2261188 -0.21517 0.331326 -0.32617 0.2261188 -0.226316	12 42 20 50 34 49 5 566 6 566 6 566 566 566 34 22 32 32 32 32 32 32 32 32 30 10 30 10 30 37 33 34 49 5 5 32 32 30 30 4 34 34 34 30 56 56 56 56 56 56 56 56 56 56 56 56 56	12 17 42 20 32 32 49 5 33 30 52 25 51 33 30 25 53 33 20 25 53 33 20 25 53 33 20 25 53 33 20 25 53 33 20 25 53 33 20 25 53 33 20 25 54 75 25 54 25 54 25 54 25 54 25 54 25 54 25 54 54 25 54 54 25 54 54 54 54 54 54 54 54 54 54 54 54 54	$\begin{array}{c} 4.2\%\\ 5.3\%\\ 7.6\%\\ 7.6\%\\ 7.6\%\\ 7.0\%\\ 7.0\%\\ 7.0\%\\ 7.2\%\\ 7.2\%\\ 7.2\%\\ 100.0\%\\ 3.0\%\\ 4.5\%\\ 3.0\%\\ 4.9\%\\ 3.0\%\\ 4.9\%\\ 3.0\%\\ 4.9\%\\ 3.0\%\\ 4.9\%\\ 5.6\%\\ 5.5\%\\ 5.5\%\\ 5.5\%\\ 5.0\%\\ 5.5\%\\ 5.0\%\\ 5.5\%\\ 5.0\%\\ 5.5\%\\ 5.0\%\\ 5.5\%\\ 5.0\%$	-0.84 [-1.68, -0.00] -0.46 [1.14, 0.22] -0.29 [-0.72, 0.14] -0.40 [-0.23, 1.03] -0.40 [-0.34, 0.35] -0.40 [-0.89, 0.08] -1.09 [-1.02, 7] -0.67 [-1.08, -0.26] -0.12 [-1.33, 1.08] -0.25 [-0.68, 0.25] -1.51 [-1.97, -1.05] -0.42 [-0.79, -0.06] -0.48 [-0.79, -0.06] -0.48 [-0.79, -0.06] -0.48 [-0.79, -0.06] -0.48 [-0.70, -0.27] -0.48 [-0.70, -0.27] -0.48 [-0.70, -0.27] -0.66 [-1.26, -0.12] -0.41 [-0.80, -0.02] -0.34 [-0.53, 1.21] -0.34 [-0.53, 1.21] -0.35 [-1.33, -0.33] -1.27 [-1.95, -0.59] -0.06 [-0.44, 0.37] -0.06 [-0.44, 0.37] -0.25 [-1.46, -0.39] -0.57 [-1.46, -0.39] -0.46 [-0.47, -0.44] -0.44 [-0.47, -0.44] -0.44 [-0.52, 0.45] -0.46 [-0.87, -0.06] -0.46 [-0.47, -0.44], -0.01] -0.45 [-1.41, 1.00]	
-0.4608 0.3478 -0.28951 0.21951 0.4 0.319539 -0.03928 0.20002 -0.40018 0.24823 -1.08832 0.4184 -0.670337 0.2103553 -0.1244 0.613101 -0.21581 0.238655 -1.509 0.234594 -0.42288 0.186871 ChF = 40.31, df = 15 (P = 0.0004); P -0.41026 0.199178 0.45026 0.291396 -0.41026 0.199178 0.45026 0.2550403 -0.343675 0.443639 -0.343675 0.443639 -0.3324666 0.2550403 -0.3326667 0.2182642 0.3343675 0.443639 -0.0575697 0.2182642 0.3343675 0.443639 -0.0575697 0.2182642 -0.0386861 -0.0575699 0.2721303 -0.05488 0.252153 -0.0355 0.246316 -0.21517 0.331326 -0.0355 0.246316 -0.21517 0.331326 -0.0355 0.246316 -0.21517 0.331326 -0.32617 0.2395622 -0.32657 0.2182842 -0.0355 0.246316	17 42 20 34 19 56 566 = 63% 25 52 32 26 52 32 26 52 32 26 52 32 26 34 20 10 10 31 34 20 30 10 37 33 44 20 36 34 49 55 36 36 36 36 36 36 36 36 36 36 37 36 36 36 36 36 36 36 36 36 36 36 36 36	17 42 20 500 32 475 475 475 51 30 25 51 30 25 51 30 25 51 30 25 51 30 25 51 30 25 51 30 25 51 30 30 25 51 30 30 25 51 30 30 22 51 30 30 22 475 50 50 22 475 50 50 50 50 50 50 50 50 50 50 50 50 50	$\begin{array}{c} 5.3\%,\\ 7.6\%,\\ 8.0\%,\\ 8.0\%,\\ 8.0\%,\\ 8.0\%,\\ 8.0\%,\\ 8.0\%,\\ 7.2\%,\\ 7.2\%,\\ 7.2\%,\\ 7.2\%,\\ 7.2\%,\\ 7.2\%,\\ 8.$	$\begin{array}{c} -0.46 \ [+1.4, 0.22] \\ -0.28 \ [+0.72, 0.14] \\ -0.29 \ [+0.72, 0.14] \\ -0.40 \ [+0.23, 1.03] \\ -0.04 \ [+0.43, 0.36] \\ -0.40 \ [+0.80, 0.09] \\ -1.09 \ [+1.90, -0.26] \\ -0.51 \ [+0.80, -0.26] \\ -0.51 \ [+1.97, -1.05] \\ -0.42 \ [+0.79, -0.06] \\ -0.48 \ [-0.70, -0.27] \\ -0.48 \ [-0.70, -0.27] \\ -0.48 \ [-0.70, -0.27] \\ -0.48 \ [-0.70, -0.27] \\ -0.48 \ [+0.70, -0.27] \\ -0.48 \ [+0.70, -0.27] \\ -0.68 \ [+1.26, -0.12] \\ -0.48 \ [+0.70, -0.27] \\ -0.68 \ [+1.26, -0.12] \\ -0.31 \ [+0.33, -0.33] \\ -0.57 \ [+1.46, -0.38] \\ -0.57 \ [+1.46, -0.38] \\ -0.57 \ [+1.46, -0.38] \\ -0.48 \ [+0.38, -0.38] \\ -0.48 \ [+0.71, 0.44] \\ -0.88 \ [+1.38, -0.38] \\ -0.44 \ [+0.52, 0.45] \\ -0.44 \ [+0.52, 0.45] \\ -0.44 \ [+0.57, -0.45] \\ -0.44 \ [+0.57, -0.45] \\ -0.44 \ [+0.57, -0.45] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.47, -0.56] \\ -0.44 \ [+0.41, -0.06] \\ -0.41 \ [+0.41, -0.06] \\$	
-0.28951 0.21951 0.4 0.319539 -0.03928 0.20002 -0.40018 0.248823 -1.08832 0.4184 -0.6703337 0.2103553 -0.1244 0.613101 -0.21581 0.238655 -1.509 0.234594 -0.42298 0.186871 ChiF= 40.31, df= 15 (P= 0.0004); P -0.688667 0.291396 -0.41026 0.199178 0.153865 0.255452 0.343675 0.25452 0.343675 0.25452 0.343675 0.25452 0.343675 0.25452 0.343675 0.25452 0.343675 0.25452 0.343675 0.25452 0.343675 0.25452 0.343675 0.25452 0.343675 0.25452 0.317059 -0.0575697 0.2113542 -0.05484 0.343092 -0.05484 0.343092 -0.05484 0.343092 -0.05486 0.255043 -0.0355 0.457053 -0.0355 0.457053 -0.21517 0.331326 -0.88039 0.292153 -0.0355 0.246316 -0.4619007 0.2061198 -0.22617 0.239662 -0.328662	42 20 50 34 49 566 63% = 63% = 63% = 63% = 63% = 25 562 32 26 32 32 32 32 32 32 34 34 20 177 103 34 20 57 56 56 56 56 56 56 56 50 50 50 50 50 50 50 50 50 50 50 50 50	42 200 32 32 33 30 52 475 51 30 25 51 30 25 51 30 25 33 20 107 103 102 30 30 20 103 42 20 30 20 475 53 20 20 475 20 20 20 20 20 20 20 20 20 20 20 20 20	$\begin{array}{c} 7.6\%, \\ 6.7\%, \\ 8.0\%, \\ 7.0\%, \\ 2.5\%, \\ 7.8\%, \\ 7.8\%, \\ 7.8\%, \\ 7.8\%, \\ 7.8\%, \\ 7.8\%, \\ 7.8\%, \\ 7.8\%, \\ 3.0\%, \\ 4.5\%, \\ 3.0\%, \\ 4.5\%, \\ 5.6\%, \\ 5.5\%, \\$	$\begin{array}{c} -0.29 \ [ 0.72 , 0.14 ] \\ -0.29 \ [ 0.72 , 0.14 ] \\ -0.40 \ [ 0.23 , 1.03 ] \\ -0.40 \ [ 0.20 , 1.03 ] \\ -0.40 \ [ 0.40 , 0.08 ] \\ -0.40 \ [ 0.40 , 0.20 ] \\ -0.75 \ [ 1.08 , 0.26 ] \\ -0.72 \ [ 1.08 \ [ 1.02 ] \\ -0.72 \ [ 1.08 \ [ 1.02 ] \\ -0.42 \ [ 0.79 , -0.06 ] \\ -0.42 \ [ 0.79 , -0.06 ] \\ -0.42 \ [ 0.79 , -0.06 ] \\ -0.42 \ [ 0.79 , -0.06 ] \\ -0.48 \ [ -0.70 , -0.27 ] \\ -0.41 \ [ -0.80 , -0.22 ] \\ -0.41 \ [ -0.80 , -0.22 ] \\ -0.41 \ [ -0.80 , -0.22 ] \\ -0.41 \ [ -0.80 , -0.22 ] \\ -0.41 \ [ -0.80 , -0.22 ] \\ -0.41 \ [ -0.80 , -0.22 ] \\ -0.41 \ [ -0.80 , -0.22 ] \\ -0.41 \ [ -0.80 \ [ -0.70 \ [ -0.44 \ [ -0.47 \ [ -0.44 \ [$	
0.4 0.319539 -0.03928 0.20002 -0.40018 0.248823 -1.08832 0.4184 -0.670337 0.2103553 -0.1244 0.613101 -0.21561 0.238655 -1.509 0.234594 -0.42298 0.186871 ChF = 4.0.31, df = 15 (P = 0.0004); P 33 (P < 0.0001) -0.688667 0.291396 -0.41026 0.255452 0.343675 0.443639 -0.343675 0.443639 -0.343675 0.443639 -0.343666 0.255043 -1.269434 0.3481429 -0.05456 0.245452 0.343675 0.443639 -0.0575697 0.2182642 0.1396861 -0.057569 0.2721303 -0.56625 0.457063 -0.215177 0.331326 -0.38039 0.256275 -0.33668 0.2525153 -0.03565 0.457063 -0.215177 0.331326 -0.32617 0.236170 -0.2681188 -0.21517 0.331326 -0.32617 0.2061188 -0.21513 -0.32617 0.236152 -0.32657 0.2295625	20 50 34 19 49 5 566 566 566 562 32 32 26 34 20 107 103 42 20 31 0 34 20 34 34 42 30 30 30 31 37 33 34 45 34 34 45 38 34 34 33 34 34 33 33 34 34 33 33 34 34	200 500 322 5 333 300 522 475 51 300 255 51 300 255 333 200 255 11 300 255 313 300 255 333 300 255 313 300 255 312 402 200 200 200 200 200 200 200 200 20	$\begin{array}{c} 5.7\% \\ 8.0\% \\ 8.0\% \\ 7.0\% \\ 4.3\% \\ 7.2\% \\ 2.5\% \\ 7.2\% \\ 8.2\% \\ 8.2\% \\ 3.0\% \\ 4.5\% \\ 3.0\% \\ 4.9\% \\ 4.9\% \\ 4.9\% \\ 4.7\% \\ 4.9\% \\ 4.9\% \\ 5.5\% \\ 5.0\% \\ 5.0\% \\ 5.0\% \\ 5.0\% \\ 2.0\% \\ 2.0\% \end{array}$	$\begin{array}{c} 0.40 \ [ 0.22, 1 \ 0.31 \\ 0.04 \ [ 0.43, 0.36 ] \\ 0.04 \ [ 0.43, 0.36 ] \\ 0.04 \ [ 0.43, 0.36 ] \\ 0.05 \ [ 1.08, 0.26 ] \\ 0.12 \ [ 1.33, 1.08 ] \\ 0.22 \ [ 0.68, 0.25 ] \\ 0.12 \ [ 1.33, 1.08 ] \\ 0.22 \ [ 0.68, 0.25 ] \\ 0.42 \ [ 0.79, 0.06 ] \\ 0.42 \ [ 1.07, 0.027 ] \\ \hline 0.48 \ [ -0.70, 0.27 ] \\ \hline 0.48 \ [ -0.34, 0.65 ] \\ 0.34 \ [ -0.53, 1.21 ] \\ -0.83 \ [ -1.38, -0.38 ] \\ -0.06 \ [ -0.74, 0.61 ] \\ 0.00 \ [ -0.77, 0.21 ] \\ \hline 0.05 \ [ -0.74, 0.61 ] \\ 0.00 \ [ -0.77, 0.21 ] \\ \hline 0.25 \ [ -1.46, 0.38 ] \\ -0.48 \ [ -1.38, -0.38 ] \\ -0.48 \ [ -1.70, 0.44 ] \\ -0.44 \ [ -0.87, -0.06 ] \\ \hline 0.44 \ [ -0.52, 0.45 ] \\ -0.46 \ [ -0.41, 1.00 ] \\ \hline 0.21 \ [ -1.41, 1.00 ] \\$	
-0.03928 0.2002 -0.40118 0.248823 -1.08832 0.4184 -0.6703337 0.2103553 -0.1244 0.613101 -0.21581 0.238655 -1.509 0.234594 -0.42298 0.186871 ChIP=40.31, df=15 (P = 0.0004); P -0.6886657 0.291396 -0.41026 0.199178 0.153865 0.24452 0.33075 0.443639 -0.824666 0.2550403 -1.26043 0.3343092 -0.0575697 0.2182642 0.033675 0.443639 -0.03824666 0.2550403 -1.26043 0.3343092 -0.0575697 0.2182642 0.0330675 0.24521 -0.056826 0.2550403 -1.26043 0.3343092 -0.0575697 0.2182642 -0.0575697 0.2182642 -0.0575697 0.2182642 -0.0575697 0.2182642 -0.057569 0.2721303 -0.256725 0.24316 -0.256725 0.246316 -0.26575 0.246316 -0.26575 0.246316 -0.25572 0.2721303 -0.25572 0.2721303 -0.25572 0.2721303 -0.25572 0.2721303 -0.25572 0.2721303 -0.25572 0.2721303 -0.25572 0.2721303 -0.25572 0.2721303 -0.2557 0.246316 -0.4619007 0.2061198 -0.032617 0.2061198 -0.032617 0.203452 -0.32617 0.203452 -0.32647 0.203452 -0.32647 0.203452 -0.32647 0.203452 -0.32647 0.203452 -0.32647 0.204316 -0.4619007 0.2061198 -0.0274 0.614402 -0.32617 0.239562 -1.55523 0.234898	50 34 19 5 88 90 67 566 625 526 26 52 26 52 26 26 32 26 34 20 107 103 42 20 30 107 103 30 30 100 103 103 42 20 55 56 56 57 56 56 57 56 57 56 57 56 57 56 57 56 57 56 57 56 57 56 57 56 57 57 56 57 56 57 56 57 56 57 56 57 56 57 56 57 56 57 56 57 56 57 57 56 57 57 56 57 57 56 57 57 56 57 57 56 57 57 57 57 57 57 57 57 57 57 57 57 57	50 32 11 49 5 33 30 52 55 51 30 52 55 51 30 32 52 55 33 32 00 30 17 103 34 22 20 30 0 36 34 42 49 9 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	8 0%, 7 0%, 4 3%, 7 0%, 4 3%, 7 0%, 4 3%, 7 0%, 100, 100, 100, 100, 100, 100, 100,	$\begin{array}{c} -0.04 \ [ 0.43 \ 0.35 ] \\ -0.04 \ [ 0.08 \ 0.09 ] \\ -1.09 \ [ 1.91 \ , 0.27 ] \\ -0.67 \ [ 1.08 \ 0.02 ] \\ -0.12 \ [ 1.33 \ 1.08 ] \\ -0.22 \ [ 0.68 \ 0.25 ] \\ -0.12 \ [ 1.33 \ 1.08 ] \\ -0.22 \ [ 0.68 \ 0.25 ] \\ -0.42 \ [ 0.79 \ -0.06 ] \\ -0.48 \ [ -0.70 \ -0.27 ] \\ -0.48 \ [ -0.70 \ -0.27 ] \\ -0.48 \ [ -0.70 \ -0.27 ] \\ -0.48 \ [ -0.70 \ -0.27 ] \\ -0.48 \ [ -0.70 \ -0.27 ] \\ -0.48 \ [ -0.70 \ -0.27 ] \\ -0.48 \ [ -0.70 \ -0.27 ] \\ -0.48 \ [ -0.70 \ -0.27 ] \\ -0.48 \ [ -0.70 \ -0.27 ] \\ -0.68 \ [ -0.48 \ -0.50 \ -0.27 ] \\ -0.68 \ [ -0.48 \ -0.50 \ -0.27 ] \\ -0.68 \ [ -0.48 \ -0.50 \ -0.27 ] \\ -0.68 \ [ -0.48 \ -0.50 \ -0.27 ] \\ -0.68 \ [ -0.48 \ -0.4$	
-0.40018 0.248023 -1.08032 0.4184 -0.6703337 0.2103553 -0.1244 0.613101 -0.21561 0.238655 -1.509 0.234594 -0.42298 0.186871 -0.42298 0.186871 -0.42298 0.186871 -0.42298 0.186871 -0.42298 0.198671 -0.41026 0.199178 -0.41026 0.291396 -0.41026 0.255452 0.334565 0.255452 0.334565 0.255452 0.334565 0.255452 0.334566 0.255043 -1.269434 0.341429 -0.05448 0.343092 0 0.398661 -0.1398661 -0.1398661 -0.1398661 -0.1398661 -0.1398661 -0.1398661 -0.1398661 -0.1398661 -0.035569 0.2721303 -0.2557629 0.2721303 -0.2557629 0.2721303 -0.255675 0.457063 -0.21517 0.331326 -0.35560 0.256275 -0.13680 0.252153 -0.0355 0.425108 -0.2451160 -0.2451160 -0.2451160 -0.2451160 -0.2451160 -0.245116 -0.245160 -0.24516 -0.23667 0.224516	34 19 49 5 5 566 = 63% = 63% = 63% = 63% = 63% 103 103 103 103 103 103 103 103 103 103	32 11 49 5 33 30 52 25 51 30 25 51 30 25 51 30 25 51 30 25 51 30 25 51 30 33 30 20 25 33 30 20 25 33 30 20 25 475	$\begin{array}{c} 7\ 0\%\\ 4\ .3\%\\ 7\ .2\%\\ 8\ .2.5\%\\ 7\ .2\%\\ 8\ .2.5\%\\ 8\ .2\%$ .2\% .2\%\ .2\% .2\%\ .2\%\ .2\%\ .2\% .2\%\ .2\%\ .2\%\ .2\%\ .2\%\ .2\%\ .2\%\ .2\%\	-0.40 [0.89, 0.09] -1.09 [+31, 0.27] -0.67 [+1.08, -0.26] -0.12 [+1.33, 1.08] -0.22 [-0.68, 0.25] -1.51 [+1.97, -1.05] -0.42 [-0.79, -0.06] -0.48 [-0.79, -0.06] -0.48 [-0.79, -0.07] -0.48 [-0.79, -0.07] -0.48 [-0.79, -0.07] -0.48 [-0.34, 0.65] -0.34 [-0.53, 1.21] -0.34 [-0.53, 1.21] -0.34 [-0.53, 1.21] -0.34 [-0.53, 1.21] -0.36 [-0.34, 0.65] -0.06 [-0.74, 0.86] -0.06 [-0.74, 0.86] -0.06 [-0.74, 0.86] -0.06 [-0.74, 0.86] -0.39 [-1.46, -0.39] -0.57 [+1.46, 0.39] -0.57 [+1.46, 0.39] -0.57 [+1.46, 0.39] -0.57 [+1.46, 0.39] -0.57 [+1.46, 0.39] -0.28 [+1.38, -0.38] -0.38 [+1.38, -0.38] -0.46 [-0.71, 0.44] -0.44 [-0.87, -0.06] -0.46 [-0.87, -0.06] -0.46 [-0.87, -0.06] -0.46 [-0.87, -0.06] -0.46 [-0.87, -0.06] -0.46 [-0.41, 1.00]	
-1.08832 0.4184 -0.6703337 0.2103553 -0.1244 0.613101 -0.21581 0.238655 -1.509 0.234594 -0.42298 0.186871 ChP = 40.31, df = 15 (P = 0.0004); P -0.688667 0.291396 -0.41026 0.199178 0.41026 0.199178 0.41026 0.199178 0.41026 0.199178 0.343675 0.443639 -0.8324666 0.2550403 -1.269434 0.343092 -0.08448 0.343092 -0.0575697 0.2182642 0.1396861 -0.0575697 0.2182642 0.1396861 -0.0575697 0.2182642 -0.343675 -0.257629 0.2721303 -0.05625 0.457063 -0.256275 -0.331326 -0.03565 0.256275 -0.13688 0.292153 -0.0355 0.246316 -0.4619007 0.2061198 -0.20774 0.614402 -0.32617 0.239562	19 5 38 90 566 52 52 32 26 52 32 26 52 32 26 34 20 10 17 103 42 20 30 0 10 37 33 4 49 5 38	111 49 5 33 300 52 475 51 1 300 25 33 20 25 33 20 7 7 103 30 20 30 30 20 30 30 20 30 42 4 20 30 30 20 20 52 25 52 475 52 52 52 52 52 52 52 52 52 52 52 52 52	4.3% 7.8% 2.5% 7.2% 7.2% 8.2% 100.0% 4.5% 5.6% 3.9% 3.9% 3.9% 3.9% 3.9% 3.9% 4.2% 4.7% 4.2% 4.7% 4.0% 4.2% 5.5% 5.5%	$\begin{array}{c} -1.00 \ [+.01,-0.27]\\ -0.67 \ [+.00,-0.26]\\ -0.12 \ [+.133,-1.08]\\ -0.22 \ [+.08,-0.26]\\ -0.22 \ [+.08,-0.27]\\ -0.42 \ [+.07,-1.05]\\ -0.42 \ [+.07,-0.027]\\ -0.48 \ [+.07,-0.027]\\ -0.48 \ [+.07,-0.027]\\ -0.48 \ [+.07,-0.027]\\ -0.48 \ [+.07,-0.027]\\ -0.48 \ [+.07,-0.027]\\ -0.48 \ [+.07,-0.027]\\ -0.48 \ [+.08,-0.48]\\ -0.34 \ [+.05,-0.59]\\ -0.06 \ [+.04,-0.37]\\ -0.06 \ [+.04,-0.37]\\ -0.06 \ [+.04,-0.38]\\ -0.37 \ [+.146,-0.38]\\ -0.37 \ [+.146,-0.38]\\ -0.37 \ [+.146,-0.38]\\ -0.38 \ [+.138,-0.38]\\ -0.48 \ [+.07,-0.44]\\ -0.48 \ [+.03,-0.45]\\ -0.48 \ [+.07,-0.44]\\ -0.44 \ [+.057,-0.44]\\ -0.44 \ [+.057,-0.44]\\ -0.44 \ [+.057,-0.44]\\ -0.44 \ [+.057,-0.44]\\ -0.44 \ [+.041,-1.00]\\ -0.21 \ [+.141,-1.00]\\ -0.21$	
-0.6703337 0.2103553 -0.1244 0.613101 -0.21561 0.238655 -1.509 0.234594 -0.42298 0.186871 ChiP=40.31, df=15 (P=0.0004); P 33 (P<0.0001) -0.688667 0.291396 -0.41026 0.199178 -0.4566 0.255452 0.343675 0.25452 0.343675 0.25452 0.343675 0.2182642 -0.05484 0.343092 -0.06448 0.343092 -0.06448 0.343092 -0.06448 0.343092 -0.06448 0.343092 -0.0575697 0.2721303 -0.65625 0.457053 -0.21517 0.331326 -0.08039 0.292153 -0.0355 0.256275 -0.13688 0.292153 -0.0355 0.266275 -0.13688 0.292153 -0.0355 0.266275 -0.13688 0.292153 -0.0355 0.246316 -0.4619007 0.2061198 -0.20774 0.614402 -0.23617 0.238622 -1.55523 0.2234988	49 38 90 67 566 = 63% 25 52 32 26 34 20 17 103 42 20 30 10 30 30 31 4 9 5 32 32 32 32 34 34 20 30 30 4 9 5 33 34 49 5 33 34 33 34 33 34 33 34 33 34 33 34 33 34 33 34 33 34 34	49 5 33 30 52 475 51 30 25 51 30 25 53 320 17 7 103 30 0 0 0 0 10 36 8 34 42 20 320 30 0 20 55 25 51 33 20 20 52 25 51 33 0 25 52 25 51 33 20 25 52 25 51 33 0 25 52 25 51 33 0 25 52 55 51 33 0 25 52 55 51 33 0 25 55 55 55 55 55 55 55 55 55 55 55 55	7.8% 2.5% 7.2% 7.3% 8.2% 100.0% 4.5% 5.8% 4.9% 3.9% 6.3% 6.3% 6.3% 6.3% 6.3% 6.3% 6.3% 6.3	$\begin{array}{c} -0.67 \left[ + 0.08, -0.26 \right] \\ -0.12 \left[ + 1.33, + 0.08 \right] \\ -0.22 \left[ + 0.68, 0.25 \right] \\ -0.51 \left[ + 1.97, -1.05 \right] \\ -0.42 \left[ + 0.79, -0.06 \right] \\ -0.48 \left[ + 0.70, -0.27 \right] \\ \hline \\ -0.48 \left[ + 0.70, -0.27 \right] \\ -0.41 \left[ + 0.80, -0.02 \right] \\ -0.38 \left[ + 0.33, -0.33 \right] \\ -0.38 \left[ + 0.33, -0.33 \right] \\ -0.08 \left[ + 0.48, -0.37 \right] \\ -0.08 \left[ + 0.48, -0.37 \right] \\ -0.28 \left[ + 1.48, -0.38 \right] \\ -0.44 \left[ + 0.77 \right] \\ +0.48 \left[ + 0.38, -0.38 \right] \\ -0.44 \left[ + 0.77 \right] \\ -0.46 \left[ + 0.87, -0.06 \right] \\ -0.41 \left[ + 0.77 \right] \\ -0.46 \left[ + 0.57 \right] \\ -0.46 \left[ + 0.57 \right] \\ -0.46 \left[ + 0.41 \right] \\ -0.41 \left[ + 1.41 \right] \\ -0.01 \left[ + 1$	
-0.1244 0.613101 -0.21681 0.238655 -1.509 0.234594 -0.42298 0.186871 ChP = 40.31, df = 15 (P = 0.0004); P 33 (P < 0.0001) -0.6886667 0.291396 -0.41026 0.199178 0.153865 0.25452 0.343675 0.443639 -0.832666 0.2550403 -1.269434 0.3481429 -0.054568 0.2560403 -0.386661 0.2560403 -0.386661 0.2560403 -0.0575697 0.2182642 0.343075 -0.05468 0.255763 -0.056625 0.457763 -0.256775 0.457763 -0.256775 0.457763 -0.25677 0.331326 -0.0380 0.226175 -0.3868 0.225153 -0.03561 0.2261188 -0.246316 -0.4619007 0.246316 -0.4619007 0.246316	5 38 90 566 = 63% 25 52 26 52 26 52 26 32 26 32 26 32 26 32 26 32 20 30 30 30 31 42 20 30 30 31 42 20 30 31 42 55 55 52 32 26 52 32 26 57 52 32 26 57 52 52 32 26 57 52 52 52 52 52 52 52 52 52 52 52 52 52	5 33 300 52 475 21 300 25 33 200 107 103 422 200 300 100 36 34 32 20 30 100 36 34 32 20 30 100 36 34 32 20 34 32 20 34 30 34 30 34 30 34 30 34 30 30 30 30 30 30 30 30 30 30 30 30 30	2.5% 7.2% 7.2% 8.2% 100.0% 4.5% 3.0% 4.9% 3.9% 6.3% 5.3% 4.2% 4.2% 4.0% 4.0% 4.0% 4.0% 5.5% 5.0% 5.0%	$\begin{array}{c} -0.12 \ [+3,3,100]\\ -0.22 \ [+0.60,0.25]\\ -0.22 \ [+0.60,0.25]\\ -0.42 \ [+0.7,-1.05]\\ -0.42 \ [+0.7,-0.06]\\ -0.48 \ [-0.70,-0.27]\\ \hline \\ -0.48 \ [-0.70,-0.27]\\ -0.48 \ [-0.70,-0.27]\\ -0.41 \ [+0.80,-0.02]\\ -0.41 \ [+0.80,-0.02]\\ -0.41 \ [+0.80,-0.02]\\ -0.41 \ [+0.80,-0.02]\\ -0.41 \ [+0.80,-0.02]\\ -0.41 \ [+0.80,-0.02]\\ -0.41 \ [+0.80,-0.02]\\ -0.65 \ [+0.40,-0.39]\\ -0.57 \ [+1.46,-0.39]\\ -0.57 \ [+1.46,-0.39]\\ -0.57 \ [+1.46,-0.39]\\ -0.57 \ [+1.46,-0.39]\\ -0.57 \ [+1.46,-0.39]\\ -0.57 \ [+1.46,-0.39]\\ -0.48 \ [+0.71,-0.44]\\ -0.44 \ [+0.52,-0.45]\\ -0.44 \ [+0.52,-0.45]\\ -0.44 \ [+0.57,-0.06]\\ -0.41 \ [+1.41,-100]\\ -0.41 \ [+1.41,-100]\\ -0.21 \ [+1.41$	
-0.21581 0.238655 -1.509 0.234594 -0.42298 0.186871 Ch/P = 40.31, df = 15 (P = 0.0004); P 33 (P < 0.0001) -0.688667 0.291396 -0.41026 0.199178 0.153865 0.25452 0.343675 0.443639 -0.824666 0.255043 -1.268434 0.3481429 -0.06448 0.343092 0.01396861 -0.0575697 0.27121303 -0.66448 0.343092 0.2157629 0.2721303 -0.56625 0.457063 -0.21617 0.331326 -0.08039 0.292153 -0.0356 0.425153 -0.0356 0.292153 -0.03680 0.292153 -0.03661 0.226176 -0.4619007 0.246316 -0.4619007 0.246316	98 907 566 63% 25 26 26 26 26 32 26 32 26 34 34 20 107 103 30 30 30 30 30 30 30 30 30 49 5 38 38 38 38 38 38 38 38 38 38 38 38 38	33 30 52 475 25 51 30 25 33 20 107 103 42 20 30 10 30 6 34 42 42 32 43 5 5 5 1 5 5 1 5 5 1 33 3 5 5 5 1 33 3 5 5 5 5	7.2% 7.3% <b>100.0%</b> 4.5% 5.6% 4.9% 3.9% 6.3% 5.3% 4.2% 4.7% 2.9% 4.0% 4.5% 5.0% 5.0% 5.0% 5.2%	$\begin{array}{c} -0.22 \ (-0.68, 0.26) \\ -0.42 \ (-0.79, -0.06) \\ -0.44 \ (-0.79, -0.06) \\ -0.48 \ (-0.70, -0.27) \\ \hline \\ -0.48 \ (-0.70, -0.27) \\ -0.41 \ (-0.80, -0.02) \\ -0.41 \ (-0.80, -0.02) \\ -0.41 \ (-0.80, -0.02) \\ -0.41 \ (-0.80, -0.02) \\ -0.41 \ (-0.80, -0.02) \\ -0.41 \ (-0.80, -0.02) \\ -0.41 \ (-0.80, -0.02) \\ -0.41 \ (-0.80, -0.02) \\ -0.41 \ (-0.80, -0.02) \\ -0.41 \ (-0.80, -0.02) \\ -0.41 \ (-0.40, -0.02) \\ -0.41 \ (-0.40, -0.02) \\ -0.41 \ (-0.40, -0.02) \\ -0.41 \ (-0.40, -0.02) \\ -0.41 \ (-0.41, -0.04) \\ -0.41 \ (-0$	
$\begin{array}{c} -1.509 \\ 0.234/584 \\ -0.42298 \\ 0.186871 \\ -0.42298 \\ 0.186871 \\ -0.42298 \\ 0.186871 \\ -0.42298 \\ -0.42298 \\ -0.41026 \\ 0.291398 \\ -0.41026 \\ 0.251398 \\ 0.25452 \\ 0.343675 \\ 0.443639 \\ -0.343675 \\ 0.443639 \\ -0.343675 \\ 0.443639 \\ -0.343676 \\ 0.256403 \\ -0.343686 \\ 0.2560403 \\ -0.343986 \\ -0.34392 \\ -0.06448 \\ 0.34392 \\ -0.034392 \\ -0.34392 \\ -0.034392 \\ -0.34312 \\ -0.34312 \\ -0.32617 \\ -0.246316 \\ -0.4619007 \\ 0.226118 \\ -0.2261198 \\ -0.23617 \\ 0.23617 \\ 0.23616 \\ -0.33616 \\ -0.33616 \\ -0.246316 \\ -0.33616 \\ -0.246316 \\ -0.33617 \\ -0.33$	90 67 566 25 52 32 32 26 34 20 10 34 42 20 34 42 30 30 30 30 30 30 31 33 33 34 45 34 34 5 38 34 34 33	30 52 475 25 51 30 25 33 20 17 103 42 20 30 10 30 30 10 34 24 32 432 49 5	7.3% 8.2% 100.0% 4.5% 5.6% 4.9% 3.0% 4.9% 3.9% 6.3% 4.2% 4.2% 4.2% 4.0% 4.5% 5.0% 5.5% 5.0% 5.0%	-1.51 [+1.97, -1.05] -0.42 [-0.79, -0.06] -0.48 [-0.70, -0.27] -0.48 [-0.70, -0.27] -0.48 [-0.70, -0.27] -0.41 [-0.80, -0.02] -0.15 [-0.34, 0.65] -0.34 [-0.53, 1.21] -0.34 [-0.53, 1.21] -0.06 [-0.74, 0.61] -0.06 [-0.74, 0.61] -0.06 [-0.74, 0.61] -0.06 [-0.74, 0.61] -0.06 [-0.74, 0.61] -0.05 [-1.46, -0.39] -0.57 [-1.46, -0.39] -0.57 [-1.46, -0.39] -0.25 [-1.38, -0.38] -0.38 [-1.38, -0.38] -0.38 [-1.71, 0.44] -0.44 [-0.52, 0.45] -0.44 [-0.57, -0.06]	
$\begin{array}{c} -0.42298 & 0.186871 \\ \text{Ch} \ensuremath{\mathbb{P}}=40.31, df=15 \ensuremath{(\mathbb{P}}=0.0004); \ensuremath{\mathbb{P}}\\ 33 \ensuremath{(\mathbb{P}}=0.0001) \\ \hline \\ -0.6886657 & 0.291396 \\ -0.41026 & 0.199178 \\ 0.153965 & 0.24452 \\ 0.343675 & 0.443639 \\ -0.8324666 & 0.2550403 \\ -1.269434 & 0.3431429 \\ -0.06448 & 0.3431022 \\ -0.06448 & 0.343092 \\ -0.0575697 & 0.2182642 \\ 0.2 & 0.317059 \\ -0.0575697 & 0.2182642 \\ 0.2 & 0.317059 \\ -0.257629 & 0.2721303 \\ -0.256725 & 0.4457063 \\ -0.256725 & 0.246316 \\ -0.418009 & 0.256275 \\ -0.13688 & 0.292153 \\ -0.0355 & 0.246316 \\ -0.4618007 & 0.2061198 \\ -0.20774 & 0.614402 \\ -0.32617 & 0.239562 \\ -1.55523 & 0.234988 \\ \end{array}$	67 566 52 52 26 34 20 10 10 30 20 30 30 30 42 20 30 30 42 20 30 31 4 49 5 33 4 49 5 38	52 475 25 51 30 25 33 20 17 103 42 20 30 10 30 10 36 34 24 32 4 32 4 5 5	8.2% 100.0% 4.5% 5.6% 4.9% 3.9% 3.9% 3.9% 6.3% 6.3% 6.3% 4.2% 4.7% 2.9% 4.0% 4.5% 5.0% 5.0% 5.20%	-1.51 [+1.97, -1.05] -0.42 [-0.79, -0.06] -0.48 [-0.70, -0.27] -0.48 [-0.70, -0.27] -0.48 [-0.70, -0.27] -0.41 [-0.80, -0.02] -0.15 [-0.34, 0.65] -0.34 [-0.53, 1.21] -0.34 [-0.53, 1.21] -0.06 [-0.74, 0.61] -0.06 [-0.74, 0.61] -0.06 [-0.74, 0.61] -0.06 [-0.74, 0.61] -0.06 [-0.74, 0.61] -0.05 [-1.46, -0.39] -0.57 [-1.46, -0.39] -0.57 [-1.46, -0.39] -0.25 [-1.38, -0.38] -0.38 [-1.38, -0.38] -0.38 [-1.71, 0.44] -0.44 [-0.52, 0.45] -0.44 [-0.57, -0.06]	
$\label{eq:chi} \begin{split} & \text{Chi} = 40.31, df = 15 \ (P = 0.0004); P \\ & -0.61026 \ 0.199178 \\ & -0.41026 \ 0.199178 \\ & 0.153665 \ 0.25452 \\ & 0.343675 \ 0.443639 \\ & -0.343675 \ 0.443639 \\ & -0.324666 \ 0.2550403 \\ & -1.269434 \ 0.341429 \\ & -0.06448 \ 0.343092 \\ & 0 \ 0.1396861 \\ & -0.0575697 \ 0.2721303 \\ & -0.66462 \ 0.317059 \\ & -0.257629 \ 0.2721303 \\ & -0.65625 \ 0.457063 \\ & -0.21517 \ 0.331326 \\ & -0.3655 \ 0.245075 \\ & -0.36808 \ 0.292153 \\ & -0.0355 \ 0.246316 \\ & -0.461900 \ 0.2061198 \\ & -0.20774 \ 0.614402 \\ & -0.23617 \ 0.236162 \\ & -0.23662 \ 0.239662 \\ & -1.55523 \ 0.234988 \end{split}$	566 = 63% 25 52 32 26 34 20 10 17 103 20 30 10 30 10 31 32 32 34 49 5 38 38 38 38 38 38 38 38 38 38	475 51 30 25 33 20 17 103 42 20 30 10 36 34 24 32 4 32 45 5	4.5% 5.6% 4.9% 3.0% 4.9% 3.9% 6.3% 4.2% 4.7% 2.9% 4.7% 2.9% 4.5% 5.5% 5.0% 5.0%	$\begin{array}{c} -0.42 \ [ 0.79, -0.06 ] \\ -0.48 \ [ -0.70, -0.27 ] \\ \hline \\ -0.69 \ [ +1.26, -0.12 ] \\ -0.41 \ [ +0.80, -0.02 ] \\ -0.41 \ [ +0.80, -0.02 ] \\ -0.41 \ [ +0.80, -0.02 ] \\ -0.44 \ [ +0.53, 1.21 ] \\ -0.83 \ [ +1.3, -0.33 ] \\ -0.34 \ [ +0.53, 1.21 ] \\ -0.83 \ [ +1.36, -0.58 ] \\ -0.06 \ [ +0.74, 0.61 ] \\ -0.06 \ [ +0.74, 0.61 ] \\ -0.06 \ [ +0.74, 0.61 ] \\ -0.06 \ [ +0.74, 0.61 ] \\ -0.36 \ [ +1.46, -0.38 ] \\ -0.57 \ [ +1.46, -0.38 ] \\ -0.57 \ [ +1.46, -0.38 ] \\ -0.48 \ [ +1.38, -0.38 ] \\ -0.48 \ [ +1.38, -0.38 ] \\ -0.48 \ [ +1.71, 0.44 ] \\ -0.44 \ [ +0.52, 0.45 ] \\ -0.46 \ [ +0.57, -0.06 ] \\ -0.24 \ [ +1.41, 1.00 ] \\ -0.21 \ [ +1.41, 1.00$	
$\begin{array}{c} -0.688667 & 0.291396 \\ -0.41026 & 0.199178 \\ 0.153865 & 0.25452 \\ 0.343675 & 0.443639 \\ -0.824666 & 0.2550403 \\ -1.269434 & 0.3481429 \\ -0.06448 & 0.343092 \\ -0.06448 & 0.343092 \\ 0.032957629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.92617 & 0.2961188 \\ -0.20774 & 0.614402 \\ -0.32617 & 0.29662 \\ -1.55523 & 0.224898 \\ \end{array}$	= 63% 25 52 26 32 26 34 20 30 30 30 30 30 30 30 31 42 20 30 30 30 42 5 33 4 49 5 38 8 38	25 51 30 25 33 20 17 10 30 30 30 30 34 24 32 4 32 4 5	4.5% 5.6% 4.9% 3.0% 6.3% 6.3% 4.2% 4.7% 2.9% 4.0% 4.5% 5.5% 5.0% 5.0%	$\begin{array}{c} -0.69 \left[ +1.26, -0.12 \right] \\ -0.41 \left[ +0.80, -0.02 \right] \\ 0.15 \left[ +0.34 \right] \\ -0.63 \left[ +1.33, -0.33 \right] \\ -0.03 \left[ +1.35, -0.59 \right] \\ -0.06 \left[ +0.74 \right] \\ 0.06 \left[ +0.74 \right] \\ 0.06 \left[ +0.27, 0.27 \right] \\ -0.06 \left[ +0.49 \right] \\ 0.03 \left[ +1.46 \right] \\ -0.39 \left[ +1.46 \right] \\ -0.38 \left[ +1.38, -0.38 \right] \\ -0.45 \left[ +1.38, -0.38 \right] \\ -0.45 \left[ +1.71 \right] \\ -0.46 \left[ +0.37 \right] \\ -0.46 \left[ +1.71 \right] \\ -0.46 \left[ +0.37 \right] \\ -0.46 \left[ +1.38 \right] \\ -0.46 \left[ +0.57 \right] \\ -0.46 \left[ +1.41 \right] \\ -0.46 \left[ +1.41 \right] \\ -0.21 \left[ +1.41 $	
$\begin{array}{c} -0.688667 & 0.291396 \\ -0.41026 & 0.199178 \\ 0.153865 & 0.25452 \\ 0.343675 & 0.443639 \\ -0.824666 & 0.2550403 \\ -1.269434 & 0.3481429 \\ -0.06448 & 0.343092 \\ -0.06448 & 0.343092 \\ 0.032957629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.9257629 & 0.2721303 \\ -0.92617 & 0.2961188 \\ -0.20774 & 0.614402 \\ -0.32617 & 0.29662 \\ -1.55523 & 0.224898 \\ \end{array}$	25 52 32 34 20 177 103 42 20 300 100 30 30 30 30 30 42 33 4 49 5 38	51 30 25 33 20 17 103 42 20 30 10 36 34 24 34 24 34 5 5	5.6% 4.9% 3.0% 4.9% 3.9% 6.3% 4.2% 4.2% 4.2% 4.0% 4.0% 4.9% 4.5% 5.5% 5.5% 2.0%	$\begin{array}{c} -0.41 \ [ +0.80, -0.02] \\ 0.15 \ [ +0.24, 0.65] \\ 0.34 \ [ +0.53, 1.21] \\ -0.83 \ [ +1.33, -0.33] \\ -1.27 \ [ +1.95, -0.59] \\ -0.06 \ [ +0.74, 0.61] \\ 0.00 \ [ +0.27, 0.27] \\ -0.06 \ [ +0.49, 0.37] \\ 0.20 \ [ +0.49, 0.38] \\ -0.57 \ [ +1.46, -0.38] \\ -0.57 \ [ +1.46, -0.38] \\ -0.25 \ [ +0.86, 0.43] \\ -0.28 \ [ +1.38, -0.38] \\ -0.14 \ [ +0.71, 0.44] \\ -0.04 \ [ +0.52, 0.45] \\ -0.44 \ [ +0.57, -0.46] \\ -0.44 \ [ +0.57, -0.46] \\ -0.46 \ [ +0.57, -0.46] \\ -0.46 \ [ +0.47, -0.06] \\ \end{array}$	
-0.688667 0.291396 -0.41026 0.199178 0.153865 0.25452 0.343675 0.443639 -0.832466 0.2550403 -1.269434 0.3481429 -0.06448 0.343092 0.1396861 -0.0575697 0.2182642 0.2 0.317059 -0.9257629 0.2721303 -0.56625 0.457063 -0.21517 0.331326 -0.38039 0.256275 -0.13688 0.292153 -0.0355 0.2246316 -0.4619007 0.2061188 -0.226178 0.2946316	52 32 26 34 20 17 103 42 20 30 10 30 30 30 30 30 49 5 38 38	51 30 25 33 20 17 103 42 20 30 10 36 34 24 34 24 34 5 5	5.6% 4.9% 3.0% 4.9% 3.9% 6.3% 4.2% 4.2% 4.2% 4.0% 4.0% 4.9% 4.5% 5.5% 5.5% 2.0%	$\begin{array}{c} -0.41 \ [ +0.80, -0.02] \\ 0.15 \ [ +0.24, 0.65] \\ 0.34 \ [ +0.53, 1.21] \\ -0.83 \ [ +1.33, -0.33] \\ -1.27 \ [ +1.95, -0.59] \\ -0.06 \ [ +0.74, 0.61] \\ 0.00 \ [ +0.27, 0.27] \\ -0.06 \ [ +0.49, 0.37] \\ 0.20 \ [ +0.49, 0.38] \\ -0.57 \ [ +1.46, -0.38] \\ -0.57 \ [ +1.46, -0.38] \\ -0.25 \ [ +0.86, 0.43] \\ -0.28 \ [ +1.38, -0.38] \\ -0.14 \ [ +0.71, 0.44] \\ -0.04 \ [ +0.52, 0.45] \\ -0.44 \ [ +0.57, -0.46] \\ -0.44 \ [ +0.57, -0.46] \\ -0.46 \ [ +0.57, -0.46] \\ -0.46 \ [ +0.47, -0.06] \\ \end{array}$	
-0.41026 0.199178 0.153085 0.25452 0.343675 0.443639 -0.8324660 0.2550403 -1.269434 0.3431429 -0.06448 0.3431922 0 0.1396861 -0.0575697 0.2182542 0.2 0.317059 -0.9257629 0.2721303 -0.256725 0.245705 -0.356025 0.246316 -0.3880.292153 -0.0355 0.246316 -0.481000 0.2061198 -0.20774 0.614402 -0.32617 0.239562	52 32 26 34 20 17 103 42 20 30 10 30 30 30 30 30 49 5 38 38	51 30 25 33 20 17 103 42 20 30 10 36 34 24 34 24 34 5 5	5.6% 4.9% 3.0% 4.9% 3.9% 6.3% 4.2% 4.2% 4.2% 4.0% 4.0% 4.9% 4.5% 5.5% 5.5% 2.0%	$\begin{array}{c} -0.41 \ [ +0.80, -0.02] \\ 0.15 \ [ +0.24, 0.65] \\ 0.34 \ [ +0.53, 1.21] \\ -0.83 \ [ +1.33, -0.33] \\ -1.27 \ [ +1.95, -0.59] \\ -0.06 \ [ +0.74, 0.61] \\ 0.00 \ [ +0.27, 0.27] \\ -0.06 \ [ +0.49, 0.37] \\ 0.20 \ [ +0.49, 0.38] \\ -0.57 \ [ +1.46, -0.38] \\ -0.57 \ [ +1.46, -0.38] \\ -0.25 \ [ +0.86, 0.43] \\ -0.28 \ [ +1.38, -0.38] \\ -0.14 \ [ +0.71, 0.44] \\ -0.04 \ [ +0.52, 0.45] \\ -0.44 \ [ +0.57, -0.46] \\ -0.44 \ [ +0.57, -0.46] \\ -0.46 \ [ +0.57, -0.46] \\ -0.46 \ [ +0.47, -0.06] \\ \end{array}$	
-0.41026 0.199178 0.153085 0.25452 0.343675 0.443639 -0.8324660 0.2550403 -1.269434 0.3431429 -0.06448 0.3431922 0 0.1396861 -0.0575697 0.2182542 0.2 0.317059 -0.9257629 0.2721303 -0.256725 0.245705 -0.356025 0.246316 -0.3880.292153 -0.0355 0.246316 -0.481000 0.2061198 -0.20774 0.614402 -0.32617 0.239562	52 32 26 34 20 17 103 42 20 30 10 30 30 30 30 30 49 5 38 38	51 30 25 33 20 17 103 42 20 30 10 36 34 24 34 24 34 5 5	5.6% 4.9% 3.0% 4.9% 3.9% 6.3% 4.2% 4.2% 4.2% 4.0% 4.0% 4.9% 4.5% 5.5% 5.5% 2.0%	$\begin{array}{c} -0.41 \ [ +0.80, -0.02] \\ 0.15 \ [ +0.24, 0.65] \\ 0.34 \ [ +0.53, 1.21] \\ -0.83 \ [ +1.33, -0.33] \\ -1.27 \ [ +1.95, -0.59] \\ -0.06 \ [ +0.74, 0.61] \\ 0.00 \ [ +0.27, 0.27] \\ -0.06 \ [ +0.49, 0.37] \\ 0.20 \ [ +0.49, 0.38] \\ -0.57 \ [ +1.46, -0.38] \\ -0.57 \ [ +1.46, -0.38] \\ -0.25 \ [ +0.86, 0.43] \\ -0.28 \ [ +1.38, -0.38] \\ -0.14 \ [ +0.71, 0.44] \\ -0.04 \ [ +0.52, 0.45] \\ -0.44 \ [ +0.57, -0.46] \\ -0.44 \ [ +0.57, -0.46] \\ -0.46 \ [ +0.57, -0.46] \\ -0.46 \ [ +0.47, -0.06] \\ \end{array}$	
0.153865 0.25452 0.343675 0.443639 -0.8324666 0.2550403 -1.269434 0.3481429 -0.06448 0.343092 0 0.1396861 -0.0575697 0.2182642 0.2 0.317059 -0.9257629 0.2721303 -0.66625 0.457063 -0.21517 0.331326 -0.88039 0.256275 -0.13688 0.292153 -0.0355 0.246316 -0.4619007 0.2061198 -0.20774 0.614402 -0.32617 0.239562 -1.53523 0.224898	32 26 34 20 17 103 42 20 30 10 37 33 23 23 23 4 9 5 38	30 25 33 20 103 42 20 30 10 36 34 24 32 49 5	4.9% 3.0% 4.9% 3.9% 6.3% 4.2% 4.2% 4.0% 4.0% 4.9% 4.5% 5.0% 5.5% 2.0%	$\begin{array}{c} 0.15 \ [+0.34, 0.65]\\ 0.34 \ [+0.53, 1.21]\\ -0.83 \ [+1.33, -0.33]\\ +1.27 \ [+1.95, -0.59]\\ -0.06 \ [+0.74, 0.61]\\ 0.00 \ [+0.27, 0.27]\\ -0.06 \ [+0.49, 0.37]\\ 0.20 \ [+0.42, 0.82]\\ -0.39 \ [+1.46, 0.33]\\ -0.25 \ [+1.46, 0.33]\\ -0.25 \ [+1.46, 1.33]\\ -0.26 \ [+0.71, 0.44]\\ -0.04 \ [+0.52, 0.45]\\ -0.46 \ [+0.71, 0.44]\\ -0.04 \ [+0.52, 0.45]\\ -0.46 \ [+0.71, 0.44]\\ -0.46 \ [+0.87, -0.06]\\ -0.21 \ [+1.41, 1.00]\\ -0.21 \ [+1.41, $	
0.343675 0.443639 -0.832466 0.2550403 -1.269434 0.3481429 -0.06448 0.343092 0 0.1396861 -0.0575697 0.2182642 0.2 0.317059 -0.957629 0.2721303 -0.56625 0.457763 -0.21517 0.331326 -0.38039 0.256275 -0.3680 0.292153 -0.3568 0.292153 -0.325617 0.246316 -0.4619007 0.2061198 -0.20774 0.614402 -0.32617 0.239562	26 34 20 17 103 20 30 10 37 33 23 23 34 49 5 38	25 33 20 17 103 42 20 30 10 36 34 24 32 49 5	3.0% 4.9% 3.9% 6.3% 5.3% 4.2% 4.7% 4.9% 4.9% 4.9% 5.0% 5.5% 2.0%	$\begin{array}{c} 0.34 \ [ 0.53, 1.21 ] \\ -0.83 \ [ 1.33, -0.33 ] \\ -1.27 \ [ 1.95, -0.59 ] \\ -0.06 \ [ 0.74, 0.61 ] \\ 0.00 \ [ -0.27, 0.27 ] \\ -0.06 \ [ -0.49, 0.37 ] \\ -0.06 \ [ -0.49, 0.37 ] \\ -0.35 \ [ 1.46, -0.39 ] \\ -0.57 \ [ 1.46, -0.39 ] \\ -0.57 \ [ 1.46, -0.39 ] \\ -0.26 \ [ -0.86, 0.43 ] \\ -0.88 \ [ -1.38, -0.38 ] \\ -0.88 \ [ -1.38, -0.38 ] \\ -0.48 \ [ -0.71, 0.44 ] \\ -0.44 \ [ -0.27, -0.44 ] \\ -0.44 \ [ -0.57, -0.46 ] \\ -0.46 \ [ -0.47, -0.44 ] \\ -0.41 \ [ -1.41, 1.00 ] \\ -0.21 \ [ $	
-0.8324666 0.2550403 -1.269434 0.3481429 -0.06448 0.343092 0 0.3386861 -0.0575607 0.2182642 0.2 0.317059 -0.9257629 0.2721303 -0.56625 0.457063 -0.21517 0.331326 -0.88039 0.256275 -0.13688 0.292153 -0.0356 0.246316 -0.4619007 0.2061198 -0.2617 0.239562 -1.53523 0.224988	34 200 17 103 42 20 30 30 30 37 33 32 34 49 5 38	33 20 17 103 42 20 30 10 36 34 24 32 49 5	4.9% 3.9% 6.3% 6.3% 4.2% 4.7% 4.9% 4.0% 4.6% 5.0% 5.5% 2.0%	$\begin{array}{c} -0.83 \left[ +1.33 , -0.33 \right] \\ -1.27 \left[ +1.95 , -0.59 \right] \\ -0.06 \left[ +0.74 , 0.61 \right] \\ 0.00 \left[ +0.74 , 0.61 \right] \\ -0.06 \left[ -0.44 , 0.37 \right] \\ -0.06 \left[ -0.44 , 0.37 \right] \\ -0.39 \left[ +1.46 , 0.33 \right] \\ -0.39 \left[ +1.46 , 0.33 \right] \\ -0.22 \left[ +0.86 , 0.43 \right] \\ -0.88 \left[ +1.38 , -0.38 \right] \\ -0.14 \left[ +0.71 , 0.44 \right] \\ -0.04 \left[ +0.57 , 0.46 \right] \\ -0.46 \left[ -0.87 , -0.06 \right] \\ -0.45 \left[ +1.41 , 1.00 \right] \end{array}$	
-1.269434 0.3481429 -0.06448 0.343092 0 0.1396861 -0.0575697 0.2182642 0.2 0.317059 -0.9257629 0.2721303 -0.96625 0.457063 -0.21517 0.331326 -0.88039 0.292153 -0.0355 0.246316 -0.4619007 0.2061188 -0.20774 0.614402 -0.32617 0.239562 -1.53523 0.234898	20 17 103 42 20 30 10 37 33 33 23 34 49 5 38	20 17 103 42 20 30 10 36 34 24 32 49 5	3.9% 3.9% 6.3% 4.2% 4.2% 4.0% 4.0% 4.9% 4.5% 5.0% 5.5% 2.0%	$\begin{array}{c} -1.27\left[+1.95,-0.50\right]\\ -0.06\left[+0.74,0.81\right]\\ 0.00\left[+0.27,0.27\right]\\ -0.06\left[+0.44,0.37\right]\\ 0.20\left[-0.42,0.82\right]\\ -0.93\left[+1.46,-0.39\right]\\ -0.57\left[+1.46,0.33\right]\\ -0.22\left[+0.86,0.43\right]\\ -0.88\left[+1.38,-0.38\right]\\ -0.18\left[+0.71,0.44\right]\\ -0.04\left[+0.57,0.46\right]\\ -0.46\left[+0.87,-0.06\right]\\ -0.46\left[+0.47,0.06\right]\\ -0.21\left[+1.41,1.00\right]\end{array}$	
-0.06448 0.343092 0.1396861 -0.0575697 0.2182642 -0.9257629 0.2721303 -0.56625 0.457063 -0.21517 0.331326 -0.88039 0.256275 -0.13688 0.292153 -0.0355 0.246316 -0.4619007 0.2061198 -0.26774 0.614402 -0.32617 0.239562 -1.53523 0.224898	17 103 42 20 30 10 37 33 23 34 49 5 5 38	17 103 42 20 30 10 36 34 24 32 49 5	3.9% 6.3% 4.2% 4.7% 2.9% 4.0% 4.9% 4.5% 5.0% 5.5% 2.0%	$\begin{array}{c} -0.06 \left[ +0.74 + 0.61 \right] \\ -0.06 \left[ +0.27 + 0.27 \right] \\ -0.06 \left[ -0.49 + 0.37 \right] \\ -0.26 \left[ -0.42 + 0.82 \right] \\ -0.33 \left[ +1.46 + 0.39 \right] \\ -0.57 \left[ +1.46 + 0.33 \right] \\ -0.57 \left[ +1.46 + 0.33 \right] \\ -0.86 \left[ +1.38 + 0.38 \right] \\ -0.86 \left[ +1.38 + 0.38 \right] \\ -0.46 \left[ +0.57 + 0.04 \right] \\ -0.46 \left[ -0.57 + 0.06 \right] \\ -0.46 \left[ -0.57 + 0.06 \right] \\ -0.21 \left[ +1.41 + 1.00 \right] \end{array}$	
0 0.1398681 -0.0575697 0.2182642 0.2 0.317059 -0.9257629 0.2721303 -0.96625 0.457063 -0.21617 0.331326 -0.88039 0.256275 -0.13688 0.292153 -0.0355 0.246316 -0.4619007 0.2061198 -0.20774 0.614402 -0.32617 0.239562 -1.53523 0.224898	103 42 20 30 10 37 33 23 34 49 5 38	103 42 20 30 10 36 34 24 32 49 5	6.3% 5.3% 4.2% 4.7% 4.0% 4.9% 4.5% 5.0% 5.5% 2.0%	$\begin{array}{c} 0.00 \left[ -0.27,  0.27 \right] \\ -0.06 \left[ -0.49,  0.37 \right] \\ 0.20 \left[ -0.42,  0.82 \right] \\ -0.57 \left[ -1.46,  -0.39 \right] \\ -0.57 \left[ -1.46,  0.33 \right] \\ -0.22 \left[ -0.86,  0.43 \right] \\ -0.88 \left[ -1.38,  -0.38 \right] \\ -0.14 \left[ -0.71,  0.44 \right] \\ -0.04 \left[ -0.57,  0.06 \right] \\ -0.46 \left[ -0.87,  -0.06 \right] \\ -0.21 \left[ -1.41,  1.00 \right] \\ -0.21 \left[ -1.41,  1.00 \right] \end{array}$	
-0.0575697 0.2182642 0.2 0.317059 -0.9257629 0.2721303 -0.56625 0.457063 -0.21617 0.331326 -0.380039 0.256275 -0.13688 0.292153 -0.0355 0.226318 -0.4619007 0.2061188 -0.20774 0.614402 -0.32617 0.239562 -1.53523 0.234898	42 20 30 10 37 33 23 34 49 5 38	42 20 30 36 34 24 32 49 5	5.3% 4.2% 2.9% 4.0% 4.9% 4.5% 5.0% 5.5% 2.0%	-0.06 [-0.49, 0.37] 0.20 [-0.42, 0.82] -0.93 [-1.46, 0.39] -0.57 [-1.46, 0.33] -0.22 [-0.86, 0.43] -0.88 [-1.38, -0.38] -0.14 [-0.71, 0.44] -0.04 [-0.57, -0.06] -0.21 [-1.41, 1.00]	
0.2 0.317059 -0.9257629 0.2721303 -0.56625 0.457063 -0.21617 0.331326 -0.80039 0.256275 -0.13608 0.292153 -0.0355 0.246316 -0.4619007 0.2061188 -0.20774 0.614402 -0.32617 0.239562 -1.53523 0.224898	20 30 10 37 33 23 34 49 5 38	20 30 36 34 24 32 49 5	4.2% 4.7% 2.9% 4.0% 4.5% 5.0% 5.5% 2.0%	0.20 [-0.42, 0.82] -0.93 [-1.46, -0.39] -0.57 [-1.46, 0.33] -0.22 [-0.86, 0.43] -0.88 [-1.38, -0.38] -0.14 [-0.71, 0.44] -0.04 [-0.52, 0.45] -0.46 [-0.87, -0.06] -0.21 [-1.41, 1.00]	
-0.9257629 0.2721303 -0.56625 0.457063 -0.21617 0.331326 -0.88039 0.256275 -0.13680 0.292153 -0.0355 0.246316 -0.4619007 0.2061188 -0.20774 0.614402 -0.32617 0.238662 -1.53523 0.234898	30 10 37 33 23 34 49 5 38	30 10 36 34 24 32 49 5	4.7% 2.9% 4.0% 4.9% 4.5% 5.0% 5.5% 2.0%	-0.93 [-1.46, -0.39] -0.57 [-1.46, 0.33] -0.22 [-0.86, 0.43] -0.88 [-1.38, -0.38] -0.14 [-0.17, 0.44] -0.04 [-0.52, 0.45] -0.46 [-0.87, -0.06] -0.21 [-1.41, 1.00]	
-0.56625 0.457063 -0.21517 0.31326 -0.80039 0.256275 -0.13688 0.292153 -0.0355 0.246316 -0.4619007 0.2061198 -0.20774 0.611402 -0.32617 0.239562 -1.53523 0.224898	10 37 33 23 34 49 5 38	10 36 34 24 32 49 5	2.9% 4.0% 4.9% 4.5% 5.0% 5.5% 2.0%	-0.57 [-1.46, 0.33] -0.22 [-0.86, 0.43] -0.88 [-1.38, -0.38] -0.14 [-0.71, 0.44] -0.04 [-0.52, 0.45] -0.46 [-0.87, -0.06] -0.21 [-1.41, 1.00]	
-0.21517 0.331326 -0.88039 0.256275 -0.13668 0.292153 -0.0355 0.246316 -0.4619007 0.2061198 -0.20774 0.614402 -0.32617 0.239562 -1.53523 0.234498	37 33 23 34 49 5 38	36 34 24 32 49 5	4.0% 4.9% 4.5% 5.0% 5.5% 2.0%	-0.22 [-0.86, 0.43] -0.88 [-1.38, -0.38] -0.14 [-0.71, 0.44] -0.04 [-0.52, 0.45] -0.46 [-0.87, -0.06] -0.21 [-1.41, 1.00]	
-0.88039 0.256275 -0.13688 0.292153 -0.0355 0.246316 -0.4619007 0.2061198 -0.20774 0.614402 -0.32617 0.239562 -1.53523 0.234898	33 23 34 49 5 38	34 24 32 49 5	4.9% 4.5% 5.0% 5.5% 2.0%	-0.88 [-1.38, -0.38] -0.14 [-0.71, 0.44] -0.04 [-0.52, 0.45] -0.46 [-0.87, -0.06] -0.21 [-1.41, 1.00]	
-0.13688 0.292153 -0.0355 0.246316 -0.4619007 0.2061198 -0.20774 0.614402 -0.32617 0.239562 -1.53523 0.234898	23 34 49 5 38	24 32 49 5	4.5% 5.0% 5.5% 2.0%	-0.14 [-0.71, 0.44] -0.04 [-0.52, 0.45] -0.46 [-0.87, -0.06] -0.21 [-1.41, 1.00]	
-0.0355 0.246316 -0.4619007 0.2061198 -0.20774 0.614402 -0.32617 0.239562 -1.53523 0.234898	34 49 5 38	32 49 5	5.0% 5.5% 2.0%	-0.04 [-0.52, 0.45] -0.46 [-0.87, -0.06] -0.21 [-1.41, 1.00]	
-0.4619007 0.2061198 -0.20774 0.614402 -0.32617 0.239562 -1.53523 0.234898	49 5 38	49 5	5.5% 2.0%	-0.46 [-0.87, -0.06] -0.21 [-1.41, 1.00]	
-0.20774 0.614402 -0.32617 0.239562 -1.53523 0.234898	5 38	5	2.0%	-0.21 [-1.41, 1.00]	
-0.32617 0.239562 -1.53523 0.234898	38				
-1.53523 0.234898		- 33			
	90		5.1%	-0.33 [-0.80, 0.14]	
		30	5.1%	-1.54 [-2.00, -1.07]	
-0.3846 0.315461	21	20	4.2%	-0.38 [-1.00, 0.23]	
-0.46855 0.187335	67	52	5.7%	-0.47 [-0.84, -0.10]	
Chi² = 67.24, df = 21 (P < 0.00001); I	808 = 69%	721	100.0%	-0.41 [-0.61, -0.21]	-
05 (P < 0.0001)					
-0.68667 0.291396	25	25	5.5%	-0.69 [-1.26, -0.12]	
-0.15526 0.207721	47	46	6.7%	-0.16 [-0.56, 0.25]	+
0.269263 0.255319	32	30	6.0%	0.27 [-0.23, 0.77]	- <b>+</b>
0.40991 0.396514	26	25	4.2%	0.41 [-0.37, 1.19]	
-0.3170632 0.2621029	30	29	5.9%	-0.32 [-0.83, 0.20]	
0.064483 0.343092	17	17	4.8%	0.06 [-0.61, 0.74]	
					+
					<b>_</b>
					<b>←</b>
					<b>_</b>
					<b>_</b>
					<b>←</b>
					[
-0.38772 0.338513					•
		507		SILE [ 0.11, 0.00]	-
96 (P = 0.05)	- 03 %				
-0.18852 0.207873	47	46	19.0%	-0.19 [-0.60, 0.22]	
	50	50	20.6%	0.07 [-0.32, 0.46]	
0.418611 0.498642	26	25	3.3%	0.42 [-0.56, 1.40]	
	23	24	9.4%		+
-0.08951 0.246423	34	32	13.6%		
	49				
	38	33			
	267			-0.07 [-0.25, 0.11]	◆
Chi <sup>2</sup> = 5.42. df = 6 (P = 0 49) <sup>1</sup> I <sup>2</sup> = 0%					-
79 (P = 0.43)					
					-2 -1 0 1
	0.160396 0.139913 0.160396 0.13913 0.094281 0.200113 0.15842 0.200113 0.15842 0.204322 0.013364 0.246302 0.013364 0.246302 0.2818715 0.2086496 0.1177483 0.2464029 0.118174 0.672952 0.207975 0.220795 0.118174 0.672952 0.338513 ChIP = 54 0.6, df = 17 (P < 0.00001); I 6 (P = 0.05) -0.18852 0.207873 0.067957 0.20059 0.418611 0.498642 -0.48652 0.25733 -0.08951 0.246423 -0.06951 0.246423 -0.063177 0.2035704 ChIP = 542, df = 6 (P = 0.49); P = 0%	0.160366 0.139913 103 0.1 0.316436 20 0.094281 0.200113 50 -1.58842 0.518687 110 -0.3865 0.294322 23 0.019384 0.246302 34 0.281877 0.2086466 49 0.1177493 0.2464029 33 -1.16174 0.872952 5 0.004905 0.237948 38 -1.25 0.227075 90 -0.59772 0.338513 14 646 ChIP = 54.06, df = 17 (P < 0.00001); P = 69% 16 (P = 0.05) -0.18852 0.207873 47 0.067957 0.200059 50 0.418611 0.498642 26 -0.48652 0.29773 23 -0.08951 0.246423 34 -0.2083177 0.204587 49 0.232167 0.238704 38 267 ChIP = 5.42, df = 6 (P = 0.49); P = 0%	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

# Figure 5. Forest plot of comparison: | Pain, outcome: 1.2 Pain - Time points. P for trend = 0.001

Intra-articular corticosteroid for knee osteoarthritis (Review)

 $\textbf{Copyright} @ 2015 \textbf{ The Cochrane Collaboration. Published by John Wiley \& Sons, Ltd. \\$ 

Table 1 presents the results of stratified analyses. We found little or no evidence for an association of SMDs with corticosteroid dosages, ultrasound guidance, local anesthetic, crystalline preparation, type of control intervention, financial support, publication type, concealment of allocation, adequate blinding of participants or therapists, or intention-to-treat analysis ( $P \ge 0.10$ ). There was some evidence of lower treatment effects in trials that randomised on average at least 50 participants per group (P = 0.05), or in trials that used viscosupplementation as a co-intervention (P = 0.08). There was strong evidence of lower treatment effects in trials that randomised on average at least 100 participants per group (P = 0.013), or in trials that used joint lavage as a co-intervention ( $P \le 0.001$ ).

#### Knee function

Figure 6 presents results of the overall analysis of knee function

reported closest to four to six weeks after end of treatment. Corticosteroids were more effective in function improvement than control interventions (SMD -0.33, 95% CI -0.56 to -0.09), which corresponds to a difference in functions scores of -0.7 units on standardised WOMAC disability scale ranging from 0 to 10. This corresponds to a difference in improvement of 13% (95% CI 4% to 22%) between corticosteroids and sham injection (Summary of findings for the main comparison), which translates into a NNTB to cause one additional treatment response on function of 10 (95% CI 7 to 33) (Summary of findings for the main comparison). An I <sup>2</sup> statistic of 69% indicated a moderate to large degree of betweentrial heterogeneity (P for heterogeneity < 0.001). A visual inspection of the funnel plot suggested asymmetry (asymmetry coefficient -4.07, 95% CI -8.08 to -0.05), and the test for asymmetry showed evidence for asymmetry (P = 0.047) (Figure 7).

Figure 6. Forest plot of comparison: 2 Function, outcome: 2.1 Function - Main.

Study or Subgroup	Std. Mean Difference	الا SE	A Corticosteroid Total		Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
Beyaz 2012	-1.09887	0.304267	25				IV, Randolli, 55% Cl
Campos 2013	-0.0041622	0.304207	52		7.9%		
Castro 2007	0.275871	0.255377	32		6.9%		
			32		6.7%		
Chao 2010	-0.972491	0.2669457					
Di Sante 2012	-0.4867452	0.321119	20		5.9%		
Gaffney 1995	0.208693	0.218826	42		7.5%		
Henriksen 2015	0.099827	0.200127	50		7.9%		
Lyons 2005	-1.130546	0.4852872	10	10	3.8%	-1.13 [-2.08, -0.18]	← → → → → → → → → → → → → → → → → → → →
Petrella 2015	0.006267	0.246184	33	33	7.1%	0.01 [-0.48, 0.49]	
Popov 1989	-1.088324	0.4184004	19	11	4.6%	-1.09 [-1.91, -0.27]	
Ravaud 1999	-0.3433526	0.2039811	49	49	7.8%	-0.34 [-0.74, 0.06]	
Raynauld 2003	0.06595	0.246252	33	33	7.1%	0.07 [-0.42, 0.55]	
Smith 2003	-0.31211	0.239426	38	33	7.2%	-0.31 [-0.78, 0.16]	
Yavuz 2012	-0.8096383	0.2178688	90	30	7.6%	-0.81 [-1.24, -0.38]	
Young 2001	-0.1579081	0.3129516	21	20	6.0%	-0.16 [-0.77, 0.46]	
Total (95% CI)			546	468	100.0%	-0.33 [-0.56, -0.09]	•
Heterogeneity: Tau <sup>2</sup> =	0.15; Chi <sup>2</sup> = 45.88, df =	14 (P < 0.0001	): I <sup>2</sup> = 69%				
Test for overall effect:							-2 -1 0 1 2
restion overall effect.	2 = 2.10 (1 = 0.001)						Favours corticosteroid Favours control

Figure 7. Contour-enhanced funnel plot for effects on knee function. Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs




Figure 8 presents results stratified according to length of followup. Benefits were small to moderate at 1 to 2 weeks after end of treatment (SMD -0.43, 95% CI -0.72 to -0.14), small at 4 to 6 weeks (SMD -0.36, 95% CI -0.63 to -0.09), no effect at 13 weeks (SMD -0.13, 95% CI -0.37 to 0.10), and no effect at 26 weeks (SMD 0.06, 95% CI -0.16 to 0.28). An I<sup>2</sup> statistic of  $\geq 62\%$ indicated a moderate to large degree of between-trial heterogeneity up to 13 weeks after end of treatment (P for heterogeneity  $\leq$ 0.004), and an I<sup>2</sup> of 0% indicated low heterogeneity at 26 weeks (P = 0.52).

			IA Corticosteroid			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Std. Mean Difference	SE	Tota	l Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
2.2.1 Function - 1-2							
Beyaz 2012		0.3154034	25		8.6%	-1.37 [-1.99, -0.75]	
Campos 2013	-0.6479	0.20129	52		11.3%	-0.65 [-1.04, -0.25]	
Di Sante 2012		0.3166154	20		8.6%	0.14 [-0.48, 0.76]	
Gaffney 1995	-0.00000005	0.218218	42		10.9%	-0.00 [-0.43, 0.43]	
Henriksen 2015		0.2001271	50		11.3%	0.10 [-0.29, 0.49]	
Petrella 2015	-0.3737276		34		10.2%	-0.37 [-0.86, 0.11]	
Popov 1989		0.4184004	19		6.6%	-1.09 [-1.91, -0.27]	
Ravaud 1999	-0.3461974		49		11.2%	-0.35 [-0.75, 0.05]	
Smith 2003	-0.17322	0.238404	38		10.4%	-0.17 [-0.64, 0.29]	
Yavuz 2012 Subtotal (95% CI)	-0.8881221	0.2192932	90 419		10.9% <b>100.0</b> %	-0.89 [-1.32, -0.46] - <b>0.43 [-0.72, -0.14]</b>	•
	= 0.15; Chi² = 32.02, df = : Z = 2.95 (P = 0.003)	9 (P = 0.000)	2); I² = 72%				
2.2.2 Function - 4-6 (	weeks						
Beyaz 2012	-1.098872	0.304267	25	i 25	7.6%	-1.10 [-1.70, -0.50]	
Campos 2013	-0.0041622	0.1970754	52	: 51	9.8%	-0.00 [-0.39, 0.38]	+
Castro 2007	0.275871	0.255377	32	: 30	8.6%	0.28 [-0.22, 0.78]	- <b>+</b>
Chao 2010	-0.97491	0.2669457	32	: 31	8.4%	-0.97 [-1.50, -0.45]	
Di Sante 2012	-0.48675	0.321119	20	20	7.3%	-0.49 [-1.12, 0.14]	
Gaffney 1995	0.208693	0.218826	42	. 42	9.4%	0.21 [-0.22, 0.64]	
Lyons 2005	-1.130546	0.4852872	10	10	4.8%	-1.13 [-2.08, -0.18]	← → ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
Petrella 2015	0.006267	0.2461836	33	33	8.8%	0.01 [-0.48, 0.49]	
Ravaud 1999	-0.3433526	0.2039811	49	49	9.7%	-0.34 [-0.74, 0.06]	
Smith 2003	-0.31211	0.239426	38	33	8.9%	-0.31 [-0.78, 0.16]	
Yavuz 2012	-0.8096383	0.2178688	90		9.4%	-0.81 [-1.24, -0.38]	
Young 2001 Subtotal (95% Cl)	-0.1579081	0.3129516	21 444		7.5% 100.0%	-0.16 [-0.77, 0.46] - <b>0.36 [-0.63, -0.09]</b>	•
	= 0.15; Chi <sup>2</sup> = 36.55, df =	11 (P = 0.00)				,,	-
Test for overall effect	: Z = 2.66 (P = 0.008)						
2.2.3 Function - 3 m	onths						
Beyaz 2012	-1.03859	0.302053	25	i 25	7.7%	-1.04 [-1.63, -0.45]	
Campos 2013	-0.0017	0.2074024	47	46	10.5%	-0.00 [-0.41, 0.40]	<b>_</b>
Castro 2007	0.38238	0.256519	32	: 30	9.0%	0.38 [-0.12, 0.89]	+
Chao 2010	-0.3785	0.275428	25	i 29	8.4%	-0.38 [-0.92, 0.16]	
Henriksen 2015	0.0083189	0.2000009	50	50	10.7%	0.01 [-0.38, 0.40]	+
Lyons 2005	-0.2928758	0.4498696	10	10	4.9%	-0.29 [-1.17, 0.59]	
Petrella 2015	0.0596708	0.2463526	34	32	9.3%	0.06 [-0.42, 0.54]	
Ravaud 1999	0.0550258	0.2024998	49	49	10.6%	0.06 [-0.34, 0.45]	<b>+</b>
Raynauld 2003	0.0659503	0.246252	33	33	9.3%	0.07 [-0.42, 0.55]	<b>-</b>
Smith 2003	0.168646	0.23838	38	33	9.5%	0.17 [-0.30, 0.64]	- <b>+</b> •
Yavuz 2012	-0.730327	0.2164402	90		10.2%	-0.73 [-1.15, -0.31]	
Subtotal (95% CI)	0.00.052 00.40 K	40.00 0.00	433	367	100.0%	-0.13 [-0.37, 0.10]	-
Heterogeneity: I au*: Test for overall effect	= 0.09; Chi <sup>2</sup> = 26.10, df = : Z = 1.10 (P = 0.27)	10 (P = 0.00)	4); IT = 62%				
2.2.4 Function - 6 m							
Campos 2013	-0.0657285		47		28.5%	-0.07 [-0.47, 0.34]	
Petrella 2015	-0.0155596		34		20.2%	-0.02 [-0.50, 0.47]	
Ravaud 1999		0.2024608	49		29.9%	0.01 [-0.39, 0.41]	<b>+</b>
Smith 2003	0.373922	0.240069	38		21.3%	0.37 [-0.10, 0.84]	<b></b>
Subtotal (95% CI)			168	160	100.0%	0.06 [-0.16, 0.28]	<b>•</b>
	= 0.00; Chi² = 2.24, df = 3	(P = 0.52); I <sup>a</sup>	*= 0%				
Test for overall effect	: Z = 0.54 (P = 0.59)						

## Figure 8. Forest plot of comparison: 2 Function, outcome: 2.2 Function - Time points. P for trend = 0.011

Test for subgroup differences: Chi<sup>2</sup> = 9.57, df = 3 (P = 0.02), I<sup>2</sup> = 68.7%

Table 2 presents the results of stratified analyses. We found little or no evidence for an association of SMDs with corticosteroid dosages, ultrasound guidance, local anaesthetic, crystalline preparation, joint lavage as a co-intervention, financial support, concealment of allocation, adequate blinding of participants or therapists, or intention-to-treat analysis ( $P \ge 0.10$ ). There was some evidence of lower treatment effects in trials that randomised on average at least 50 participants per group (P = 0.023), in unpublished trials (P = 0.023), in trials that used no intervention as control (P =0.031), or in trials that used intra-articular viscosupplementation as a co-intervention (P = 0.06).

#### Secondary outcomes

Figure 9 presents results of the overall analysis on quality of life reported closest to four to six weeks after end of treatment. Corticosteroids had no effect on quality of life compared to control interventions (SMD -0.01, 95% CI -0.30 to 0.28). An I<sup>2</sup> statistic of 0% indicated a low degree of between-trial heterogeneity (P for heterogeneity = 0.96). Figure 10 presents results of the overall

-1 0 1 Favours conticosteroid Favours control 2

analysis on joint space narrowing reported closest to four to six weeks after end of treatment. Corticosteroids had no effect in joint space narowing compared to control interventions (SMD -0.02, 95% CI -0.49 to 0.46). An I<sup>2</sup> statistic was not estimable because only one trial was included in this analysis. There was not enough data to report results according to the pre-specified time points neither for quality of life nor joint space narrowing outcomes.

Figure 9. Forest plot of comparison: 3 Quality of life, outcome: 3.1 Quality of life - Main.

Study or Subgroup	Std. Mean Difference	SE	IA Corticosteroid Total		Weight	Std. Mean Difference IV, Random, 95% CI			lean Differe andom, 95%			
Gaffney 1995	0	0.218218	42	42	45.7%	0.00 [-0.43, 0.43]						
Henriksen 2015	-0.01571	0.200003	50	50	54.3%	-0.02 [-0.41, 0.38]						
Total (95% CI)			92	92	100.0%	-0.01 [-0.30, 0.28]			•			
Heterogeneity: Tau² : Test for overall effect	= 0.00; Chi² = 0.00, df = 1 :: Z = 0.06 (P = 0.95)	(P = 0.96);	I <sup>2</sup> = 0%				-2 Fav	-1 ours corticoste	o o eroid Favo	urs contri	ol	2

#### Figure 10. Forest plot of comparison: 7 Joint space narrowing, outcome: 7.1 Joint space narrowing - Main.

			IA Corticosteroid	Control		Std. Mean Difference	Std. Mean Differen	ce
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Random, 95% Cl	IV, Random, 95%	CI
Raynauld 2003	-0.0184	0.242541	34	34	100.0%	-0.02 [-0.49, 0.46]		
Total (95% CI)			34	34	100.0%	-0.02 [-0.49, 0.46]	-	
Heterogeneity: Not ap Test for overall effect:							-2 -1 0 Favours corticosteroid Favour	1 2 s control

Figure 11 presents results of the overall analysis on number of participants experiencing any type of adverse event. We included 2 trials with a total of 84 participants and 46 events in this analysis. Participants on corticosteroids were 11% less likely to experience adverse events, but confidence intervals included the null effect (RR 0.89, 95% CI 0.64 to 1.23). An I<sup>2</sup> statistic of 0% indicated a low degree of between-trial heterogeneity (P for heterogeneity = 0.44). Due to the imprecision in results, we were not able to calculate meaningful NNTHs.

## Figure 11. Forest plot of comparison: 4 Number of participants experiencing any adverse event, outcome: 4.1 Number of participants experiencing any adverse event - Main.




Figure 12 presents results of the overall analysis on number of participants who withdraw because of adverse events. We included 2 trials with a total of 204 participants and 5 events in this analysis. Participants on corticosteroids were 67% less likely to withdraw because of adverse events, but confidence intervals were wide and included the null effect (RR 0.33, 95% CI 0.05 to 2.07). An I<sup>2</sup> statistic of 0% indicated a low degree of between-trial heterogeneity (P for heterogeneity = 1.00). Due to the imprecision in results, we were not able to calculate meaningful NNTHs.

# Figure 12. Forest plot of comparison: 5 Number of participants who withdraw because of adverse events, outcome: 5.1 Number of participants who withdraw because of adverse events -Main.

	IA Corticost	eroid	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Campos 2013	0	52	1	52	33.0%	0.33 [0.01, 8.00]	
Henriksen 2015	1	50	3	50	67.0%	0.33 [0.04, 3.10]	
Total (95% CI)		102		102	100.0%	0.33 [0.05, 2.07]	
Total events	1		4				
Heterogeneity: Tau² = Test for overall effect			= 1 (P = 1	.00); l²:	= 0%		0.01 0.1 1 10 100 Favours corticosteroid Favours control

Figure 13 presents results of the overall analysis on number of participants experiencing serious adverse events. We included 5 trials with a total of 331 participants and 8 events in this analysis. Participants on corticosteroids were 27% less likely to withdraw because of adverse events, but confidence intervals were wide and included the null effect (RR 0.63, 95% CI 0.15 to 2.67). An I<sup>2</sup> statistic of 0% indicated a low degree of between-trial heterogeneity (P for heterogeneity = 0.46). Due to the imprecision in results, we were not able to calculate meaningful NNTHs.

# Figure 13. Forest plot of comparison: 6 Number of participants experiencing any serious adverse event, outcome: 6.1 Number of participants experiencing any serious adverse event - Main.

	IA Corticosteroid Control		ol	Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Henriksen 2015	1	50	3	50	42.1%	0.33 [0.04, 3.10]	
Lyons 2005	0	10	0	10		Not estimable	
Ozturk 2006	0	23	0	24		Not estimable	
Petrella 2015	2	33	2	33	57.9%	1.00 [0.15, 6.68]	
Ravaud 1999	0	49	0	49		Not estimable	
Total (95% CI)		165		166	100.0%	0.63 [0.15, 2.67]	
Total events	3		5				
Heterogeneity: Tau <sup>2</sup> =	= 0.00; Chi <sup>2</sup> = 0	).54, df=	= 1 (P = 0	.46); I <sup>z</sup> :	= 0%		
Test for overall effect:	Z=0.63 (P=	0.53)					0.01 0.1 1 10 100 Favours corticosteroid Favours control

#### Quality of the evidence (GRADE)

We graded the quality of the evidence as 'low' for all outcomes because treatment effect estimates were inconsistent with great variation across trials, pooled estimates were imprecise and did not rule out relevant or irrelevant clinical effects, and because most trials had a high or unclear risk of bias.

## DISCUSSION

## Summary of main results

In this update of the systematic review and meta-analysis by Bellamy (Bellamy 2006), we found most of the identified trials that compared intra-articular corticosteroids with sham or non-intervention control to be small and hampered by low methodological quality, and graded the quality of evidence for the major outcomes as 'low'. Only one trial was considered large according to our prespecified criteria (Fri as 2004), with an average sample size of 100 participants or more per group, but this trial did not report adequate randomisation, participant blinding, or an intention-totreat analysis. Conversely, only one trial reported adequate randomisation, participant blinding, and an intention-to-treat analysis (Henriksen 2015), but it was of moderate size only. An analysis of multiple time points suggested that effects decrease over time  $(P \le 0.011)$ , and our analysis provides no evidence that an effect remains six months after a corticosteroid injection. Whether there are clinically important benefits after one to six weeks remains unclear in view of the overall quality of the evidence. A single trial included in this review described adequate measures to consistently minimise biases (Henriksen 2015); this trial did not find any benefit of intra-articular corticosteroids (SMD 0.04, 95% CI -0.43 to 0.35).

## Quality of the evidence

The overall analyses of pain and function were difficult to interpret in view of the large extent of heterogeneity between trials. Stratified analyses suggested an association of estimates of treatment effects with sample size ( $P \le 0.05$ ), and funnel plots appeared asymmetrical, even though the accompanying asymmetry test was positive only for function (P = 0.047). Stratified analyses according to components of methodological quality showed negative interaction tests. Conversely, trials with protocol-mandated concomitant lavage or viscosupplementation treatment in both experimental and control groups appeared to show smaller benefits of corticosteroids as compared with control.

The largest trial used joint lavage as concomitant treatment in all participants (Fri as 2004). It therefore ultimately remains unclear whether the lack of treatment effect in this trial is a function of

study size in the presence of small-study effects (Nüesch 2010), or a function of the concomitant use of joint lavage, which may act as an effect modifier even in the absence of a specific therapeutic effect (Reichenbach 2010). However, among the three largest trials, which included at least 50 participants per group, only one used lavage (Fri as 2004), another used viscosupplementation as concomitant treatment (Campos 2013), and the third used neither (Henriksen 2015). When pooling these moderate-to-large trials, we found only a small, clinically irrelevant, and statistically nonsignificant effect on pain and function with a low degree of heterogeneity.

For other clinical characteristics including the use of ultrasound to guide injections, crystalline preparations, and prednisone equivalent doses, we did not find a treatment by subgroup interaction. Only two trials used ultrasound guidance to ensure proper placement of needles (Di Sante 2012, Henriksen 2015), however contradictory results and insufficient data are available to determine whether ultrasound guidance is associated with larger treatment effects.

## Potential biases in the review process

We based our review on an extensive literature search, and so it seems unlikely that we missed relevant trials, provided that they were published as full-text articles or accessible in conference proceedings or trial registries (Egger 2003). Two review authors independently performed selection of trials and data extraction in order to reduce bias and transcription errors (Egger 2001; Gøtzsche 2007). We are therefore confident that potential biases during the review process were minimised.

# Agreements and disagreements with other studies or reviews

Our update of the previous systematic review and meta-analysis by Bellamy identified 14 new trials that compared intra-articular corticosteroids with sham or non-intervention control (Bellamy 2006). In view of the overall body of evidence, we are as confident as Bellamy et al that no effect of intra-articular corticosteroids remains after six months, but are less confident than Bellamy that there is a clinically relevant short-term effect in view of large heterogeneity and possible small-study effects.

The most recent systematic review and network meta-analysis on intra-articular corticosteroids in knee osteoarthritis (Bannuru 2015), carried out in August 2014, identified seven trials comparing intra-articular corticosteroids to intra-articular placebo, all of which we included in our analysis. Again, we are less confident than these authors that there is a clinically relevant shortterm effect of intra-articular corticosteroids considering the issues described above.

## AUTHORS' CONCLUSIONS

## Implications for practice

It remains unclear whether there are clinically important benefits one to six weeks after corticosteroid injection in view of the low quality of the included trials, the large amount of heterogeneity, and the likely presence of small-study effects (Nüesch 2010). Intra-articular corticosteroids should therefore be considered experimental in knee osteoarthritis and not be routinely used until adequately powered and properly designed trials clearly indicate a short- to mid-term benefit.

## Implications for research

An adequately designed, multicentre, randomised, double-blind, sham-controlled, parallel-group trial is required to confirm or refute clinically relevant short- to mid-term benefits of intra-articular corticosteroids in knee osteoarthritis. A sample size of 100 participants per group would yield 80% power to detect a clinically meaningful moderate effect size of 0.4 standard deviation units in terms of pain reduction. The trial should use ultrasound guidance to ensure intra-articular needle placement as recently described by Henriksen et al (Henriksen 2015).

## ACKNOWLEDGEMENTS

We acknowledge Dr. med. Marcello Di Nisio for his contribution with reference screening. We are grateful to Dr. Janne Estill and Elena Jüni for their translation of the Popov 1989 trial. We would also like to acknowledge the authors of the original version of this review: Nicholas Bellamy, Jane Campbell, Vivian Welch, Travis L Gee, Robert Bourne, and George A Wells.

## REFERENCES

#### References to studies included in this review

#### Beyaz 2012 {published data only}

\* Beyaz S G. Comparison of efficacy of intra-articular morphine and steroid in patients with knee osteoarthritis. *Journal of Anaesthesiology Clinical Pharmacology* 2012;**28**(4): 496–500.

## Campos 2013 {published data only}

Campos G C. Evaluation of the effect of adding corticosteroid to viscosupplementation: A prospective and randomized study. *Osteoarthritis and Cartilage* 2011;**19**: S236.

Campos G C, Rezende M U, Fruchi R, Pasqualin T, Hissadomi M I. Adding triamcinolone to viscosupplementation: One year outcome of randomized trial. *Osteoarthritis and Cartilage* 2014;**22**:S198.

\* Campos G C, Rezende M U, Pailo A F, Frucchi R, Camargo O P. Adding triamcinolone improves viscosupplementation: A randomized clinical trial. *Clinical Orthopaedics and Related Research* 2013;**471**(2):613–20. Campos G C, Rezende M U, Pailo A F, Frucchi R, Pasqualin T. Evaluation of the effect of adding corticosteroid to viscosupplementation: A prospective and randomized study. *Osteoarthritis and Cartilage* 2012;**20**:S169–70.

#### Castro 2007 {published data only}

\* Castro M, Font P, Escudero A, Frias G, Mun oz E, Collantes E. Evaluation of effectiveness of five modalities of intraarticular treatment in patients with osteoarthritis of the knee. *Annals of the Rheumatic Diseases* 2007;**66(Suppl II)**:515.

#### Cederlof 1966 {published data only}

\* Cederlof S, Jonson G. Intraarticular prednisolone injection for osteoarthritis of the knee. A double blind test with placebo. *Acta Chirurgica Scandinavica* 1966;**132**(5):532–7.

#### Chao 2010 {published data only}

\* Chao J, Wu C, Sun B, Hose M K, Quan A, Hughes T H, et al. Inflammatory characteristics on ultrasound predict poorer long-term response to intraarticular corticosteroid injections in knee osteoarthritis. *Journal of Rheumatology* 2010;**37**(3):650–5.

Chao J, Wu C, Sun B, Hose M, Quan A, May S, et al. Inflammatory characteristics on ultrasound predict poorer long-term response to intraarticular corticosteroid injections in knee osteoarthritis. *Osteoarthritis and Cartilage* 2009;**17**: \$153.

#### Dieppe 1980 {published data only}

\* Dieppe P A, Sathapatayavongs B, Jones H E. Intraarticular steroids in osteoarthritis. *Rheumatology and Rehabilitation* 1980;**19**(4):212–7.

## Di Sante 2012 {published data only}

\* Di Sante L, Paoloni M, Dimaggio M, Colella L, Cerino A, Bernetti A, et al. Ultrasound-guided aspiration and corticosteroid injection compared to horizontal therapy for treatment of knee osteoarthritis complicated with Baker's cyst: a randomized controlled trial. *European Journal of Physical & Rehabilitation Medicine* 2012;**48**(4):561–7.

#### Fri as 2004 {published data only}

\* Fri as G, Caracuel M A, Escudero A, Rumbao J, Pe

<sup>r</sup> rez-Gujo V, Carmen Castro M, et al. Assessment of the efficacy of joint lavage versus joint lavage plus corticoids in patients with osteoarthritis of the knee. *Current Medical Research and Opinion* 2004;**20**(6):861–7.

## Friedman 1980 {published data only}

\* Friedman D M, Moore M E. The efficacy of intraarticular steroids in osteoarthritis: A double-blind study. *Journal of Rheumatology* 1980;7(6):850–6.

#### Gaffney 1995 {published data only}

\* Gaffney K, Ledingham J, Perry J D. Intra-articular triamcinolone hexacetonide in knee osteoarthritis: Factors influencing the clinical response. *Annals of the Rheumatic Diseases* 1995;**54**(5):379–81.

## Grecomoro 1992 {published data only}

\* Grecomoro G, Piccione F, Letizia G. Therapeutic synergism between hyaluronic acid and dexamethasone in the intra-articular treatment of osteoarthritis of the knee: a preliminary open study. *Current Medical Research and Opinion* 1992;**13**(1):49–55.

## Henriksen 2015 {published data only}

\* Henriksen M, Christensen R, Klokker L, Bartholdy C, Bandak E, Ellegaard K, et al. Evaluation of the benefit of corticosteroid injection before exercise therapy in patients with osteoarthritis of the knee. A randomized clinical trial. *JAMA Internal Medicine* 2015;**175**(6):923–30. [DOI: 10.1001/jamainternmed.2015.0461]

## Jones 1996 {published data only}

\* Jones A, Doherty M. Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response. *Annals of the Rheumatic Diseases* 1996;**55**(11): 829–32.

## Lyons 2005 {published data only}

\* Lyons C, Majeed A, Banarsee R. Effectiveness of high volume intra-articular injection of cortisone and lignocaine in osteoarthritis of the knee. Pilot study. *North & West London journal of general practice: NWLJGP* 2005;**11(1)**: 23–8.

#### Miller 1958 {published data only}

\* Miller J H, White J, Norton T H. The value of intraarticular injections in osteoarthritis of the knee. *Journal of Bone & Joint Surgery - British Volume* 1958;**40-B**(4):636–43.

#### NCT00414427 {published data only}

\* NCT00414427. Using ultrasound to predict response to intraarticular corticosteroids in knee osteoarthritis. ClinicalTrials.gov (acessed 19 October 2015).

## Ozturk 2006 {published data only}

\* Ozturk C, Atamaz F, Hepguler S, Argin M, Arkun R. The safety and efficacy of intraarticular hyaluronan with/ without corticosteroid in knee osteoarthritis: 1-year, singleblind, randomized study. *Rheumatology International* 2006; **26**(4):314–9.

#### Petrella 2015 {published data only}

Petrella R J, Eamans P, Alleyne J, Maroney M. A prospective, multi-center, randomized, double-blind feasibility study to evaluate the safety and performance of hydros joint therapy and hydros-ta joint therapy for management of pain associated with osteoarthritis in the knee. *Osteoarthritis and Cartilage* 2012;**20**:S172–3.

\* Petrella R J, Emans P J, Alleyne J, Dellaert F, Gill D P, Maroney M. Safety and performance of Hydros and Hydros-TA for knee osteoarthritis. A prospective, multicenter, randomized, double-blind feasibility trial. *BMC Musculoskeletal Disorders* 2015;**16:57**:1–9.

#### Popov 1989 {published data only}

\* Popov V V, Bunchuk N V, Apenysheva N P. Treatment of patients with gonarthrosis by intra-articular administration of drugs. *Klinicheskaia Meditsina (Moskva)* 1989;**67**(4): 104–8.

#### Ravaud 1999 {published data only}

\* Ravaud P, Moulinier L, Giraudeau B, Ayral X, Guerin C, Noel E, et al. Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. *Arthritis & Rheumatology* 1999;**42**(3):475–82.

#### Raynauld 2003 {published data only}

\* Raynauld J P, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. [Erratum appears in Arthritis & Rheumatology 2003; Nov;48(11):3300]. *Arthritis & Rheumatology* 2003; **48**(2): 370–7.

## Schue 2011 {published data only}

\* Schue J R. Treatment of knee osteoarthritis with intraarticular infliximab may improve knee function and reduce synovial inflitration by macrophages: Proceedings of the ACR 2011 Conference. American College of Theumatology. 2011.

#### Smith 2003 {published data only}

\* Smith M D, Wetherall M, Darby T, Esterman A, Slavotinek J, Roberts-Thomson P, et al. A randomized placebo-controlled trial of artroscopic lavage versus lavage plus intra-articular corticosteroids in the management of symptomatic osteoarthritis of the knee. *Rheumatology* 2003; **42**(12):1477–85.

Smith M, Wetherall M, Roberts-Thomson P, Ahem M. Is intra-articular depot corticosteroid treatment effective in symptomatic osteoarthritis of the knee joint? [abstract]. *Australian and New Zealand Journal of Medicine* 2000;**30** (4):527.

#### Wright 1960 {published data only}

Wright V, Chandler G N, Morison R A, Hartfall S J. Intra-articular therapy in osteo-arthritis; comparison of hydrocortisone acetate and hydrocortisone tertiarybutylacetate. *Annals of the Rheumatic Diseases* 1960;**19**: 257–61.

#### Yavuz 2012 {published data only}

\* Yavuz U, Sokucu S, Albayrak A, Ozturk K. Efficacy comparisons of the intraarticular steroidal agents in the patients with knee osteoarthritis. *Rheumatology International* 2012;**32**(11):3391–6.

#### Young 2001 {published data only}

\* Young L, Katrib A, Cuello C, Vollmer-Conna U, Bertouch J V, Roberts-Thomson P J, et al. Effects of intraarticular glucocorticoids on macrophage infiltration and mediators of joint damage in osteoarthritis synovial membranes: findings in a double-blind, placebo-controlled study. *Arthritis & Rheumatism* 2001;44(2):343–50.

#### Zhilyayev 2012 {published data only}

\* Zhilyayev E, Zagrebneva A, Glazunov A, Glazunov P, Alkhimenko T. Efficacy of intraarticular and periarticular glucocorticoid injections in patients with knee osteoarthritis: A randomized double-blind study. *International Journal of Rheumatic Diseases* 2012;**15**:95.

## References to studies excluded from this review

#### Abdulla 2013 {published data only}

Abdulla A, Adams N, Bone M, Elliott A M, Gaffin J, Jones D, et al. Guidance on the management of pain in older people. *Age and Ageing* 2013;**42 Suppl** 1:i1–57.

## Anonymous 1978 {published data only}

Anonymous. Intra-articular steroids. *British Medical Journal* 1978;**1**:600–1.

## Anonymous 2011 {published data only}

Anonymous. Knee osteoarthritis. [Original report in American Family Physician. 2011 Jun 1;83(11):1287-92; PMID: 21661710]. *American Family Physician* 2011;**83**: 1294.

### Arroll 2004 {published data only}

Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the knee: meta-analysis. *BMJ* 2004;**328**: 869.

#### Arroll 2005 {published data only}

Arroll B, Goodyear-Smith F, Shoor S. Review: Intraarticular corticosteroid injections are better than placebo for improving symptoms of knee osteoarthritis. *Evidence-Based Medicine* 2005;**10**:23.

#### Avouac 2010 {published data only}

Avouac J, Vicaut E, Bardin T, Richette P. Efficacy of joint lavage in knee osteoarthritis: Meta-analysis of randomized controlled studies. *Rheumatology* 2010;**49**:334–40.

#### Baker 1969 {published data only}

Baker D M, Burland W L. Intra-articular injection of corticosteroid for degenerative arthritis. *Practitioner* 1969; **202**:431–2.

#### Bannuru 2013 {published data only}

Bannuru R R, McAlindon T E, Wong J B, Kent D, Schmid C. Comparative effectiveness of pharmacological interventions for knee osteoarthritis: A network metaanalysis. *Arthritis and Rheumatism* 2013;**65**:S915–6.

## Bannuru 2014 {published data only}

Bannuru R R, Schmid C H, Sullivan M C, Kent D M, Wong J B, McAlindon T E. Differential response of placebo treatments in osteoarthritis trials: A systematic review and network meta-analysis. *Osteoarthritis and Cartilage* 2014; **22**:S24–5.

#### Bannuru 2015 {published data only}

Bannuru R R, Schmid C H, Kent D M, Vaysbrot E E, Wong J B, McAlindon T E. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: A systematic review and network meta-analysis. *Annals of Internal Medicine* 2015;**162**:46–54.

#### Baratham 2010 {published data only}

Baratham A, Lukert B P, Lindsley H B. Effects of intraarticular (IA) corticosteroid injections on bone markers and endogenous cortisol in patients with knee osteoarthritis (OA), a pilot study. *Arthritis and Rheumatism* 2010;**62**:943.

## Bellamy 2005 {published data only}

Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. *Cochrane Database of Systematic Reviews* 2005, Issue 2. [DOI: 10.1002/14651858.CD005328.pub2]

## Bellamy 2006 {published data only}

Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. *Cochrane Database of Systematic Reviews* 2006, Issue 2. [: DOI: 10.1002/14651858.CD005328.pub2]

#### Bennell 2012 {published data only}

Bennell K L, Hunter D J, Hinman R S. Management of osteoarthritis of the knee. BMJ (Online) 2012;345:1–8.

#### Bjordal 2007 {published data only}

Bjordal J M, Klovning A, Ljunggren A E, Slordal L. Shortterm efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. *European Journal of Pain* 2007;**11**: 125–38.

#### Blanke 2008 {published data only}

Blanke M, Gusinde J, Dobre A, Brem M H. Treatment of knee osteoarthritis. *MMW Fortschritte der Medizin* 2008; **150**:26-9; quiz 30.

#### Bourne 1985 {published data only}

Bourne I H. Injecting painful knees with triamcinolone. *Practitioner* 1985;**229**:33–4.

## Brys 2004 {published data only}

Brys D A. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. *Journal of Bone & Joint Surgery - American Volume* 2004;**86-**A:874; author reply 874-5.

#### Canillas 2011 {published data only}

Canillas M, Kandavanam R, Reilly K. Do intra-articular (IA) steroid injections relieve pain and improve outcomes beyond two weeks for patients with osteoarthritis (OA) of the knee. *Journal - Oklahoma State Medical Association* 2011;**104**:262–3.

## Cats 1979b {published data only}

Cats A, JA I J, Davinova Y, Werthauer-Rodrigues Pereira M, Blakemore C B, Steiner F J. The efficacy of intra-articularly administered MYC 2095, triamcinolone hexacetonide and placebo in gonarthritis. A combined double-blind clinical trial. *Scandinavian Journal of Rheumatology* 1979;**8**: 199–203.

#### Charalambous 2004 {published data only}

Charalambous C P. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. *Journal of Bone & Joint Surgery - American Volume* 2004;**86-A**:874; author reply 874.

Intra-articular corticosteroid for knee osteoarthritis (Review)

#### Cheng 2012 {published data only}

Cheng O T, Souzdalnitski D, Vrooman B, Cheng J. Evidence-based knee injections for the management of arthritis. *Pain Medicine (United States)* 2012;**13**:740–53.

#### Courtney 2009 {published data only}

Courtney P, Doherty M. Editorial: Intra-articular corticosteroid injection for osteoarthritis. *International Journal of Clinical Rheumatology* 2009;**4**:621–5.

#### Douglas 2012 {published data only}

Douglas R J. Corticosteroid injection into the osteoarthritic knee: drug selection, dose, and injection frequency. *International Journal of Clinical Practice* 2012;**66**:699–704.

#### Gait 2014 {published data only}

Gait A D, Hodgson R, Cootes T F, Marjanovic E J, Parkes M, O'Neill T W, et al. Late synovial enhancement detects effects of intraarticular steroids on synovitis better than synovial volume. *Osteoarthritis and Cartilage* 2014;**22**: S240–1.

#### Garg 2013 {published data only}

Garg N, Deodhar A. A systematic review of comparative efficacy of various corticosteroid preparations for intraarticular and soft tissue injections. *Annals of the Rheumatic Diseases* 2013;**72**:A720.

#### Garg 2014 {published data only}

Garg N, Perry L, Deodhar A. Intra-articular and soft tissue injections, a systematic review of relative efficacy of various corticosteroids.. *Clinical Rheumatology* 2014;**33**:1695–706.

#### Gerlag 2008a {published data only}

Gerlag D M, Tak P P. Prolonged effect of intra-articularly administered corticosteroids in combination with arthroscopic lavage in patients with an inflammatory arthritis of the knee [Verlenging van het effect van intra-articulair toegediende corticosteroiden door combinatie hiervan met artroscopische lavage bij patienten met een inflammatoire artritis van de knie]. *Nederlands Tijdschrift Voor Geneeskunde* 2008;**152**:1953–5.

#### Godwin 2004 {published data only}

Godwin M, Dawes M. Intra-articular steroid injections for painful knees. Systematic review with meta-analysis. *Canadian Family Physician* 2004;**50**:241–8.

#### Habib 2009 {published data only}

Habib G S. Systemic effects of intra-articular corticosteroids. *Clinical Rheumatology* 2009;**28**:749–56.

#### Habib 2010 {published data only}

Habib G S, Saliba W, Nashashibi M. Local effects of intraarticular corticosteroids. *Clinical Rheumatology* 2010;**29**: 347–56.

#### Hepper 2009 {published data only}

Hepper C T, Halvorson J J, Duncan S T, Gregory A J M, Dunn W R, Spindler K P. The efficacy and duration of intraarticular corticosteroid injection for knee osteoarthritis: A systematic review of level I studies. *Journal of the American Academy of Orthopaedic Surgeons* 2009;**17**:638–46.

#### Hirsch 2013 {published data only}

Hirsch G, Kitas G, Klocke R. Intra-articular corticosteroid injection in osteoarthritis of the knee and hip: factors predicting pain relief--a systematic review. *Seminars in Arthritis & Rheumatism* 2013;**42**:451–73.

## Ivanov 1981 {published data only}

Ivanov B A, Koliago S A. Use of hydrocortisone in treating arthrosis deformans of the extremities. *Voenno-Meditsinskii Zhurnal* 1981, (6):56–7.

## Jarner 1992 {published data only}

Jarner D, Aaboe T, Andersen L A. Intra-articular indomethacin versus triamcinolone hexacetonide injections in osteoarthritis and hydrarthrosis. *Scandinavian Journal of Rheumatology. Supplement* 1992;**93**:67.

#### Jones 1993 {published data only}

Jones A, Regan M, Ledingham J, Pattrick M, Manhire A, Doherty M. Importance of placement of intra-articular steroid injections. *BMJ* 1993;**307**:1329–30.

#### Jones 2014 {published data only}

Jones T, Kelsberg G, Safranek S. FPIN's clinical inquiries: Intra-articular corticosteroid injections for osteoarthritis of the knee. *American Family Physician* 2014;**90**:115–6.

## Keagy 1967 {published data only}

Keagy R D, Keim H A. Intra-articular steroid therapy: repeated use in patients with chronic arthritis. *American Journal of the Medical Sciences* 1967;**253**:45–51.

#### Khitrov 1997 {published data only}

Khitrov N A, Silvestrov V P, Tsurko V V. A comparative evaluation of local therapy methods in treating osteoarthrosis deformans. *Terapevticheskii Arkhiv* 1997;**69**:53–4.

## Kizilkaya 2004 {published data only}

Kizilkaya M, Yildirim O S, Dogan N, Kursad H, Okur A. Analgesic effects of intraarticular sufentanil and sufentanil plus methylprednisolone after arthroscopic knee surgery. *Anesthesia and Analgesia* 2004;**98**(4):1062–5.

#### Kizilkaya 2005 {published data only}

Kizilkaya M, Yildirim O S, Ezirmik N, Kursad H, Karsan O. Comparisons of analgesic effects of different doses of morphine and morphine plus methylprednisolone after knee surgery. *European Journal of Anaesthesiology* 2005;**22** (8):603–8.

#### Koyonos 2009 {published data only}

Koyonos L, Yanke A B, McNickle A G, Kirk S S, Kang R W, Lewis P B, et al. A randomized, prospective, double-blind study to investigate the effectiveness of adding DepoMedrol to a local anesthetic injection in postmeniscectomy patients with osteoarthritis of the knee. *American Journal of Sports Medicine* 2009;**37**(6):1077–82.

#### Krause 1971 {published data only}

Krause W. Intra-articular steroid therapy in knee joint diseases. *Medizinische Welt* 1971;**46**:1841–5.

#### Legre-Boyer 2015 {published data only}

Legre-Boyer V. Viscosupplementation: Techniques, indications, results.. *Orthop Traumatol Surg Res* 2015;**9**: \$101–108.

#### Lequesne 1970 {published data only}

Lequesne M, Bensasson M, Kemmer C, Amouroux J. Painful juxtameniscal areas in certain arthropathies of the knee and their treatment by juxtameniscal cortisone infiltration. *Annals of the Rheumatic Diseases* 1970;**29**:689.

#### Maricar 2013 {published data only}

Maricar N, Parkes M J, Callaghan M J, Felson D T, O'Neill T W. A systematic review of where and how to inject in the knee?. *Osteoarthritis and Cartilage* 2013;**21**:S300.

#### Maricar 2013c {published data only}

Maricar N, Callaghan M J, Felson D T, O'Neill T W. Predictors of response to intra-articular steroid injections in knee osteoarthritis-a systematic review. *Rheumatology* (*United Kingdom*) 2013;**52**:1022–32.

#### Maricar 2014 {published data only}

Maricar N, Parkes M J, Forsythe L M, Felson D T, O'Neill T W. Do psychological factors predict response to intraarticular steroid therapy in knee osteoarthritis?. *Osteoarthritis and Cartilage* 2014;**22**:S381.

## McAlindon 2014 {published data only}

McAlindon T E, Bannuru R R, Sullivan M C, Arden N K, Berenbaum F, Bierma-Zeinstra S M, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis and Cartilage* 2014;**22**:363–88.

#### Murdoch 1959 {published data only}

Murdoch W R, Will G. Prednisolone trimethylacetate in intra-articular therapy. *British Medical Journal* 1959;1: 1267–70.

#### Murdoch 1959a {published data only}

Murdoch W R, Will G. Synovial fluid changes in intraarticular therapy: effect of prednisolone trimethylacetate. *British Medical Journal* 1959;**1**:1271–4.

#### Neame 2003 {published data only}

Neame R L, Doherty M. Managing osteoarthritis. *Practitioner* 2003;**247**:768-70, 773, 775.

#### Nicol 1972 {published data only}

Nicol W J, Sarkin T L. Indications for intra-articular steroid in osteo-arthritis of the knee. *South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde* 1972;**46**:379.

#### No named author {published data only}

Steroid injections effective for knee osteoarthritis. *Journal of Family Practice* 2004;**53**:606.

## No named author a {published data only}

Intraarticular injections in gonarthrosis [Intraartikulare injektionen bei gonarthrose]. *Pharma-Kritik* 2006;**28**:1–2.

#### No named author b {published data only}

Intra-articular injections for osteoarthritis of the knee. Medical Letter on Drugs and Therapeutics 2006;48:25-7.

## No named author c {published data only}

Corticosteroids for knee OA. *Pharmaceutical Journal* 2004; **272**:465.

#### Parmigiani 2010 {published data only}

Parmigiani L, Furtado R N V, Lopes R V, Ribeiro L H C, Natour J. Joint lavage associated with triamcinolone

hexacetonide injection in knee osteoarthritis: A randomized double-blind controlled study. *Clinical Rheumatology* 2010; **29**:1311–5.

#### Pendleton 2008 {published data only}

Pendleton A, Millar A, O'Kane D, Wright G D, Taggart A J. Can sonography be used to predict the response to intraarticular corticosteroid injection in primary osteoarthritis of the knee?. *Scandinavian Journal of Rheumatology* 2008;**37**: 395–7.

## Punzi 2001 {published data only}

Punzi L. Intra-articular sodium hyaluronate reduces pain and improves function in osteoarthritis of knee. *Clinical* and Experimental Rheumatology 2001;**19**:9–10.

#### Rasmussen 1998 {published data only}

Rasmussen S, Larsen A S, Thomsen S T, Kehlet H. Intraarticular glucocorticoid reduces pain, inflammatory response and convalescence after arthroscopic meniscectomy [abstract]. *Acta Orthopaedica Scandinavica* 1998;**69**(Suppl 282):53–4.

## Rasmussen 1998a {published data only}

Rasmussen S, Larsen A S, Thomsen S T, Kehlet H. Intraarticular glucocorticoid, morphine and bupivacaine reduces pain, inflammatory response and convalescence after arthroscopic meniscectomy [abstract]. *Acta Orthopaedica Scandinavica* 1998;**69**(Suppl 280):45.

#### Rasmussen 1998b {published data only}

Rasmussen S, Larsen A S, Thomsen S T, Kehlet H. Intra-articular glucocorticoid, bupivacaine and morphine reduces pain, inflammatory response and convalescence after arthroscopic meniscectomy [abstract]. *Pain* 1998;**78**: 131–4.

#### Reshetov 2000 {published data only}

Reshetov P P, Tverdokhleb I P, Bezmenov V A. The use of hydrocortisone combined with ultrasound with gonarthrosis patients. *Voprosy Kurortologii, Fizioterapii, i Lechebnoi Fizicheskoi Kultury* 2000, (4):47–8.

## Ronchetti 2001 {published data only}

Ronchetti I P, Guerra D, Taparelli F, Boraldi F, Bergamini G, Mori G, et al. Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis. *Rheumatology* 2001;**40**:158–69.

#### Roskos 2005 {published data only}

Roskos S E. Intra-articular corticosteroid for treating osteoarthritis of the knee. *American Family Physician* 2005; **72**:1222–3.

#### Saito 1971 {published data only}

Saito H, Asai H, Nakamura R. Effect of intra-articular injection of steroid in deforming arthrosis of the knee. *Seikei Geka - Orthopedic Surgery* 1971;**22**:612–4.

## Shah 1967 {published data only}

Shah K D, Wright V. Intra-articular hydrocortisone in osteo-arthrosis. *Annals of the Rheumatic Diseases* 1967;**26**: 316–8.

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright  $\textcircled{\sc 0}$  2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### Sheldon 1973 {published data only}

Sheldon P, Beer T C. Synovitis of the knee treated by intraarticular hydrocortisone acetate, hydrocortisone acetate plus saline, or saline alone. A double-blind trial. *Rheumatology and Rehabilitation* 1973;**12**:37–41.

## Stein 1996 {published data only}

Stein A, Helmke K, Szopko C, Stein C, Yassouridis A. Intraarticular morphine versus steroid application in gonarthrosis and arthritis in case of acute painful joint [Intraartikulare morphin – versus steroidapplikation bei gonarthrose und arthritis im akut schmerzhaften gelenk]. *Deutsche Medizinische Wochenschrift* 1996;**121**:255.

#### Stitik 2006 {published data only}

Stitik T P, Kumar A, Foye P M. Corticosteroid injections for osteoarthritis. *American Journal of Physical Medicine & Rehabilitation* 2006;**85**:S51-65; quiz S66.

#### Stojanovic 1969 {published data only}

Stojanovic I, Spasojevic L, Koturovic L, Josipovic D. Our results in treatment of gonarthrosis. *Reumatizam* 1969;**16**: 65–9.

## Talke 1986 {published data only}

Talke M. Intra-articular corticoid therapy with triamcinolone hexacetonide. *Fortschritte der Medizin* 1986; **104**:742–4.

#### Van Middelkoop 2013 {published data only}

Van Middelkoop M, Dziedzic K S, Doherty M, Zhang W, Bijlsma J W, McAlindon T E, et al. Individual patient data meta-analysis of trials investigating the effectiveness of intra-articular glucocorticoid injections in patients with knee or hip osteoarthritis: an OA Trial Bank protocol for a systematic review. *Systems Review* 2013;**2**:54.

## Van Middelkoop 2013a {published data only}

Van Middelkoop M, Dziedzic K, Doherty M, Zhang W, Bijlsma J W, McAlindon T, et al. The OA trial bank: Individual patient data meta-analysis of trials investigating the effectiveness of intra-articular corticosteroid injections in patients with knee or hip oa. Annals of the Rheumatic Diseases. 2013; Vol. 72.

## Van Middelkoop 2013b {published data only}

Van Middelkoop M, Dziedzic K, Doherty M, Zhang W, Bijlsma J, McAlindon T, et al. The oa trial bank: Individual patient data meta-analysis of trials investigating the effectiveness of intra-articular corticosteroid injections in patients with knee or hip oa. *Osteoarthritis and Cartilage* 2013;**21**:S259.

#### Van Middelkoop 2014 {published data only}

Van Middelkoop M, Arden N, Atchia I, Birrell F, Chao J, Lambert R, et al. The OA trial bank: Meta-analysis of individual patient data show that patients with severe pain or with inflammatory signs detected by ultrasound especially benefit from intra-articular glucocorticoids for knee or hip OA. *Annals of the Rheumatic Diseases* 2014;**73**:749.

## Van Middelkoop 2014a {published data only}

Van Middelkoop M, Arden N, Atchia I, Birrell F, Chao J, Lambert R G, et al. The OA trial bank: Meta-analysis of individual patient data show that patients with severe pain or with inflammatory signs detected by ultrasound especially benefit from intra-articular glucocorticoids for knee or hip OA. Osteoarthritis and Cartilage 2014;**22**:S474–5.

#### Wang 1998 {published data only}

Wang J J, Ho S T, Lee S C, Tang J J S, Liaw W J. Intraarticular triamcinolone acetonide for pain control after arthroscopic knee surgery. *Anesthesia and Analgesia* 1998;**87** (5):1113–6.

## Wang 2015 {published data only}

Wang F, He X. Intra-articular hyaluronic acid and corticosteroids in the treatment of knee osteoarthritis: A meta-analysis. *Experimental and Therapeutic Medicine* 2015; **9**:493–500.

## Wramner 1959 {published data only}

Wramner T. The effect of intra-articular hydrocortisone therapy upon the joint temperature in osteoarthritis and rheumatoid arthritis. *Acta Rheumatologica Scandinavica* 1959;**5**:59–65.

#### Yamamoto 1970 {published data only}

Yamamoto M, Fukuma H. Intra-articular injection of adrenocortical steroid hormone in osteoarthritis of the knee. *Seikei Geka - Orthopedic Surgery* 1970;**21**:103–6.

### Zhang 2008 {published data only}

Zhang W, Moskowitz R W, Nuki G, Abramson S, Altman R D, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis and Cartilage* 2008;**16**:137–62.

#### Zhang 2010 {published data only}

Zhang W, Nuki G, Moskowitz R W, Abramson S, Altman R D, Arden N K, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. *Osteoarthritis Cartilage* 2010;**18**:476–99.

## Zuckner 1958 {published data only}

Zuckner J, Machek O. Intra-articular injections of hydrocortisone, prednisolone, and their tertiary-butylacetate derivatives in patients with rheumatoid arthritis and osteoarthritis. *Journal of Chronic Diseases* 1958;**8**:637–44.

#### References to studies awaiting assessment

#### Ellis 2011 {published data only}

Ellis M E, Lun V M Y, Preston Wiley J. Combination treatment for knee osteoarthritis. *Clinical Journal of Sport Medicine* 2011;**21**(4):374–5.

#### Friedman 1978 {published data only}

Friedman D M, Moore M F. The efficacy of intraarticular corticosteroid for osteoarthritis of the knee. *Arthritis and Rheumatism* 1978;**21**:556.

## Hall 2013 {published data only}

Hall M, Courtney P, Doherty S, Latief K, Zhang W, Doherty M. Ultrasound response following intra-articular corticosteroid and a placebo injection in symptomatic

Intra-articular corticosteroid for knee osteoarthritis (Review)

osteoarthritic knees: A pilot study. *Annals of the Rheumatic Diseases* 2013;7**2**:54.

### Hall 2014 {published data only}

Hall M, Doherty S, Courtney P, Latief K, Zhang W, Doherty M. Ultrasound detected synovial change and pain response following intra-articular injection of corticosteroid and a placebo in symptomatic osteoarthritic knees: A pilot study. *Annals of the Rheumatic Diseases* 2014;**73**:1590–1.

## Motyl 2013 {published data only}

Motyl J M, Driban J B, McAdams E, McAlindon T E. Reliability and sensitivity of the 20-meter walk test among patients with knee osteoarthritis. *Osteoarthritis and Cartilage* 2013;**21**:S137.

#### Motyl 2013a {published data only}

Motyl J M, Driban J B, McAdams E, Price L L, McAlindon T E. Test-retest reliability and sensitivity of the 20-meter walk test among patients with knee osteoarthritis. *BMC Musculoskeletal Disorders* 2013;14:166.

## O'Neill 2014 {published data only}

O'Neill T W, Parkes M J, Maricar N, Gait A D, Cootes T F, Marjanovic E J, et al. Bone marrow lesions may not respond to anti-inflammatory treatments in knee osteoarthritis (OA). *Osteoarthritis and Cartilage* 2014;**22**:S475.

#### Raynauld 1999 {published data only}

Raynauld J P. Clinical trials: Impact of intraarticular steroid injections on the progression of knee osteoarthritis. *Osteoarthritis and Cartilage* 1999;7:348–9.

## Rezende 2012 {published data only}

Rezende M U, Campos G C, Pailo A F, Frucchi R, Pasqualim T. Evaluation of the effect of adding corticosteroid to viscosupplementation: A prospective and randomized study. *Osteoporosis International* 2012;**23**:S132–3.

#### Singh 1996 {published data only}

Singh G K, Jain S, Das S K, Sharma V. Conservative treatment of osteoarthritis (OA) of the knee vs add on intraarticular (IA) steroid injection [abstract]. *Journal of Clinical Epidemiology* 1996;**49 Suppl 1**:8s.

## Additional references

#### Altman 1996

Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. *Osteoarthritis and Cartilage* 1996;4(4):217–43.

#### Bellamy 1995

Bellamy N. Outcome measurement in osteoarthritis clinical trials. *The Journal of Rheumatology. Supplement* 1995;**43**: 49–51.

### Brandt 1996

Brandt KD. *Diagnosis and Nonsurgical Management of Osteoarthritis*. 1st Edition. Caddo, OK: Professional Communications, Inc., 1996.

#### Brandt 2001

Brandt K D. Management of osteoarthritis. In: Ruddy S, Harris E D Jr, Sledge C B editor(s). *Kelley's Textbook of Rheumatology*. 6th Edition. Philadelphia: W. B. Saunders Company, 2001:1419-32.

#### Clegg 2006

Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *The New England Journal of Medicine* 2006;**354**(8):795–808.

#### Cohen 1988

Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd Edition. Hillsdale, NJ: Lawrence Earlbaum Associates, 1988.

## Creamer 1997

Creamer P. Intra-articular corticosteroid injections in osteoarthritis: do they work and if so, how?. *Annals of the Rheumatic Diseases* 1997;**56**(11):634-6.

## da Costa 2012

da Costa B R, Nüesch E, Reichenbach S, Jüni P, Rutjes A W S. Doxycycline for osteoarthritis of the knee or hip. *Cochrane Database of Systematic Reviews* 2012, Issue 11. [DOI: 10.1002/14651858.CD007323.pub3]

#### da Costa 2012a

da Costa BR, Rutjes AWS, Johnston BC, Reichenbach S, Nüesch E, Tonia T, et al. Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study. *International Journal of Epidemiology* 2012;**41**(5):1445–59.

#### da Costa 2013

da Costa BR, Nüesch E, Rutjes AW, Johnston BC, Reichenbach S, Trelle S, et al. Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. *Journal of Clinical Epidemiology* 2013;**66**(8):847–55.

### da Costa 2014

da Costa BR, Nüesch E, Kasteler R, Husni E, Welch V, Rutjes AW, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. *Cochrane Database of Systematic Reviews* 2014, Issue 9. [DOI: 10.1002/14651858.CD003115.pub4]

#### da Costa 2014a

da Costa BR, Jüni P. Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. *European Heart Journal* 2014;**35**:3336–45.

#### DerSimonian 1986

DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials* 1986;7(3):177–88.

#### Dickersin 1994

Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. *BMJ* 1994;**309**(6964): 1286–91.

#### Dworkin 2008

Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance

Intra-articular corticosteroid for knee osteoarthritis (Review)

of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *Journal of Pain* 2008;**9**: 105–21.

## Dworkin 2009

Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. *Pain* 2009;**146**: 238–44.

# Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**(7109):629–34.

#### Egger 2001

Egger M, Smith GD. Principles of and procedures for systematic reviews. In: Egger M, Smith GD, Altman DG editor(s). *Systematic Reviews in Health Care: Meta-Analysis in Context.* London: BMJ Books, 2001:23–42.

#### Egger 2003

Egger M, Jüni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. *Health Technology Assessment (Winchester, England)* 2003;7(1):1–76.

#### Felson 2000

Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JA, et al. Osteoarthritis: New insights. Part 1: The disease and its risk factors (NIH Conference). *Annals of Internal Medicine* 2000;**133**(8):635-46.

## Felson 2000a

Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Minor MA, Blair SN, et al. Osteoarthritis: New insights. Part 2: Treatment approaches (NIH Conference). *Annals of Internal Medicine* 2000;**133**(9):726-37.

#### Guyatt 2008

Guyatt G, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;**336**(7650):924–6.

#### Gøtzsche 2007

Gøtzsche PC, Hróbjartsson A, Maric K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. *JAMA* 2007;**298**(4):430–7.

#### Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327** (7414):557–60.

#### Higgins 2011

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;**343**: 1–9.

#### Hochberg 2012

Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology

2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Care and Research* 2012;**64**(4): 465–74.

## Jüni 2001

Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ* 2001;**323**(7303):42–6.

#### Jüni 2006

Jüni P, Reichenbach S, Dieppe P. Osteoarthritis: rational approach to treating the individual. *Best Practice & Research. Clinical Rheumatology* 2006;**20**(4):721–40.

### Lefebvre 2008

Lefebvre C, Eisinga A, McDonald S, Paul N. Enhancing access to reports of randomized trials published world-wide-the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library. *Emerging Themes in Epidemiology* 2008; **5**(13):1–13.

#### McColl 2000

McColl GJ, Dolezal H, Eizenberg N. Common corticosteroid injections. An anatomical and evidence based review. *Australian Family Physician* 2000;**29**:922–6.

## Nüesch 2009

Nüesch E, Trelle S, Reichenbach S, Rutjes AWS, Bürgi E, Scherer M, et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: metaepidemiological study. *BMJ* 2009;**339**:b3244.

#### Nüesch 2010

Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. *BMJ* 2010;**341**:c3515.

#### Nüesch 2013

Nüesch E, Häuser W, Bernardy K, Barth J, Jüni P. Comparative efficacy of pharmacological and nonpharmacological interventions in fibromyalgia syndrome: network meta-analysis. *Annals of the Rheumatic Diseases* 2013;**72**(6):955–62.

#### Peters 2008

Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. *Journal of Clinical Epidemiology* 2008;**61**(10):991–6.

## Pham 2004

Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. *Osteoarthritis and Cartilage* 2004;**12**(5):389–99.

## Reichenbach 2007

Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. *Annals of Internal Medicine* 2007;**146** (8):580–90.

Intra-articular corticosteroid for knee osteoarthritis (Review)

#### Reichenbach 2010

Reichenbach S, Rutjes AW, Nüesch E, Trelle S, Jüni P. Joint lavage for osteoarthritis of the knee. *Cochrane Database* of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/ 14651858.CD007320.pub2]

## RevMan 2014

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

#### Rozental 2000

Rozental TD, Sculco TP. Intra-articular corticosteroids: an updated overview. *American Journal of Orthopedics* 2000;**29** (1):18–23.

#### Rucker 2008

Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. *BMC Medical Research Methodology* 2008;**8**(1):79.

## Rutjes 2009

Rutjes AW, Nüesch E, Sterchi R, Kalichman L, Hendriks E, Osiri M, et al. Transcutaneous electrostimulation for osteoarthritis of the knee. *Cochrane Database of Systematic Reviews* 2009, Issue 4. [DOI: 10.1002/14651858.CD002823.pub2]

#### Rutjes 2009a

Rutjes AW, Nuesch E, Reichenbach S, Jüni P. S-Adenosylmethionine for osteoarthritis of the knee or hip. *Cochrane Database of Systematic Reviews* 2009, Issue 4. [DOI: 10.1002/14651858.CD007321.pub2]

#### Rutjes 2010

Rutjes AW, Nuesch E, Sterchi R, Jüni P. Therapeutic ultrasound for osteoarthritis of the knee or hip. *Cochrane Database of Systematic Reviews* 2010, Issue 1. [DOI: 10.1002/14651858.CD003132.pub2]

#### Sterne 2001

Sterne JA, Egger M. Funnel plots for detecting bias in metaanalysis: guidelines on choice of axis. *Journal of Clinical Epidemiology* 2001;**54**(10):1046–55.

#### Sterne 2011

Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;**343**:d4002.

#### Thompson 1999

Thompson SG, Sharp SJ. Explaining heterogeneity in metaanalysis: a comparison of methods. *Statistics in Medicine* 1999;**18**(20):2693–708.

\* Indicates the major publication for the study

# CHARACTERISTICS OF STUDIES

# Characteristics of included studies [ordered by study ID]

# Beyaz 2012

Methods	Randomised controlled trial 3-arm parallel-group design Trial duration: 12 weeks
Participants	82 participants with knee osteoarthritis were randomised 73 participants were reported at baseline Number of females: 59 of 73 (81%) Mean age: 69.1 years
Interventions	Experimental intervention 40 mg triamcinolone acetonide (1 ml) plus 20 mg bupivacaine (4 ml), single intra- articular injection <i>Control intervention</i> 1 ml saline plus 20 mg bupivacaine (4 ml), single intra-articular injection
Outcomes	Extracted pain outcome: WOMAC pain Extracted function outcome: WOMAC function Maximum follow-up: 12 weeks
Notes	Funding: Boztepe State Hospital, Ordu, Republic of Turkey

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Patients were randomized by the closed-envelope technique into three groups". Because the "closed-envelope technique" was not further specified, the risk of selection bias was considered unclear
Allocation concealment (selection bias)	Unclear risk	Quote: "Patients were randomized by the closed-envelope technique into three groups". Because the "closed-envelope technique" was not further specified, the risk of selection bias was considered unclear
Blinding of participants?	Low risk	Quote: "Since the solutions were in differ- ent colors, sticker was used to cover injec- tors to hide to ensure blinding."
Blinding of health care provider(s)	Low risk	Quote: "Injections were administered by another blinded investigator."

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright @ 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Beyaz 2012 (Continued)

Intention-to-treat analysis performed? Pain	High risk	9 out of 82 participants were excluded be- cause (quote) "they did not come for fol- low-up"
Intention-to-treat analysis performed? Function	High risk	9 out of 82 participants were excluded be- cause (quote) "they did not come for fol- low-up"

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 24 weeks
Participants	104 participants with knee osteoarthritis were randomised 104 participants were reported at baseline Number of females: 79 out of 104 (76%) Mean age: 63.0 years
Interventions	<ul> <li>Experimental intervention</li> <li>20 mg triamcinolone hexacetonide (1 ml) plus 6 ml hylan GF-20, single intra-articular injection</li> <li>Control intervention</li> <li>6 ml hylan GF-20 intra-articularly, single intra-articular injection</li> <li>Quote: "Patients with bilateral disease had both knees treated with the same drug, but only one knee (reported by the patient as the worst) was included in the study"</li> </ul>
Outcomes	Extracted pain outcome: WOMAC Pain Extracted function outcome: WOMAC Global Maximum follow-up: 24 weeks
Notes	Funding: São Paulo Research Foundation (FAPESP) (Sao Paulo, Brazil)

Campos 2013

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Randomization was performed by a computer-generated program (available at: http://www.randomization.com/)."
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Low risk	Quote: "Patients were blinded (blocked from watching the procedures by the use of

# Campos 2013 (Continued)

		a windscreen sunshade and did not know to which group they were assigned)."
Blinding of health care provider(s)	Unclear risk	Physicians were not explicitly described as blinded, so the risk of performance bias was unclear
Intention-to-treat analysis performed? Pain	High risk	5 of 52 participants excluded in experimen- tal group, 6 of 52 participants excluded in control group
Intention-to-treat analysis performed? Function	High risk	5 of 52 participants excluded in experimen- tal group, 6 of 52 participants excluded in control group

# Castro 2007

Methods	Randomised controlled trial 5-arm parallel-group design Trial duration: 12.9 months
Participants	150 participants with knee osteoarthritis were randomised Unclear number of participants with knee osteoarthritis reported at baseline Number of females: 115 Mean age: 65.4
Interventions	<i>Experimental intervention</i> Triamcinolone acetonide (no dosage or unit specified) + joint lavage, single intra-articular application <i>Control intervention</i> Joint lavage, single intra-articular application
Outcomes	Extracted pain outcome: WOMAC Pain Extracted function outcome: WOMAC Function Maximum follow-up: 12.9 months
Nexes	

## Notes

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so

#### Castro 2007 (Continued)

		the risk of selection bias was unclear
Blinding of participants?	Unclear risk	It was unclear if method used to blind par- ticipants was appropriate
Blinding of health care provider(s)	Unclear risk	Physicians were not explicitly described as blinded, so the risk of performance bias was unclear
Intention-to-treat analysis performed? Pain	Low risk	All randomised participants included in the analysis
Intention-to-treat analysis performed? Function	Low risk	All randomised participants included in the analysis

#### Cederlof 1966

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 8 weeks
Participants	51 injections in 44 knees belonging to 44 participants with knee osteoarthritis were randomised Unclear number of participants reported at baseline Number of females: 41 of 44 (93.2%) Mean age: Not reported
Interventions	<i>Experimental intervention</i> 50 mg prednisolone acetate (2 ml), single intra-articular injection <i>Control intervention</i> 2 ml physiologic saline, single intra-articular injection
Outcomes	Extracted pain outcome: Patient global assessment
Notes	Funding: Aktiebolaget Ferrosan, Malmö, Sweden

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "The out-patient department nurse decided which fluid was to be injected by tossing a coin"
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear

#### Cederlof 1966 (Continued)

Blinding of participants?	Unclear risk	It was unclear if method used to blind par- ticipants was appropriate
Blinding of health care provider(s)	Unclear risk	Physicians were not explicitly described as blinded, so the risk of performance bias was unclear
Intention-to-treat analysis performed? Pain	Low risk	All randomised participants included in the analysis
Intention-to-treat analysis performed? Function	Unclear risk	Did not report extractable function out- come data
Chao 2010		
Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 12 weeks	
Participants	79 participants with knee osteoarthritis were randomised 79 participants were reported at baseline Number of females: 2 of 79 (2.5%) Mean age: 64.3 years	
Interventions	Experimental intervention 40 mg triamcinolone acetonide (1 ml), single intra-articular injection Control intervention 1 ml 0.9% saline, single intra-articular injection	
Outcomes	Extracted pain outcome: WOMAC Pain Extracted function outcome: WOMAC Global Maximum follow-up: 12 weeks	
Notes	Funding: National Skeletal Muscle Research Center, NIH Grant HD050837	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear

Blinding of participants?	Low risk	Quote: "Patients and assessors were blinded to treatment status" "Patients were then randomized to receive an injection of either () triamcinolone acetonide or () saline, which were drawn into a syringe covered with opaque tape prior to the patient en- counter."
Blinding of health care provider(s)	High risk	Quote: "Injections were given () by a non-blinded physician"
Intention-to-treat analysis performed? Pain	High risk	9 of 40 participants excluded in experimen- tal group, 9 of 39 participants excluded in control group
Intention-to-treat analysis performed? Function	High risk	9 of 40 participants excluded in experimen- tal group, 9 of 39 participants excluded in control group
Di Sante 2012		
Methods	Randomised controlled trial 3-arm parallel-group design Trial duration: 4 weeks	
Participants	60 participants with knee osteoarthritis were randomised 60 participants were reported at baseline Mean age: 70.6	
Interventions	<ul> <li><i>Experimental interventions</i></li> <li>40 mg methylprednisolone acetate and lidocaine hydrochloride, single intra-articular injection + Horizontal therapy* locally (10 times over 2 weeks, each lasting 30 minutes) <i>Control intervention</i></li> <li>Horizontal therapy* locally (10 times over 2 weeks, each lasting 30 minutes) Treatment duration: 4 weeks</li> <li>*Horizontal therapy was described as (quote): "Placement of 4 cutaneous electrodal pads (8 x 13 cm), one in center of the popliteal, one on the patella and two others at the posterior proximal site of the thighs, with a stimulation frequency oscillating at 100 Hz between 4400 and 12346 Hz for 30 minutes"</li> </ul>	
Outcomes	Extracted pain outcome: Pain overall Extracted function outcome: WOMAC Function Maximum follow-up: 4 weeks	
Notes		

#### Di Sante 2012 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "() using a computer generated 1: 1:1 allocation sequence."
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	High risk	No intra-articular sham injection in the placebo group (local therapy only)
Blinding of health care provider(s)	High risk	No intra-articular sham injection in the placebo group (local therapy only)
Intention-to-treat analysis performed? Pain	Low risk	All randomised participants included in the analysis
Intention-to-treat analysis performed? Function	Low risk	All randomised participants included in the analysis

# Dieppe 1980

Methods	Randomised controlled trial 2-arm cross-over design Trial duration: 2 weeks
Participants	24 knees belonging to 16 participants with knee osteoarthritis were randomised 24 knees belonging to 16 participants were reported at baseline Mean age: 65 Number of females: 13 out of 16 (81%)
Interventions	<ul> <li>Experimental intervention</li> <li>20 mg triamcinalone hexacetonide (1 ml), single intra-articular injection</li> <li>Control intervention</li> <li>1 ml of saline, single intra-articular injection</li> <li>Cross-over after 1 week. Every participant received 1 injection (experimental and control)</li> <li>each</li> </ul>
Outcomes	Extracted pain outcome: Pain overall Maximum follow-up: 1 week
Notes	2 trials were reported in the same paper. Trial A did not report pain outcomes seperately for treatment and intervention and was excluded. Trial B was included in the analysis

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	High risk	Quote: Described as "single-blind, blind- observer", implying that participants were not blinded
Blinding of health care provider(s)	High risk	Quote: Described as "single-blind, blind-observer", implying that healthcare providers were not blinded
Intention-to-treat analysis performed? Pain	Low risk	All randomised participants included in the analysis
Intention-to-treat analysis performed? Function	Unclear risk	Not applicable, no function outcome re- ported

#### Friedman 1980

Randomised controlled trial 2-arm parallel-group design Trial duration: 8 weeks
34 participants with knee osteoarthritis were randomised 34 participants were reported at baseline Number of females: Not reported Mean age: 60.0 years
<i>Experimental intervention</i> 20 mg triamcinolone hexacetonide, single intra-articular injection <i>Control intervention</i> "Polysorbate, sorbitol solution, benzyl alcohol and water", single intra-articular injection
Extracted pain outcome: Pain overall Maximum follow-up: 8 weeks
Funding: Grant from the Eastern Pennsylvania Chapter of the Arthritis Foundation and by the Philadelphia Foundation

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not clearly reported, so the risk of selection bias was unclear. Quote: "Half of the patients, selected according to a predetermined random schedule, were treated ()."
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Low risk	Quote: "During the time of [the injection] (), the physician and patient were posi- tioned so that neither could see the nurse's face nor the material she injected. Thus, neither had any direct information con- cerning what was injected and, practically speaking, had no contact with the only per- son who knew"
Blinding of health care provider(s)	Low risk	Quote: "The physician-experimenter per- formed the arthrocentesis () a nurse-assis- tant entered the room and performed the injection through the intraarticular needle, and left the room. During the time of this taking place, the physician and patient were positioned so that neither could see the nurse's face nor the material she injected. Thus, neither had any direct information concerning what was injected and, practi- cally speaking, had no contact with the only person who knew"
Intention-to-treat analysis performed? Pain	Low risk	All randomised participants included in the analysis. Quote: "All patients were seen 1 wk, 4 wk, 6 wk and 8 wk post-injection ex- cept those whose pain scores at any subse- quent evaluation were the same as their pre- treatment scores; they were not seen fur- ther. It was assumed that their scores would no longer improve and they were counted as remaining at their pre-treatment level throughout the experiment"
Intention-to-treat analysis performed? Function	Unclear risk	Not applicable, no function outcome re- ported

Fri as 2004

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 12 weeks
Participants	299 knees belonging to 205 participants with knee osteoarthritis were randomised 299 knees belonging to 205 participants were reported at baseline Number of females: 234 (78%) of 299 knees belonged to female participants Mean age: 67.0 years
Interventions	<i>Experimental intervention</i> 40 mg triamcinolone acetonide plus lavage (3 L of cold (8°C) saline), single intra-articular application <i>Control intervention</i> Lavage (3 L of cold (8°C) saline), single intra-articular application
Outcomes	Extracted pain outcome: Pain overall Maximum follow-up: 12 weeks

Notes

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	Although the authors stated "Glucocor- ticoid treatment with triamcinolone ace- tonide was always given on a blind basis", they also stated that this was an open trial (Quote: "The study was of the longitudi- nal, open, prospective, controlled type"). The risk of performance bias was therefore considered unclear
Blinding of health care provider(s)	Unclear risk	Although the authors stated "Glucocor- ticoid treatment with triamcinolone ace- tonide was always given on a blind basis", they also stated that this was an open trial (Quote: "The study was of the longitudi- nal, open, prospective, controlled type"). The risk of performance bias was therefore considered unclear

#### Fri as 2004 (Continued)

Intention-to-treat analysis performed? Pain	High risk	82 of 299 knees were excluded at 1 month, 51 of 299 knees were excluded at 3 months
Intention-to-treat analysis performed? Function	Unclear risk	Not applicable, no function outcome re- ported

Gaffney 1995

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 6 weeks
Participants	84 participants with knee osteoarthritis were randomised 84 participants were reported at baseline Number of females: 60 out of 84 (71%) Mean age: 67.0 years
Interventions	<i>Experimental intervention</i> 20 mg triamcinolone hexacetonide (1 ml), single intra-articular injection <i>Control intervention</i> 1 ml of 0.9% normal saline, single intra-articular injection
Outcomes	Extracted pain outcome: Pain overall Extracted function outcome: Other function composite Maximum follow-up: 6 weeks
Notes	

#### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Low risk	Quote: "Although this study was not, by strict definition, double-blinded, we at- tempted to ensure that patients were not aware of the treatment allocated to them, by shielding the identity of the treatment received from their view at the time of in- jection; only the injecting physician (IL) was aware of the nature of the injection ad-

		ministered."
Blinding of health care provider(s)	High risk	Quote: "Although this study was not, by strict definition, double-blinded, we at- tempted to ensure that patients were not aware of the treatment allocated to them, by shielding the identity of the treatment received from their view at the time of in- jection; only the injecting physician (IL) was aware of the nature of the injection ad- ministered."
Intention-to-treat analysis performed? Pain	Unclear risk	2 of 42 participants in control group with- drew. It was unclear whether all participants randomised were also analysed
Intention-to-treat analysis performed? Function	Unclear risk	2 of 42 participants in control group with- drew. It was unclear whether all participants randomised were also analysed

Grecomoro 1992

Methods	Randomised controlled trial 2-arm cross-over design Trial duration: 8.6 weeks	
Participants	40 participants with knee osteoarthritis wer 40 participants were reported at baseline Number of females: 27 out of 40 (67.5%) Mean age: 42.3 years	re randomised
Interventions	<ul> <li>Experimental intervention</li> <li>0.4 mg dexamethasonephosphate plus 20 mg sodium hyaluronate in 2 ml phosphate buffer, 5 intra-articular injections, 1 weekly for 5 weeks</li> <li>Control intervention</li> <li>20 mg sodium hyaluronate in 2 ml phosphate buffer, 5 intra-articular injections, 1 weekly for 5 weeks</li> </ul>	
Outcomes	Extracted pain outcome: Pain on activities other than walking Maximum follow-up: 8.6 weeks	
Notes		
Risk of bias		
Bias	Authors' judgement	Support for judgement

#### Grecomoro 1992 (Continued)

Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	High risk	Quote: "The trial design was open and ran- domized."
Blinding of health care provider(s)	High risk	Quote: "The trial design was open and ran- domized."
Intention-to-treat analysis performed? Pain	Low risk	All randomised participants included in the analysis
Intention-to-treat analysis performed? Function	Unclear risk	Not applicable, no function outcome re- ported

# Henriksen 2015

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 26 weeks
Participants	100 participants with knee osteoarthritis were randomised 100 participants were reported at baseline Number of females: 61 out of 100 (61%) Mean age: 63.4 years
Interventions	<i>Experimental intervention</i> 40 mg methylprednisolone acetate (1 ml) dissolved in 4 ml of lidocaine hydrochloride, single intra-articular injection + 12-week exercise program <i>Control intervention</i> 1 ml isotonic saline mixed with 4 ml of lidocaine hydrochloride, single intra-articular injection + 12-week exercise program
Outcomes	Extracted pain outcome: Other pain composite Extracted pain function: Other function composite Maximum follow-up: 26 weeks
Notes	Funding: Grants by: 10-093704 from the Danish Council for Independent Research Medical Science, Oak Foundation, Association of Danish Physiotherapists, Lundbeck Foundation, Capital Region of Denmark

## Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "A computer-generated random- ization sequence was produced before any patients were enrolled that allocated partic- ipants in permuted blocks of 2 to 6 to the corticosteroid or the placebo group (1:1)."
Allocation concealment (selection bias)	Low risk	Quote: "The randomization sequence was prepared by a biostatistician with no clini- cal involvement in the trial (R.C.). The al- location was concealed in a password-pro- tected computer file only accessible by the biostatistician. Individual allocations were held in sealed, opaque, consecutively num- bered envelopes."
Blinding of participants?	Low risk	Quote: "To ensure blinding of the partici- pants and the clinician performing the in- jections, the syringes were prepared by the study nurse in the absence of participants and blinded study staff. Because the cor- ticosteroid liquid is milky white and the saline is clear, the syringes were masked with opaque tape to prevent disclosure of the content during the injection procedure. "
Blinding of health care provider(s)	Low risk	Quote: "To ensure blinding of the partici- pants and the clinician performing the in- jections, the syringes were prepared by the study nurse in the absence of participants and blinded study staff. Because the cor- ticosteroid liquid is milky white and the saline is clear, the syringes were masked with opaque tape to prevent disclosure of the content during the injection procedure. "
Intention-to-treat analysis performed? Pain	Low risk	All randomised participants included in the analysis
Intention-to-treat analysis performed? Function	Low risk	All randomised participants included in the analysis

Jones 1996

Jones 1770		
Methods	Randomised controlled trial 2-arm cross-over design Trial duration: 16 weeks	
Participants	59 participants with knee osteoarthritis were randomised 59 participants were reported at baseline Number of females: 37 out of 59 (63%) Mean age: 70.6 years	
Interventions	Experimental intervention 40 mg methyl prednisolone acetate (1 ml), single intra-articular injection <i>Control intervention</i> 1 ml 0.9% saline, single intra-articular injection Cross-over after 8 weeks. Every participant received 1 injection (experimental and con- trol) each	
Outcomes	Extracted pain outcome: Pain on activities other than walking Maximum follow-up: 8 weeks	
Notes		
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	Quote: "Each injection was given by a sec- ond operator, thus blinding both patient and assessor." No further description of blinding
Blinding of health care provider(s)	Unclear risk	Quote: "Each injection was given by a sec- ond operator, thus blinding both patient and assessor." No further description of blinding
Intention-to-treat analysis performed? Pain	High risk	Quotes: "As some data was missing due to patient withdrawal, all analyses were

all participants randomised were analysed. Quote: "One patient failed to enter the

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright @ 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

performed on a last measures carried forward, intention to treat basis", but still not

		study and received no injection, leaving 59 patients available for the analysis."
Intention-to-treat analysis performed? Function	Unclear risk	Not applicable, no function outcome re- ported

#### Lyons 2005

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 8.6 weeks
Participants	20 participants with knee osteoarthritis were randomised Unclear number of participants with knee osteoarthritis reported at baseline Number of females: 11 Mean age: 59.7
Interventions	<i>Experimental intervention</i> 80 mg methylprednisolone (2 ml) + 5 ml 1% lignocaine, single intra-articular injection <i>Control intervention</i> 10 ml of 1% lignocaine, single intra-articular injection
Outcomes	Extracted pain outcome: Pain overall Extracted function outcome: Global disability score Maximum follow-up: 8.6 weeks
Notes	Funding: West London Research Network, Primary Care Scientist Award funded by the Department of Health

## Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	It was unclear if method used to blind healthcare providers was appropriate
Blinding of health care provider(s)	High risk	Quote: "(The study) was single blind, with the principal investigator administering the treatment and also measuring outcome."

#### Lyons 2005 (Continued)

Intention-to-treat analysis performed? Pain	Low risk	All randomised participants included in the analysis
Intention-to-treat analysis performed? Function	Low risk	All randomised participants included in the analysis

Miller 1958

Methods	Randomised controlled trial 5-arm parallel-group design Trial duration: 33.8 weeks
Participants	202 participants with knee osteoarthritis were randomised Unclear number of participants reported at baseline Number of females: 122 Mean age: not reported
Interventions	<i>Experimental intervention</i> 50 mg of hydrocortisone (2 ml) + 8 ml of physiological normal saline, 5 intra-articular injections, interval of 2 weeks <i>Control intervention</i> Physiological normal saline solution (no dosage), 5 intra-articular injections, interval of 2 weeks
Outcomes	Extracted pain outcome: Patients' global assessment Maximum follow-up: 25.8 weeks
Notes	

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	It was unclear if method used to blind par- ticipants was appropriate
Blinding of health care provider(s)	Unclear risk	Physicians were not explicitly described as blinded, so the risk of performance bias was unclear

#### Miller 1958 (Continued)

Intention-to-treat analysis performed? Pain	High risk	21 of 202 participants were excluded
Intention-to-treat analysis performed? Function	Unclear risk	Not applicable, no function outcome re- ported

# NCT00414427

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 12 weeks
Participants	79 participants with knee osteoarthritis were randomised 79 participants were reported at baseline Number of females: 3 out of 79 (4%) Mean age: 63.0 years
Interventions	<i>Experimental intervention</i> 40 mg triamcinolone acetonide, single intra-articular injection <i>Control intervention</i> 0.9% saline (no dosage), single intra-articular injection
Outcomes	Extracted pain outcome: WOMAC Pain Maximum follow-up: 12 weeks
Notes	Funding: University of California, San Diego

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	It was unclear if method used to blind par- ticipants was appropriate
Blinding of health care provider(s)	Unclear risk	It was unclear if method used to blind healthcare providers was appropriate
Intention-to-treat analysis performed? Pain	High risk	7 of 40 participants excluded in experimen- tal group, 5 of 39 participants excluded in control group

## NCT00414427 (Continued)

Intention-to-treat analysis Function	performed?	Unclear risk	Not applicable, no function outcome re- ported
Ozturk 2006			
Methods		Randomised controlled trial 2-arm parallel-group design Trial duration: 52 weeks	
Participants		47 participants with knee osteoarthritis were randomised 40 participants were reported at baseline Number of females: 39 out of 47 (83%) Mean age: 58.0 years	
Interventions		<i>Experimental intervention</i> 40 mg triamcinolone acetonide (1 ml) plus 2 ml sodium hyaluronate. Sodium hyaluronate was administered in 3 intra-articular injections in the first month and 3 intra-articular injections during the sixth month, triamcinolone acid was added prior to the first and fourth application <i>Control intervention</i> 2 ml sodium hyaluronate, 3 intra-articular injections in the first month, and 3 intra- articular injections during the sixth month	
Outcomes		Extracted pain outcome: WOMAC Pain Maximum follow-up: 25.9 weeks	
N.			

Notes

## Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Patients were assigned to one of the two treatment groups based on a table of randomly assorted digits: A and B."
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	It was unclear if participants were blinded (trial described as "single blind" but no de- scription of who was blinded)
Blinding of health care provider(s)	Unclear risk	It was unclear if healthcare providers were blinded (trial described as "single blind" but no description of who was blinded)

#### Ozturk 2006 (Continued)

Intention-to-treat analysis performed? Pain	High risk	7 of 23 participants excluded in experimen- tal group, 0 of 24 participants excluded in control group
Intention-to-treat analysis performed? Function	Unclear risk	Not applicable, no function outcome re- ported

#### Petrella 2015

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 26 weeks
Participants	98 participants with knee osteoarthritis were randomised 98 participants were reported at baseline Number of females: 56 out of 98 (57%) Mean age: 59.7 years
Interventions	<i>Experimental intervention</i> 10 mg triamcinolone acetonide + hyaluronan solution (no dosage stated), 6 ml total, single intra-articular injection <i>Control intervention</i> Hyaluronan solution (no dosage stated), single intra-articular injection
Outcomes	Extracted pain outcome: WOMAC Pain Extracted function outcome: WOMAC Function Maximum follow-up: 26 weeks
Notes	Funding: Carbylan Therapeutics

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "The randomization treatment was computer generated and was stratified by study center."
Allocation concealment (selection bias)	Unclear risk	Quote: "The randomization treatment was computer generated and was stratified by study center."
Blinding of participants?	Unclear risk	It was unclear if method used to blind par- ticipants was appropriate
Blinding of health care provider(s)	High risk	Quote: "An injecting physician delivered the randomized treatment and remained

#### Petrella 2015 (Continued)

		unblinded."
Intention-to-treat analysis performed? Pain	High risk	2 of 33 participants excluded in experimen- tal group, 1 of 33 participants excluded in control group
Intention-to-treat analysis performed? Function	High risk	2 of 33 participants excluded in experimen- tal group, 1 of 33 participants excluded in control group
Popov 1989		
Methods	Randomised controlled trial 5-arm parallel-group design Trial duration: 2.7 weeks	
Participants	48 participants with knee osteoarthritis were randomised Unclear number of participants with knee osteoarthritis reported at baseline Number of females: 38 Mean age: 55 years	
Interventions	<i>Experimental interventions</i> Intervention (A): 40 mg triamcinolone, 3 intra-articular injections, interval 1 week Intervention (B): 50 mg hydrocortisone, 3 intra-articular injections, interval 1 week <i>Control intervention</i> Saline solution (no dosage stated), 2 intra-articular injections, interval 1 week	
Outcomes	Extracted pain outcome: (A)-(B): other algofunctional Extracted function outcome: (A)-(B): other algofunctional Maximum follow-up: 0.7 weeks	
Notes		

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	It was unclear if method used to blind par- ticipants was appropriate

#### Popov 1989 (Continued)

Blinding of health care provider(s)	Unclear risk	It was unclear if method used to blind healthcare providers was appropriate
Intention-to-treat analysis performed? Pain	Unclear risk	It was unclear whether all participants ran- domised were also analysed
Intention-to-treat analysis performed? Function	Unclear risk	It was unclear whether all participants ran- domised were also analysed
Ravaud 1999		
Methods	Randomised controlled trial 2 x 2 factorial design Trial duration: 24 weeks	
Participants	98 participants with knee osteoarthritis were randomised 98 participants were reported at baseline Number of females: 66 out of 98 (67%) Mean age: 65.4	
Interventions	<i>Experimental interventions</i> Intervention (A): 3.75 mg cortivazol (1.5 ml), single intra-articular injection Intervention (B): Lavage, single intra-articular application + 3.75 mg cortivazol (1.5 ml) , single intra-articular injection <i>Control intervention</i> Intervention (A): 1.5 ml 0.9% normal saline, single intra-articular injection Intervention (B): Lavage, single intra-articular application	
Outcomes	Extracted pain outcome: Pain overall Extracted function outcome: Lequesne index Maximum follow-up: 24 weeks	
Notes	Funding: Société Française de Rhumatologie and the Direction de la Recherche Clinique (Assistance Publique - Hôpitaux de Paris)	

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear

Blinding of participants?	Unclear risk	Quote: "The study was double-blind in re- lation to the IA corticosteroid and open with regard to joint lavage."
Blinding of health care provider(s)	Unclear risk	Quote: "The study was double-blind in re- lation to the IA corticosteroid and open with regard to joint lavage. However, the procedure (joint lavage and/or IA injection) was performed by a physician other than the blinded evaluator."
Intention-to-treat analysis performed? Pain	Low risk	All randomised participants included in the analysis. Quote: "The last observation-car- ried-forward procedure was used to adjust for missing values."
Intention-to-treat analysis performed? Function	Low risk	All randomised participants included in the analysis. Quote: "The last observation-car- ried-forward procedure was used to adjust for missing values."

Raynauld 2003

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 54 weeks
Participants	68 participants with knee osteoarthritis were randomised 68 participants were reported at baseline Number of females: 42 out of 68 (68%) Mean age: 63.2 years
Interventions	Experimental intervention 40 mg triamcinolone acetonide (1 ml), 8 intra-articular injections, interval 3 months, over 21 months <i>Control intervention</i> 1 ml saline intra-articularly, 8 intra-articular injections, interval 3 months, over 21 months
Outcomes	Extracted pain outcome: WOMAC Pain. After end of treatment (during follow-up) Extracted function outcome: WOMAC Function. After end of treatment (during follow- up) Maximum follow-up: 12.9 weeks
Notes	Funding: Fonds de la recherche en santé du Québec
Risk of bias	

#### Raynauld 2003 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Patients were randomly assigned to the IA steroid or IA saline group based on a table of randomly assorted digits."
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	Study described as double-blind but no de- scription of method of blinding provided
Blinding of health care provider(s)	High risk	Study described as double-blind. The fol- lowing statements indicate that "double- blind" in this trial means that only patients and outcome assessors were blinded: "In order to preserve the blind, the injections were given by a rheumatologist (DC or BH) other than the evaluators." "Investigators performed these evaluations in a blinded manner using validated measures."
Intention-to-treat analysis performed? Pain	High risk	1 of 34 participants excluded in experimen- tal group, 1 of 34 participants excluded in control group
Intention-to-treat analysis performed? Function	High risk	1 of 34 participants excluded in experimen- tal group, 1 of 34 participants excluded in control group

#### Schue 2011

Methods	Randomised controlled trial 3-arm parallel-group design Trial duration: 8 weeks
Participants	16 participants with knee osteoarthritis were randomised Unclear number of participants with knee osteoarthritis reported at baseline Number of females: not reported Mean age: not reported
Interventions	<i>Experimental intervention</i> 80 mg methylprednisolone, single intra-articular injection <i>Control intervention</i> Saline (no dosage specified), single intra-articular injection

#### Schue 2011 (Continued)

Outcomes	Extracted pain outcome: WOMAC Global Maximum follow-up: 8 weeks	
Notes		
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	It was unclear if method used to blind par- ticipants was appropriate
Blinding of health care provider(s)	Unclear risk	Physicians were not explicitly described as blinded, so the risk of performance bias was unclear
Intention-to-treat analysis performed? Pain	Unclear risk	It was unclear whether all participants ran- domised were also analysed
Intention-to-treat analysis performed? Function	Unclear risk	Not applicable, no function outcome re- ported

#### Smith 2003

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 24 weeks
Participants	77 participants with knee osteoarthritis were randomised 71 participants were reported at baseline Number of females: 27 out of 77 (35%) Mean age: 66.8 years
Interventions	Experimental intervention 120 mg methylprednisolone acetate following joint lavage, single intra-articular injection Control intervention Treatment duration: 1 day Normal saline (no dosage) following joint lavage, single intra-articular injection

#### Smith 2003 (Continued)

Outcomes	Extracted pain outcome: WOMAC Pain Extracted function outcome: WOMAC Function Maximum follow-up: 24 weeks
Notes	Funding: National Health and Medical Research Council (Australia) Arthritis Founda- tion of Australia

## Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Randomization was computer- generated by a member of the hospital pharmacy department, who also prepared a blinded intra-articular injection"
Allocation concealment (selection bias)	Low risk	Quote: "Randomization was computer- generated by a member of the hospital pharmacy department, who also prepared a blinded intra-articular injection"
Blinding of participants?	Unclear risk	It was unclear if method used to blind par- ticipants was appropriate
Blinding of health care provider(s)	Unclear risk	It was unclear if method used to blind healthcare providers was appropriate
Intention-to-treat analysis performed? Pain	High risk	Quote: "In the event of relapse as defined above, the last documented outcome vari- ables were carried forward". Still, 6 partic- ipants were excluded (those needing surgi- cal intervention because of the arthroscopic findings at baseline)
Intention-to-treat analysis performed? Function	High risk	Quote: "In the event of relapse as defined above, the last documented outcome vari- ables were carried forward". Still, 6 partic- ipants were excluded (those needing surgi- cal intervention because of the arthroscopic findings at baseline)

Wright 1960

Methods	Randomised controlled trial 3-arm parallel-group design Trial duration: 20 weeks
Participants	38 knees belonging to 25 participants with knee osteoarthritis were randomised Unclear number of participants with knee osteoarthritis reported at baseline Number of females: not stated Mean age: not stated
Interventions	<ul> <li><i>Experimental intervention</i></li> <li>Intervention (A): 25 mg hydrocortisone acetate (1 ml), 4 intra-articular injections, interval 2 weeks over 6 weeks</li> <li>Intervention (B): 25 mg hydrocortisone tertiary-butylacetate (1 ml), 4 intra-articular injections, interval 2 weeks over 6 weeks</li> <li><i>Control intervention</i></li> <li>1 ml of placebo, 4 intra-articular injections, interval 2 weeks over 6 weeks</li> <li>Cross-over design, every participant received 3 x 4 injections</li> </ul>
Outcomes	Only information on adverse events was extracted
Notes	There was no extractable data on pain or function

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "The order of courses in each pa- tient was randomized from a master sheet in which names were entered consecutively. "
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	It was unclear if method used to blind par- ticipants was appropriate
Blinding of health care provider(s)	Unclear risk	Physicians were not explicitly described as blinded, so the risk of performance bias was unclear
Intention-to-treat analysis performed? Pain	Unclear risk	Did not report extractable pain outcome data
Intention-to-treat analysis performed? Function	Unclear risk	Did not report extractable function out- come data excluded in control group

Yavuz 2012

Methods	Randomised controlled trial 4-arm parallel-group design Trial duration: 12 weeks
Participants	120 participants with knee osteoarthritis were randomised 120 participants were reported at baseline Number of females: 76 out of 120 (63%) Mean age: 60.0 years
Interventions	<i>Experimental intervention</i> Intervention (A): 40 mg triamsinolon acetonate (1 ml), single intra-articular injection Intervention (B): 3 mg betametazone disodium phosphate (1 ml), single intra-articular injection Intervention (C): 40 mg methylprednisolone acetate (1 ml), single intra-articular injec- tion <i>Control intervention</i> 1 ml 0.9% sodium chloride, single intra-articular injection
Outcomes	Extracted pain outcome (A)-(C): Pain overall Extracted function outcome (A)-(C): Lequesne index Maximum follow-up: 12 weeks
Notes	

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Quote: "A total of 120 eligible patients with knee osteoarthritis were included (accord- ing to their admission date) and random- ized into four groups."
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	It was unclear if participants were blinded
Blinding of health care provider(s)	Unclear risk	Physicians were not explicitly described as blinded, so the risk of performance bias was unclear
Intention-to-treat analysis performed? Pain	Unclear risk	It was unclear whether all participants ran- domised were also analysed
Intention-to-treat analysis performed? Function	Unclear risk	It was unclear whether all participants ran- domised were also analysed

Young 2001

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 4.3 weeks
Participants	41 knees belonging to 40 participants with knee osteoarthritis were randomised Unclear number of participants with knee osteoarthritis reported at baseline Number of females: 16 Mean age: 66.5 years
Interventions	<i>Experimental intervention</i> 120 mg methylprednisolone acetate, single intra-articular injection <i>Control intervention</i> Normal saline (no dosage stated), single intra-articular injection
Outcomes	Extracted pain outcome: WOMAC Global Extracted function outcome: Other function composite Maximum follow-up: 4.3 weeks
Notes	Funding: National Health and Medical Research Council, The Clive and Vera Ramaciotti Trust, The Rebecca L. Cooper Foundation, University of New South Wales, The Arthritis Foundation of Australia, The Royal Australasian College of Physicians

# Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear
Allocation concealment (selection bias)	Unclear risk	Method used to conceal the random se- quence of allocation was not reported, so the risk of selection bias was unclear
Blinding of participants?	Unclear risk	It was unclear if method used to blind par- ticipants was appropriate
Blinding of health care provider(s)	Unclear risk	Physicians were not explicitly described as blinded, so the risk of performance bias was unclear
Intention-to-treat analysis performed? Pain	Unclear risk	It was unclear whether all participants ran- domised were also analysed
Intention-to-treat analysis performed? Function	Unclear risk	It was unclear whether all participants ran- domised were also analysed

#### Zhilyayev 2012

Methods	Randomised controlled trial 4-arm parallel-group design Trial duration: 12 weeks
Participants	209 knees belonging to 112 participants were randomised Unclear number of participants with knee osteoarthritis reported at baseline Number of females: not stated Mean age: not stated
Interventions	<ul> <li>Experimental intervention</li> <li>20 mg triamcinolone acetonid plus 10 ml 0.5% procaine, single intra-articular injection</li> <li><i>Control intervention</i></li> <li>10 ml 0.5% procaine, single intra-articular injection</li> </ul>
Interventions Outcomes	20 mg triamcinolone acetonid plus 10 ml 0.5% procaine, single intra-articular injection <i>Control intervention</i>

Notes

#### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "joints were randomized by en- velopes to one of 4 treatments"
Allocation concealment (selection bias)	Unclear risk	Quote: "joints were randomized by en- velopes to one of 4 treatments"
Blinding of participants?	Unclear risk	It was unclear if method used to blind par- ticipants was appropriate
Blinding of health care provider(s)	Unclear risk	Physicians were not explicitly described as blinded, so the risk of performance bias was unclear
Intention-to-treat analysis performed? Pain	Unclear risk	It was unclear whether all participants ran- domised were also analysed
Intention-to-treat analysis performed? Function	Unclear risk	Not applicable, no function outcome re- ported

IA: intra-articular WOMAC: Western Ontario and McMaster Universities Arthritis Index

# Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Abdulla 2013	Recent systematic review
Anonymous 1978	Wrong study design
Anonymous 2011	Wrong study design
Arroll 2004	Recent systematic review
Arroll 2005	Wrong study design
Avouac 2010	Recent systematic review
Baker 1969	Active comparator
Bannuru 2013	Wrong study design: Abstract to relevant systematic review, no references listed
Bannuru 2014	Wrong study design: Abstract to relevant systematic review, no references listed
Bannuru 2015	Recent systematic review
Baratham 2010	Wrong outcomes
Bellamy 2005	Recent systematic review
Bellamy 2006	Recent systematic review
Bennell 2012	Wrong study design
Bjordal 2007	Recent systematic review
Blanke 2008	Wrong study design
Bourne 1985	Wrong study design
Brys 2004	Wrong study design
Canillas 2011	Wrong study design
Cats 1979b	Wrong study population
Charalambous 2004	Wrong study design
Cheng 2012	Recent systematic review

#### (Continued)

Courtney 2009	Wrong study design
Douglas 2012	Wrong study design
Gait 2014	Wrong study design
Garg 2013	Wrong study design: Abstract to relevant systematic review , no references listed
Garg 2014	Reason for exclusion
Gerlag 2008a	Wrong study design
Godwin 2004	Recent systematic review
Habib 2009	Wrong study design
Habib 2010	Wrong study design
Hepper 2009	Reason for exclusion
Hirsch 2013	Reason for exclusion
Ivanov 1981	Wrong comparator
Jarner 1992	Active comparator
Jones 1993	Wrong study design
Jones 2014	Wrong study design
Keagy 1967	Wrong study design
Khitrov 1997	Active comparator
Kizilkaya 2004	Postsurgical setting
Kizilkaya 2005	Postsurgical setting
Koyonos 2009	Postsurgical setting
Krause 1971	Wrong study design
Legre-Boyer 2015	Wrong study design
Lequesne 1970	Wrong study design

#### (Continued)

Maricar 2013	Wrong study design: Abstract to relevant systematic review , no references listed
Maricar 2013c	Recent systematic review
Maricar 2014	Wrong study design
McAlindon 2014	Wrong study design
Murdoch 1959	Wrong study design
Murdoch 1959a	Wrong study design
Neame 2003	Wrong study design
Nicol 1972	Wrong study design
No named author	Wrong study design
No named author a	Wrong study design
No named author b	Wrong study design
No named author c	Wrong study design
Parmigiani 2010	Duplicate reference
Pendleton 2008	Wrong study design
Punzi 2001	Wrong intervention
Rasmussen 1998	Postsurgical setting
Rasmussen 1998a	Postsurgical setting
Rasmussen 1998b	Postsurgical setting
Reshetov 2000	Wrong comparator
Ronchetti 2001	Active comparator
Roskos 2005	Wrong study design
Saito 1971	Wrong study design
Shah 1967	Wrong comparator

#### (Continued)

Sheldon 1973	Wrong study population
Stein 1996	Active comparator
Stitik 2006	Wrong study design
Stojanovic 1969	Wrong study design
Talke 1986	Wrong study design
Van Middelkoop 2013	Wrong study design: Abstract to relevant systematic review , no references listed
Van Middelkoop 2013a	Wrong study design: Abstract to relevant systematic review , no references listed
Van Middelkoop 2013b	Wrong study design
Van Middelkoop 2014	Wrong study design: Abstract to relevant systematic review , no references listed
Van Middelkoop 2014a	Wrong study design: Abstract to relevant systematic review , no references listed
Wang 1998	Postsurgical setting
Wang 2015	Wrong study design
Wramner 1959	Wrong study design
Yamamoto 1970	Wrong study design
Zhang 2008	Wrong study design
Zhang 2010	Wrong study design
Zuckner 1958	Active comparator

# Characteristics of studies awaiting assessment [ordered by study ID]

#### Ellis 2011

Methods	Randomised controlled trial 2-arm parallel-group design Trial duration: 12 weeks
Participants	16 participants with knee osteoarthritis were randomised
Interventions	<ul> <li>Experimental intervention</li> <li>3-month exercise program plus 40 mg triamcinolone mixed with 4 ml 1% lidocaine, single intra-articular injection</li> <li>Control intervention</li> <li>3-month exercise program plus 1 ml normal saline mixed with 4 ml 1% lidocaine, single intra-articular injection</li> </ul>
Outcomes	Maximum follow-up: 12 weeks Outcome data (KOOS pain and function, WOMAC pain and function) not extractable

Notes

#### Friedman 1978

Methods	Unclear				
Participants	Unclear				
Interventions	Unclear				
Outcomes	Outcome data not extractable				
Notes					

#### Hall 2013

Methods	Randomised controlled trial 2-arm parallel-group design
Participants	25 participants with knee osteoarthritis were randomised
Interventions	<i>Experimental intervention</i> 40 mg methylprednisolone acetate, single intra-articular injection <i>Control intervention</i> saline, single intra-articular injection Cross-over design: Every participant received 1 injection each
Outcomes	Maximum follow-up: 1 week Outcome data (WOMAC pain, pain overall, ICOAP questionnaire, ultrasound examination) not extractable
Notes	

Intra-articular corticosteroid for knee osteoarthritis (Review)

 $\textbf{Copyright} @ 2015 \textbf{ The Cochrane Collaboration. Published by John Wiley \& Sons, Ltd. \\$ 

## Hall 2014

Methods	Randomised controlled trial 2-arm parallel-group design
Participants	25 participants with knee osteoarthritis were randomised
Interventions	<i>Experimental intervention</i> 40 mg methylprednisolone acetate, single intra-articular injection <i>Control intervention</i> saline, single intra-articular injection Cross-over design: Every participant received 1 injection each
Outcomes	Maximum follow-up: 1 week Outcome data (WOMAC pain, pain overall, ICOAP questionnaire, ultrasound examination) not extractable
Notes	

#### Motyl 2013

Methods	Measurement reliability study on participants later taking part in a randomised controlled trial for intra-arti corticosteroid injection in knee osteoarthritis					
Participants	15 participants with knee osteoarthritis					
Interventions	Unclear Data for the study was collected before the intra-articular injection					
Outcomes	Outcome data not extractable					
Notes						

#### Motyl 2013a

Methods	Measurement reliability study on participants later taking part in a randomised controlled trial for intra-articu corticosteroid injection in knee osteoarthritis					
Participants	15 participants with knee osteoarthritis					
Interventions	Unclear Data for the study was collected before the intra-articular injection					
Outcomes	Outcome data not extractable					
Notes						

## O'Neill 2014

Methods	Open-label clinical trial				
Participants	100 participants with knee osteoarthritis				
Interventions	<i>Experimental intervention</i> Corticosteroid, single intra-articular injection, type and dosage of corticosteroid unclear The study analysed the changes in MRI scans before and after the intra-articular corticosteroid injection. All partic- ipants received the experimental intervention, there was no control group				
Outcomes	Outcome data not extractable				
Notes					

#### Raynauld 1999

Methods	Randomised controlled trial 2-arm parallel-group design
Participants	80 participants with knee osteoarthritis were randomised
Interventions	<i>Experimental intervention</i> 40 mg triamcinolone hexacetonide, 8 intra-articular injections, 3 months interval <i>Control intervention</i> Placebo, 8 intra-articular injections, 3 months interval
Outcomes	Outcome data (pain overall, WOMAC) not extractable
Notes	

#### Rezende 2012

Methods	Randomised controlled trial 2-arm parallel-group design					
Participants	104 participants with knee osteoarthritis were randomised					
Interventions	<i>Experimental intervention</i> 20 mg of hexacetonide triamcinolone plus 6 ml of hylan GF-20, single intra-articular injection <i>Control intervention</i> 6 ml of hylan GF-20, single intra-articular injection					
Outcomes	Maximum follow-up: 24 weeks Outcome data (VAS, WOMAC, and Lequesne) not extractable					
Notes						

#### Singh 1996

Methods	Unclear				
Participants	Jnclear				
Interventions	Unclear				
Outcomes	Outcome data not extractable				
Notes					

ICOAP: Intermittent and Constant Osteoarthritis Pain KOOS: Knee Injury and Osteoarthritis Outcome Score MRI: magnetic resonance imaging VAS: visual analogue scale

WOMAC: Western Ontario and McMaster Universities Arthritis Index

## DATA AND ANALYSES

## Comparison 1. Pain

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Pain - Main	26	1749	Std. Mean Difference (Random, 95% CI)	-0.40 [-0.58, -0.22]
2 Pain - Timepoints	26		Std. Mean Difference (Random, 95% CI)	Subtotals only
2.1 Pain- 1-2 week	16	1041	Std. Mean Difference (Random, 95% CI)	-0.48 [-0.70, -0.27]
2.2 Pain- 4-6 week	22	1529	Std. Mean Difference (Random, 95% CI)	-0.41 [-0.61, -0.21]
2.3 Pain- 3 months	18	1233	Std. Mean Difference (Random, 95% CI)	-0.22 [-0.44, 4.12]
2.4 Pain- 6 months	7	526	Std. Mean Difference (Random, 95% CI)	-0.07 [-0.25, 0.11]

# Comparison 2. Function

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Function - Main	15	1014	Std. Mean Difference (Random, 95% CI)	-0.33 [-0.56, -0.09]
2 Function - Timepoints	15		Std. Mean Difference (Random, 95% CI)	Subtotals only
2.1 Function - 1-2 weeks	10	763	Std. Mean Difference (Random, 95% CI)	-0.43 [-0.72, -0.14]
2.2 Function - 4-6 weeks	12	818	Std. Mean Difference (Random, 95% CI)	-0.36 [-0.63, -0.09]
2.3 Function - 3 months	11	800	Std. Mean Difference (Random, 95% CI)	-0.13 [-0.37, 0.10]
2.4 Function - 6 months	4	328	Std. Mean Difference (Random, 95% CI)	0.06 [-0.16, 0.28]

#### Comparison 3. Quality of life

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Quality of life - Main	2	184	Std. Mean Difference (Random, 95% CI)	-0.01 [-0.30, 0.28]

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Comparison 4. Number of participants experiencing any adverse event

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of participants experiencing any adverse event - Main	2	84	Risk Ratio (IV, Random, 95% CI)	0.89 [0.64, 1.23]

#### Comparison 5. Number of participants who withdraw because of adverse events

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of participants who with draw because of adverse events -Main	2	204	Risk Ratio (IV, Random, 95% CI)	0.33 [0.05, 2.07]

# Comparison 6. Number of participants experiencing any serious adverse event

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of participants experiencing any serious adverse event - Main	5	331	Risk Ratio (IV, Random, 95% CI)	0.63 [0.15, 2.67]

# Comparison 7. Joint space narrowing

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Joint space narrowing - Main	1	68	Std. Mean Difference (Random, 95% CI)	-0.02 [-0.49, 0.46]

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Analysis I.I. Comparison I Pain, Outcome I Pain - Main.

Review: Intra-articular corticosteroid for knee osteoarthritis

Comparison: I Pain

Outcome: I Pain - Main

Std. Mean Difference IV,Random,95% CI	Weight	Std. Mean Difference IV,Random,95% Cl	Std. Mean Difference (SE)	Control N	IA Corticosteroid N	Study or subgroup
-0.69 [ -1.26, -0.12 ]	3.8 %		-0.68667 (0.291396)	25	25	Beyaz 2012
-0.41 [ -0.80, -0.02 ]	4.8 %		51	-0.4102612 (0.1991779)	52	Campos 2013
0.15 [ -0.34, 0.65 ]	4.2 %	<del></del>	0.153865 (0.25452)	30	32	Castro 2007
0.34 [ -0.53, 1.21 ]	2.6 %		0.343675 (0.443639)	25	26	Cederlof 1966
-0.83 [ -1.33, -0.33 ]	4.2 %		33	-0.8324666 (0.2550403)	34	Chao 2010
-1.27 [ -1.95, -0.59 ]	3.3 %	<del></del>	20 -	-1.269434 (0.3481429)	20	Di Sante 2012
-0.84 [ -1.68, 0.00 ]	2.7 %		12	-0.8378893 (0.4273436)	12	Dieppe 1980
-0.06 [ -0.74, 0.61 ]	3.3 %		-0.06448 (0.343092)	17	17	Friedman 1980
0.0 [ -0.27, 0.27 ]	5.4 %	+	0 (0.1396861)	103	103	Fri as 2004
-0.05 [ -0.48, 0.38 ]	4.6 %		42	-0.0516039 (0.2182551)	42	Gaffney 1995
0.20 [ -0.42, 0.82 ]	3.6 %	<u> </u>	0.2 (0.3170589)	20	20	Grecomoro 1992
-0.04 [ -0.43, 0.35 ]	4.8 %		50	-0.0392837 (0.2000197)	50	Henriksen 2015
-0.93 [ -1.46, -0.39 ]	4.0 %		30	-0.9257629 (0.2721303)	30	Jones 1996
-0.57 [ -1.46, 0.33 ]	2.5 %		10	-0.566251 (0.4570631)	10	Lyons 2005
-0.22 [ -0.86, 0.43 ]	3.4 %		36	-0.2151739 (0.3313255)	37	Miller 1958
-0.88 [ -1.38, -0.38 ]	4.2 %	<del></del>	34	-0.8803853 (0.2562751)	33	NCT00414427
-0.14 [ -0.71, 0.44 ]	3.8 %		24	-0.1368758 (0.2921525)	23	Ozturk 2006
-0.04 [ -0.52, 0.45 ]	4.3 %		-0.0355 (0.2463161)	32	34	Petrella 2015
-1.09 [ -1.91, -0.27 ]	2.7 %		11 -	-1.088324 (0.4184004)	19	Popov 1989
-0.46 [ -0.87, -0.06 ]	4.7 %		49	-0.4619007 (0.2061198)	49	Ravaud 1999
0.12 [ -0.37, 0.60 ]	4.3 %	<del></del>	33	0.1177483 (0.2464029)	33	Raynauld 2003
-0.21 [-1.41, 1.00]	1.7 %		5	-0.207736 (0.6144019)	5	Schue 2011
-0.33 [ -0.80, 0.14 ]	4.4 %	<b>-</b> _	33	-0.3261666 (0.2395615)	38	Smith 2003
-1.54 [ -2.00, -1.07 ]	4.4 %		-1.53523 (0.234898) -	30	90	Yavuz 2012
-0.38 [ -1.00, 0.23 ]	3.6 %	<b>_</b>	20	-0.3845994 (0.3154607)	21	Young 2001


-2 -1 0 1 2


Favours corticosteroid Favours control

(Continued . . . )

Intra-articular corticosteroid for knee osteoarthritis (Review)

 $\textbf{Copyright} @ 2015 \textbf{ The Cochrane Collaboration. Published by John Wiley \& Sons, Ltd. \\$ 





Review: Intra-articular corticosteroid for knee osteoarthritis

Comparison: I Pain

Outcome: 2 Pain - Timepoints

Study or subgroup	IA Corticosteroid	Control	Std. Mean Difference (SE)	C	Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Ν		IV,Ran	dom,95% Cl		IV,Random,95% CI
I Pain- I-2 week							
Beyaz 2012	25	25	-0.83381 (0.295368)			6.1 %	-0.83 [ -1.41, -0.25 ]
Campos 2013	52	52	-0.61535 (0.200793)		-	8.0 %	-0.62 [ -1.01, -0.22 ]
Cederlof 1966	26	25	-0.33873 (0.356857)			5.1 %	-0.34 [ -1.04, 0.36 ]
Di Sante 2012	20	20	-0.27 (0.317743)		<b></b>	5.7 %	-0.27 [ -0.89, 0.35 ]
Dieppe 1980	12	12	-0.83789 (0.427344)			4.2 %	-0.84 [ -1.68, 0.00 ]
Friedman 1980	17	17	-0.4608 (0.3478)			5.3 %	-0.46 [ -1.14, 0.22 ]
Gaffney 1995	42	42	-0.28951 (0.21951)		<b></b>	7.6 %	-0.29 [ -0.72, 0.14 ]
Grecomoro 1992	20	20	0.4 (0.319539)			5.7 %	0.40 [ -0.23, 1.03 ]
Henriksen 2015	50	50	-0.03928 (0.20002)	-	•	8.0 %	-0.04 [ -0.43, 0.35 ]
Petrella 2015	34	32	-0.40018 (0.248823)			7.0 %	-0.40 [ -0.89, 0.09 ]
			-2 Favours co	- I	0 I Favours cont	2 trol	

(Continued ...)

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright  $\textcircled{\sc 0}$  2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

Study or subgroup	IA Corticosteroid N	Control N	Std. Mean Difference (SE)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continue Sto Mear Difference IV,Random,95% C
Popov 1989	19	11	-1.08832 (0.4184)		4.3 %	-1.09 [ -1.91, -0.27
Ravaud 1999	49	-0.6703337 (0.2103553)	49		7.8 %	-0.67 [ -1.08, -0.26
Schue 2011	5	5	-0.1244 (0.613101)		2.5 %	-0.12 [ -1.33, 1.08
Smith 2003	38	33	-0.21581 (0.238655)		7.2 %	-0.22 [ -0.68, 0.25
Yavuz 2012	90	30	-1.509 (0.234594)	- <b>-</b> -	7.3 %	-1.51 [ -1.97, -1.05
Zhilyayev 2012	67	52	-0.42298 (0.186871)		8.2 %	-0.42 [ -0.79, -0.06
Test for overall effect: Z =		<b>475</b> f = 15 (P = 0.00041); l <sup>2</sup> = 15)	63%	•	100.0 % <i>-</i> 0	.48 [ -0.70, -0.27
2 Pain- 4-6 week Beyaz 2012	25	25	-0.688667 (0.291396)		4.5 %	-0.69 [ -1.26, -0.12
Campos 2013	52	51	-0.41026 (0.199178)		5.6 %	-0.41 [ -0.80, -0.02
Castro 2007	32	30	0.153865 (0.25452)	<del></del>	4.9 %	0.15 [ -0.34, 0.65
Cederlof 1966	26	25	0.343675 (0.443639)		3.0 %	0.34 [ -0.53, 1.21
Chao 2010	34	-0.8324666 (0.2550403)	33	<u> </u>	4.9 %	-0.83 [ -1.33, -0.33
Di Sante 2012	20	-1.269434 (0.3481429)	20		3.9 %	-1.27 [ -1.95, -0.59
Friedman 1980	17	17	-0.06448 (0.343092)		3.9 %	-0.06 [ -0.74, 0.61
Fri <sup>r</sup> as 2004	103	103	0 (0.1396861)	-	6.3 %	0.0 [ -0.27, 0.27
Gaffney 1995	42	-0.0575697 (0.2182642)	42		5.3 %	-0.06 [ -0.49, 0.37
Grecomoro 1992	20	20	0.2 (0.317059)		4.2 %	0.20 [ -0.42, 0.82
Jones 1996	30	-0.9257629 (0.2721303)	30	<del>````</del>	4.7 %	-0.93 [ -1.46, -0.39
Lyons 2005	10	10	-0.56625 (0.457063)		2.9 %	-0.57 [ -1.46, 0.33
Miller 1958	37	36	-0.21517 (0.331326)		4.0 %	-0.22 [ -0.86, 0.43
NCT00414427	33	34	-0.88039 (0.256275)		4.9 %	-0.88 [ -1.38, -0.38
Ozturk 2006	23	24	-0.13688 (0.292153)	<u> </u>	4.5 %	-0.14 [ -0.71, 0.44
Petrella 2015	34	32	-0.0355 (0.246316)		5.0 %	-0.04 [ -0.52, 0.45
Ravaud 1999	49	-0.4619007 (0.2061198)	49		5.5 %	-0.46 [ -0.87, -0.06
Schue 2011	5	5	-0.20774 (0.614402)		2.0 %	-0.2  [ -1.4 , 1.00
Smith 2003	38	33	-0.32617 (0.239562)		5.1 %	-0.33 [ -0.80, 0.14
Yavuz 2012	90	30	-1.53523 (0.234898)		5.1 %	-1.54 [ -2.00, -1.07
Young 2001	21	20	-0.3846 (0.315461)		4.2 %	-0.38 [ -1.00, 0.23
Zhilyayev 2012	67	52	-0.46855 (0.187335)		5.7 %	-0.47 [ -0.84, -0.10

Favours corticosteroid


Favours control

(Continued . . . )

Intra-articular corticosteroid for knee osteoarthritis (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

Study or subgroup	IA Corticosteroid	Control	Std. Mean Difference (SE)	Std. Mean Difference	Weight	( Continued Std. Mean Difference
Subtotal (95% CI)	N 808	N 721		IV,Random,95% Cl	100.0.%	IV,Random,95% CI
		$f = 21 (P < 0.00001); I^2 = 6$	9%		100.0 /0	-0.41 [ -0.01, -0.21 ]
Test for overall effect: Z	= 4.05 (P = 0.00005	51)				
3 Pain- 3 months Beyaz 2012	25	25	-0.68667 (0.291396)		5.5 %	-0.69 [ -1.26, -0.12 ]
Campos 2013	47	46	-0.15526 (0.207721)		6.7 %	-0.16 [ -0.56, 0.25 ]
·			, , , , , , , , , , , , , , , , , , ,			
Castro 2007	32	30	,		6.0 %	0.27 [ -0.23, 0.77 ]
Cederlof 1966	26	25	0.40991 (0.396514)		4.2 %	0.41 [ -0.37, 1.19 ]
Chao 2010	30	-0.3170632 (0.2621029)	29		5.9 %	-0.32 [ -0.83, 0.20 ]
Friedman 1980	17	17	0.064483 (0.343092)		4.8 %	0.06 [ -0.61, 0.74 ]
Fri'as 2004	103	103	0.160396 (0.139913)		7.7 %	0.16 [ -0.11, 0.43 ]
Grecomoro 1992	20	20	0.1 (0.316436)		5.1 %	0.10 [ -0.52, 0.72 ]
Henriksen 2015	50	50	0.094281 (0.200113)		6.9 %	0.09 [ -0.30, 0.49 ]
Lyons 2005	10	10	-1.58842 (0.519697)	<b>←</b>	3.0 %	-1.59 [ -2.61, -0.57 ]
Ozturk 2006	23	24	-0.365 (0.294322)		5.5 %	-0.37 [ -0.94, 0.21 ]
Petrella 2015	34	32	0.019364 (0.246302)	<b>_</b>	6.2 %	0.02 [ -0.46, 0.50 ]
Ravaud 1999	49	-0.2818715 (0.2086496)	49		6.7 %	-0.28 [ -0.69, 0.13 ]
Raynauld 2003	33	0.1177483 (0.2464029)	33		6.1 %	0.12 [ -0.37, 0.60 ]
Schue 2011	5	5	-1.16174 (0.672952)	• • • • • • • • • • • • • • • • • • • •	2.1 %	-1.16 [ -2.48, 0.16 ]
Smith 2003	38	33	0.004905 (0.237948)	_	6.3 %	0.00 [ -0.46, 0.47 ]
Yavuz 2012	90	30	-1.25 (0.227075)		6.4 %	-1.25 [ -1.70, -0.80 ]
Zhilyayev 2012	14	26	, , , , , , , , , , , , , , , , , , ,		4.9 %	-0.60 [ -1.26, 0.07 ]
Subtotal (95% CI)		587	0.57772 (0.550575)	•		-0.22 [ -0.44, 0.00 ]
(· - )		$f = 17 (P < 0.00001); I^2 = 6$	9%		100.0 /0	0.22 [ 0.11, 0.00 ]
Test for overall effect: Z	= 1.96 (P = 0.050)					
4 Pain- 6 months Campos 2013	47	46	-0.18852 (0.207873)		19.0 %	-0.19 [ -0.60, 0.22 ]
Henriksen 2015	50		0.067957 (0.200059)		20.6 %	0.07 [ -0.32, 0.46 ]
Miller 1958			· · · · ·			
	26	25	· · · · ·		3.3 %	0.42 [ -0.56, 1.40 ]
Ozturk 2006	23	24	-0.45625 (0.295733)	_	9.4 %	-0.46 [ -1.04, 0.12 ]
Petrella 2015	34	32	,		13.6 %	-0.09 [ -0.57, 0.39 ]
Ravaud 1999		-0.2053177 (0.2045287)	49		19.7 %	-0.21 [ -0.61, 0.20 ]
Smith 2003	38	33	0.223167 (0.238704)	· · · · · ·	14.4 %	0.22 [ -0.24, 0.69 ]
				2 -1 0 I orticosteroid Favours co	2 ontrol	(Continued





Review: Intra-articular corticosteroid for knee osteoarthritis

Comparison: 2 Function

-

-

Outcome: I Function - Main


Study or subgroup	IA Corticosteroid N	Control N	Std. Mean Difference (SE)	Diffe IV,Randor	Std. Mean rence n,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Beyaz 2012	25	25	-1.09887 (0.304267)			6.1 %	-1.10 [ -1.70, -0.50 ]
Campos 2013	52	-0.0041622 (0.1970754)	51		-	7.9 %	0.00 [ -0.39, 0.38 ]
Castro 2007	32	30	0.275871 (0.255377)	+	<b>-</b>	6.9 %	0.28 [ -0.22, 0.78 ]
Chao 2010	32	-0.972491 (0.2669457)	31			6.7 %	-0.97 [ -1.50, -0.45 ]
Di Sante 2012	20	-0.4867452 (0.321119)	20			5.9 %	-0.49 [ -1.12, 0.14 ]
Gaffney 1995	42	42	0.208693 (0.218826)		<b>_</b>	7.5 %	0.21 [ -0.22, 0.64 ]
Henriksen 2015	50	50	0.099827 (0.200127)			7.9 %	0.10 [ -0.29, 0.49 ]
Lyons 2005	10	-1.130546 (0.4852872)	10	•		3.8 %	-1.13 [ -2.08, -0.18 ]
Petrella 2015	33	33	0.006267 (0.246184)			7.1 %	0.01 [ -0.48, 0.49 ]
Popov 1989	19	-1.088324 (0.4184004)	П			4.6 %	-1.09 [ -1.91, -0.27 ]
Ravaud 1999	49	-0.3433526 (0.2039811)	49			7.8 %	-0.34 [ -0.74, 0.06 ]
Raynauld 2003	33	33	0.06595 (0.246252)	-		7.1 %	0.07 [ -0.42, 0.55 ]
				-2 -1 0	I 2 Favours control		

(Continued . . . )

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright  $\textcircled{\sc 0}$  2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	IA Corticosteroid N	Control N	Std. Mean Difference (SE)		Std. Mean fference om,95% Cl	Weight	( Continued) Std. Mean Difference IV,Random,95% Cl
Smith 2003	38	33	-0.31211 (0.239426)		+	7.2 %	-0.31 [ -0.78, 0.16 ]
Yavuz 2012	90	-0.8096383 (0.2178688)	30			7.6 %	-0.81 [ -1.24, -0.38 ]
Young 2001	21	-0.1579081 (0.3129516)	20		<u> </u>	6.0 %	-0.16 [ -0.77, 0.46 ]
<b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for subgroup diff	: Z = 2.70 (P = 0.00	,	=69%	•		100.0 %	-0.33 [ -0.56, -0.09 ]
				-2 - I	0 I 2 Favours cont		



Review: Intra-articular corticosteroid for knee osteoarthritis

Comparison: 2 Function

Outcome: 2 Function - Timepoints

Study or subgroup	IA Corticosteroid N	Control N	Std. Mean Difference (SE)		Std. Mean Difference ndom,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
I Function - I-2 weeks							
Beyaz 2012	25	-1.367485 (0.3154034)	25			8.6 %	-1.37 [ -1.99, -0.75 ]
Campos 2013	52	52	-0.6479 (0.20129)		-	11.3 %	-0.65 [ -1.04, -0.25 ]
Di Sante 2012	20	0.1365441 (0.3166154)	20	-		8.6 %	0.14 [ -0.48, 0.76 ]
Gaffney 1995	42	42	-5E-8 (0.218218)			10.9 %	0.00 [ -0.43, 0.43 ]
Henriksen 2015	50	0.0998268 (0.2001271)	50			11.3 %	0.10 [ -0.29, 0.49 ]
Petrella 2015	34	-0.3737276 (0.2485014)	32		•	10.2 %	-0.37 [ -0.86, 0.11 ]
Popov 1989	19	-1.088324 (0.4184004)	H		-	6.6 %	-1.09 [ -1.91, -0.27 ]
Ravaud 1999	49	-0.3461974 (0.204095)	49	-		11.2 %	-0.35 [ -0.75, 0.05 ]
				2 -1	0 1	2	
			Favours co	orticosteroid	Favours co	ntrol	
							(Continued )

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright  $\textcircled{\sc 0}$  2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

Study or subgroup	IA Corticosteroid N	Control N	Std. Mean Difference (SE)	Std. Mean Difference IV,Random,95% Cl	Weight	( Continue Sto Mea Differenc IV,Random,95% C
Smith 2003	38	33	-0.17322 (0.238404)		10.4 %	-0.17 [ -0.64, 0.29
Yavuz 2012	90	-0.8881221 (0.2192932)	30	_ <b>_</b>	10.9 %	-0.89 [ -1.32, -0.46
Subtotal (95% CI)	419	344		•		.43 [ -0.72, -0.14
	15; Chi <sup>2</sup> = 32.02, d	$f = 9 (P = 0.00020); I^2 = 7$	2%			
Beyaz 2012	25	25	-1.098872 (0.304267)		7.6 %	-1.10 [ -1.70, -0.50
Campos 2013	52	-0.0041622 (0.1970754)	51		9.8 %	0.00 [ -0.39, 0.38
Castro 2007	32	30	0.275871 (0.255377)		8.6 %	0.28 [ -0.22, 0.78
Chao 2010	32	31	-0.97491 (0.2669457)		8.4 %	-0.97 [ -1.50, -0.45
Di Sante 2012	20	20	-0.48675 (0.321119)		7.3 %	-0.49 [ -1.12, 0.14
Gaffney 1995	42	42	0.208693 (0.218826)		9.4 %	0.21 [ -0.22, 0.64
Lyons 2005	10	-1.130546 (0.4852872)	10 .	·	4.8 %	-1.13 [ -2.08, -0.18
Petrella 2015	33	33	0.006267 (0.2461836)		8.8 %	0.01 [ -0.48, 0.49
Ravaud 1999	49	-0.3433526 (0.2039811)	49		9.7 %	-0.34 [ -0.74, 0.06
Smith 2003	38	33	-0.3 2   (0.239426)		8.9 %	-0.31 [ -0.78, 0.16
Yavuz 2012	90	-0.8096383 (0.2178688)	30	_ <b></b>	9.4 %	-0.81 [ -1.24, -0.38
Young 2001	21	-0.1579081 (0.3129516)	20		7.5 %	-0.16 [ -0.77, 0.46
Subtotal (95% CI)	444	374		•	100.0 % -0	.36 [ -0.63, -0.09
Test for overall effect: Z = 3 Function - 3 months	= 2.66 (P = 0.0079)				77.00	
Beyaz 2012	25	25	-1.03859 (0.302053)		7.7 %	-1.04 [ -1.63, -0.45
Campos 2013	47	46	-0.0017 (0.2074024)		10.5 %	0.00 [ -0.41, 0.40
Castro 2007	32	30	0.38238 (0.256519)		9.0 %	0.38 [ -0.12, 0.89
Chao 2010	25	29	-0.3785 (0.275428)		8.4 %	-0.38 [ -0.92, 0.16
Henriksen 2015		0.0083189 (0.2000009)	50		10.7 %	0.01 [ -0.38, 0.40
Lyons 2005		-0.2928758 (0.4498696)	10		4.9 %	-0.29 [ -1.17, 0.59
Petrella 2015		0.0596708 (0.2463526)	32		9.3 %	0.06 [ -0.42, 0.54
Ravaud 1999	49	0.0550258 (0.2024998)	49		10.6 %	0.06 [ -0.34, 0.45
Raynauld 2003	33		0.0659503 (0.246252)		9.3 %	0.07 [ -0.42, 0.55
Smith 2003	38	33	0.168646 (0.23838)		9.5 %	0.17 [ -0.30, 0.64
Yavuz 2012	90	-0.730327 (0.2164402)	30		10.2 %	-0.73 [ -1.15, -0.31

(Continued . . . )


Intra-articular corticosteroid for knee osteoarthritis (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

(... Continued)

						(··· containaed)
Study or subgroup	IA Corticosteroid	Control	Std. Mean Difference (SE)	Std. Mean Difference	Weight	Std. Mean Difference
	N	Ν		IV,Random,95% CI		IV,Random,95% CI
Subtotal (95% CI	) 433	367		•	100.0 %	-0.13 [ -0.37, 0.10 ]
Heterogeneity: $Tau^2 = 0$	0.09; Chi <sup>2</sup> = 26.10, d	$f = 10 (P = 0.004); I^2 = 62$	%			
Test for overall effect: Z	= 1.10 (P = 0.27)					
4 Function - 6 months						
Campos 2013	47	-0.0657285 (0.2074596)	46		28.5 %	-0.07 [ -0.47, 0.34 ]
Petrella 2015	34	-0.0155596 (0.2462999)	32		20.2 %	-0.02 [ -0.50, 0.47 ]
Ravaud 1999	49	0.0082512 (0.2024608)	49		29.9 %	0.01 [ -0.39, 0.41 ]
Smith 2003	38	33	0.373922 (0.240069)	+	21.3 %	0.37 [ -0.10, 0.84 ]
<b>Subtotal (95% CI</b> Heterogeneity: $Tau^2 = 0$ Test for overall effect: Z	).0; Chi <sup>2</sup> = 2.24, df =	<b>160</b> 3 (P = 0.52); I <sup>2</sup> =0.0%		•	100.0 %	0.06 [ -0.16, 0.28 ]
	,	$f = 3 (P = 0.02), I^2 = 69\%$				
lest let sabgroup differe	, icos, c.i. , io,, d					
-					2	
			=	2 -1 0 1	2	

Favours corticosteroid Favours control



Review: Intra-articular corticosteroid for knee osteoarthritis

Comparison: 3 Quality of life

Outcome: I Quality of life - Main

Study or subgroup	IA Corticosteroid N	Control N	Std. Mean Difference (SE)		Std. Mean Difference Idom,95%		Weight	Std. Mean Difference IV,Random,95% Cl
Gaffney 1995	42	42	0 (0.218218)	-	-		45.7 %	0.0 [ -0.43, 0.43 ]
Henriksen 2015	50	50	-0.01571 (0.200003)	-	•		54.3 %	-0.02 [ -0.41, 0.38 ]
Total (95% CI)	<b>92</b> = 0.0; Chi <sup>2</sup> = 0.00, df =	<b>92</b>	12 -0.0%		•		100.0 %	-0.01 [ -0.30, 0.28 ]
Test for overall effect:	Z = 0.06 (P = 0.95)	r (r = 0.70),	1 -0.070					
Test for subgroup diffe	rences: Not applicable							
				-2 -1	0	1 2		
			Favou	rs corticosteroid	Favo	ours control		

# Analysis 4.1. Comparison 4 Number of participants experiencing any adverse event, Outcome 1 Number of participants experiencing any adverse event - Main.

Review: Intra-articular corticosteroid for knee osteoarthritis

Comparison: 4 Number of participants experiencing any adverse event

Outcome: I Number of participants experiencing any adverse event - Main

Study or subgroup	IA Corticosteroid	Control		Risk Ratio	Weight	Risk Ratio
Petrella 2015	n/N	n/N		om,95% Cl	98.9 %	IV,Random,95% CI
	21/33	24/33				0.88 [ 0.63, 1.22 ]
Wright 1960	1/9	0/9		· · · · · ·	1.1 %	3.00 [ 0.14, 65.16 ]
Total (95% CI)	42	42	•		100.0 %	0.89 [ 0.64, 1.23 ]
Total events: 22 (IA Cort						
	0; $Chi^2 = 0.61$ , $df = 1$ (P = 0.	44); I <sup>2</sup> =0.0%				
Test for overall effect: Z = Test for subgroup differer						
	ices. Not applicable					
			0.01 0.1	1 10 100		
			Favours corticosteroid	Favours control		

### Analysis 5.1. Comparison 5 Number of participants who withdraw because of adverse events, Outcome I Number of participants who with draw because of adverse events -Main.

Review: Intra-articular corticosteroid for knee osteoarthritis

Comparison: 5 Number of participants who withdraw because of adverse events

Outcome: I Number of participants who with draw because of adverse events -Main

Study or subgroup	IA Corticosteroid n/N	Control n/N			lisk Ratio om,95% Cl		Weight	Risk Ratio IV,Random,95% Cl
Campos 2013	0/52	1/52					33.0 %	0.33 [ 0.01, 8.00 ]
Henriksen 2015	1/50	3/50		<mark>-</mark> -			67.0 %	0.33 [ 0.04, 3.10 ]
Total (95% CI)	102	102		-	-		100.0 %	0.33 [ 0.05, 2.07 ]
Total events: I (IA Cortio	costeroid), 4 (Control)							
Heterogeneity: $Tau^2 = 0$ .	.0; Chi <sup>2</sup> = 0.0, df = 1 (P = 1.0	0); l <sup>2</sup> =0.0%						
Test for overall effect: Z	= 1.18 (P = 0.24)							
Test for subgroup differe	nces: Not applicable							
			0.01	0.1	1 10	100		

Favours corticosteroid

Favours control

# Analysis 6.1. Comparison 6 Number of participants experiencing any serious adverse event, Outcome I Number of participants experiencing any serious adverse event - Main.

Review: Intra-articular corticosteroid for knee osteoarthritis

Comparison: 6 Number of participants experiencing any serious adverse event

Outcome: I Number of participants experiencing any serious adverse event - Main


Study or subgroup	IA Corticosteroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	IV,Random,95% CI		IV,Random,95% CI
Henriksen 2015	1/50	3/50		42.1 %	0.33 [ 0.04, 3.10 ]
Lyons 2005	0/10	0/10			Not estimable
Ozturk 2006	0/23	0/24			Not estimable
Petrella 2015	2/33	2/33	<b></b>	57.9 %	1.00 [ 0.15, 6.68 ]
Ravaud 1999	0/49	0/49			Not estimable
Total (95% CI)	165	166	-	100.0 %	0.63 [ 0.15, 2.67 ]
Total events: 3 (IA Corti	costeroid), 5 (Control)				
Heterogeneity: $Tau^2 = 0$	0.0; $Chi^2 = 0.54$ , $df = 1$ (P = 0.	.46); l <sup>2</sup> =0.0%			
Test for overall effect: Z	= 0.63 (P = 0.53)				
Test for subgroup differe	nces: Not applicable				
			0.01 0.1 1 10	100	
			Favours corticosteroid Favours of	control	

#### Analysis 7.1. Comparison 7 Joint space narrowing, Outcome I Joint space narrowing - Main.

Review: Intra-articular corticosteroid for knee osteoarthritis

Comparison: 7 Joint space narrowing

Outcome: I Joint space narrowing - Main



## ADDITIONAL TABLES

Table 1. Stratified analyses: Pain

Variable	Number of studies	N of partici- pants corticos- teroids		Pain intensity SMD (95% CI)		P value*
All trials	26	922	827	-0.40 (-0.58 to - 0.22)	68%	
Allocation conce	0.15					
Adequate	2	88	83	-0.16 (-0.46 to 0. 14)	0%	
Inadequate or unclear	24	834	744	-0.42 (-0.62 to - 0.22)	69%	
Blinding of parti	cipants					0.64
Adequate	6	220	218	-0.34 (-0.61 to - 0.06)	49%	
Inadequate or unclear	20	702	609	-0.42 (-0.65 to - 0.19)	72%	

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Table 1. Stratified analyses: Pain (Continued)

Blinding of thera	pists					0.45
Adequate	3	92	92	-0.24 (-0.66 to 0. 17)	44%	
Inadequate or unclear	23	830	735	-0.42 (-0.62 to - 0.22)	70%	
Intention-to-trea	t analysis					0.29
Yes	9	236	233	-0.26 (-0.57 to 0. 06)	59%	
No or unclear	17	686	594	-0.47 (-0.69 to - 0.24)	71%	
Type of control i	ntervention					0.08
Sham injection	19	614	526	-0.50 (-0.72 to - 0.28)	65%	
No intervention	7	284	280	-0.18 (-0.47 to 0. 11)	63%	
Funding indepen	dent of industry					0.80
Yes	11	341	333	-0.37 (-0.55 to - 0.18)	26%	
No or unclear	15	581	494	-0.41 (-0.70 to - 0.12)	78%	
Trial size						0.05
≥ 50 per trial group	3	205	204	-0.13 (-0.37 to 0. 12)	34%	
< 50 per trial group	23	717	623	-0.44 (-0.65 to - 0.24)	67%	
Trial size						0.013
$\geq$ 100 per trial group	1	103	103	0.00 (-0.27 to 0. 27)	N/A	
< 100 per trial group	25	819	724	-0.42 (-0.61 to - 0.23)	66%	

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Table 1. Stratified analyses: Pain (Continued)

Publication type	:					0.93
Full journal arti- cle	22	785	706	-0.40 (-0.61 to - 0.20)	70%	
Other type or unpublished ma- terial	4	137	121	-0.38 (-0.84 to - 0.08)	65%	
Ultrasound guid	ance of injections					0.71
Yes	2	70	70	-0.62 (-1.83 to 0. 58)	89%	
No or unclear	24	852	757	-0.39 (-0.57 to - 0.20)	67%	
Use of local anae	esthetic					0.41
Yes	5	172	157	-0.55 (-0.93 to - 0.16)	62%	
No or unclear	21	750	670	-0.36 (-0.57 to - 0.15)	70%	
Concomitant vis	cosupplementatio	n				0.08
Yes	4	129	127	-0.16 (-0.42 to 0. 09)	4%	
No or unclear	22	793	700	-0.46 (-0.67 to - 0.25)	71%	
Concomitant joi	nt lavage					≤ 0.001
Yes	4	197	187	-0.06 (-0.26 to 0. 15)	0%	
No or unclear	26	725	640	-0.57 (-0.78 to - 0.35)	72%	
Use of crystalline	e preparation					0.82
Yes	18	623	562	-0.47 (-0.69 to - 0.24)	72%	
No or unclear	12	299	265	-0.52 (-0.90 to - 0.14)	76%	

#### Table 1. Stratified analyses: Pain (Continued)

Prednisolone equivalence dose							
≥ 50 mg	17	520	470	-0.55 (-0.85 to - 0.25)	80%		
< 50 mg	13	402	357	-0.43 (-0.66 to - 0.20)	56%		

Number of randomised comparisons are shown in "number of studies" for stratified analyses according to use of lavage as co-intervention, crystalline preparation, prednisolone equivalence. \*P value for interaction. N/A: not available.

CI: confidence interval

SMD: standardised mean difference

#### Table 2. Stratified analyses: Function

Variable	Number of studies	N of partici- pants corticos- teroids	-	Function SMD (95% CI)	Heterogeneity I <sup>2</sup> (%)	P value*
All trials	15	546	468	-0.33 (-0.56 to - 0.09)	69%	
Allocation conce	alment					0.25
Adequate	2	88	83	-0.09 (-0.49 to 0. 32)	43%	
Inadequate or unclear	13	458	385	-0.37 (-0.64 to - 0.10)	72%	
Blinding of parti	cipants					0.97
Adequate	5	201	199	-0.32 (-0.82 to 0. 18)	83%	
Inadequate or unclear	10	345	269	-0.33 (-0.59 to - 0.07)	58%	
Blinding of thera	pists					0.78
Adequate	2	75	75	-0.48 (-1.65 to 0. 70)	91%	
Inadequate or unclear	13	471	393	-0.31 (-0.55 to - 0.06)	66%	
Intention-to-trea	t analysis					0.49

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright  $\textcircled{\sc 0}$  2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Table 2. Stratified analyses: Function (Continued)

Yes	5	161	159	-0.21 (-0.59 to 0. 17)	62%	
No or unclear	10	385	309	-0.38 (-0.69 to - 0.07)	73%	
Type of control i	ntervention					0.031
Sham injection	11	409	334	-0.45 (-0.74 to - 0.15)	73%	
No intervention	4	137	134	-0.01 (-0.27 to 0. 25)	13%	
Funding indepen		0.73				
Yes	9	310	302	-0.36 (-0.66 to - 0.07)	68%	
No or unclear	6	236	166	-0.27 (-0.71 to 0. 16)	76%	
Trial size						0.023
≥ 50 per trial group	2	102	101	0.05 (-0.23 to 0. 32)	0%	
< 50 per trial group	13	444	367	-0.40 (-0.67 to - 0.13)	70%	
Trial size						N/A
$\geq$ 100 per trial group	0	0	0	N/A	N/A	
< 100 per trial group	15	546	468	-0.33 (-0.56 to - 0.09)	69%	
Publication type						0.023
Full journal arti- cle	14	514	438	-0.37 (-0.61 to - 0.13)	68%	
Other type or unpublished ma- terial	1	32	30	0.28 (-0.22 to 0. 78)	N/A	
Ultrasound guida	ance of injections					0.49

#### Table 2. Stratified analyses: Function (Continued)

Yes	2	70	70	-0.14 (-0.70 to 0. 43)	58%				
No or unclear	13	476	398	-0.36 (-0.62 to - 0.09)	71%				
Use of local ana	esthetic					0.34			
Yes	4	105	105	-0.60 (-1.25 to 0. 05)	78%				
No or unclear	11	441	363	-0.25 (-0.51 to 0. 00)	68%				
Concomitant vi	Concomitant viscosupplementation								
Yes	2	85	84	-0.00 (-0.30 to 0. 30)	0%				
No or unclear	13	461	384	-0.39 (-0.66 to - 0.12)	72%				
Concomitant jo	int lavage					0.18			
Yes	3	94	84	-0.13 (-0.55 to 0. 28)	48%				
No or unclear	16	452	384	-0.46 (-0.71 to - 0.21)	70%				
Use of crystallin	e preparation					0.66			
Yes	12	365	319	-0.37 (-0.66 to - 0.08)	73%				
No or unclear	7	181	149	-0.47 (-0.83 to - 0.11)	61%				
Prednisolone eq	uivalence dose					0.16			
≥ 50 mg	12	328	277	-0.52 (-0.83 to - 0.20)	74%				
< 50 mg	7	218	191	-0.22 (-0.48 to 0. 05)	47%				

Number of randomised comparisons are shown in "number of studies" for stratified analyses according to use of lavage as co-intervention, crystalline preparation, prednisolone equivalence. \*P value for interaction. N/A: not available.

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# APPENDICES

# Appendix I. MEDLINE and PubMed search strategies

MEDLINE*			PubMed†		
Search line	Search Terms	No. citations	Search line	Search Terms	No. citations
1	*Adrenal Cortex Hormones/ or *17- Hydroxycorticos- teroids/ or *11-Hy- droxycorticosteroids/ or *Hydroxycorticos- teroids/ or *Ketos- teroids/ or *17-Ke- tosteroids/ or *10-Ke- tosteroids/ or *10-Ke- toster	104853	1	((((((osteoarthritis*[tw] OR osteoarthro*[tw] OR gonarthrit*[tw] OR gonarthro*[tw] OR coxarthrit*[tw] OR coxarthro*[tw] OR arthros*[tw] OR arthrot*[tw] OR ((knee*[tw] OR hip[tw] OR hips[tw] OR joint*[tw]) near/3 (pain*[tw] OR ache[tw] OR aches[tw] OR ache[tw] OR aches[tw] OR aching[tw] OR achy[tw] OR ((knee*[tw] OR aching[tw]) OR hips[tw] OR hip[tw]) OR hips[tw] OR joint*[tw]) near/3 stiff*[tw]) ))) AND ((adrenal cortex hormone*[tw] OR adrenal cortical hormone*[tw] OR adrenocortical hor- mone*[tw] OR adrenocorti- cal steroid*[tw] OR adrenocortical steroid*[tw] OR cortical steroid*[tw] OR cortical steroid*[tw] OR cortico-steroid*[tw] OR corticosteroid*[tw] OR corticosteroid*[tw] OR der- mocorticosteroid*[tw] OR der- m	

2	(adrenal cortex hor-	429888	hydroxycorticosteroid*[tw] OR ketosteroid*[tw] OR androstenedion*[tw] OR steroid[tw] OR triamci- nolone hexacetonide[tw] OR hydrocortison*[tw] OR prednisolone[tw] OR Pred- nison*[tw] OR cortison*[tw] OR Pregnadiene*[tw])) ) AND ((intraartic*[tw] OR intra-artic*[tw] OR in- ject*[tw] OR infiltration*[tw] OR infiltrating[tw]))) AND (((clinical[Title/Abstract]) OR "clinical trial"[tw] OR "clinical trials"[tw] OR ran- dom*[tw] OR "therapeutic	
	mone* or adrenal cor- tical hormone* or adrenal steroid* or adrenocortical hormone* or adreno- cortical steroid* or adrenocorticals- teroid* or adrenocor- ticosteroid* or corti- cal steroid* or corti- cal steroid* or cor- tico-steroid* or cor- tico-steroid* or der- mocorticosteroid* or glucocortic* or hy- droxycorticosteroid* or ketosteroid* or an- drostenedion* or steroid or triamci- nolone hexacetonide or hydrocortison* or prednisolone or Pred- nison* or cortison* or Pregnadiene*).mp		dom*[tw] OR "therapeutic use"[tw] OR placebo[tw] OR sham[tw]))) AND publisher[sb]	
3	or/1-2	430785		
4	(intraartic* or intra- artic* or inject* or in-	831275		

	filtration* or infiltrat- ing).mp		
5	exp osteoarthritis/	44274	
6	(osteoarthriti\$ or os- teoarthro\$ or gonarthriti\$ or go- narthro\$ or coxarthriti\$ or coxarthro\$).ti,ab,sh	62668	
7	(arthros\$ or arthrot\$) .ti,ab.	26671	
8	((knee\$ or hip\$ or joint\$) adj3 (pain\$ or ach\$ or discomfort\$) ).ti,ab	20156	
9	((knee\$ or hip\$ or joint\$) adj3 stiff\$).ti, ab.	2914	
10	or/5-9	101715	
11	(randomized con- trolled trial or con- trolled clinical trial). pt	465958	
12	(randomized or placebo or randomly or groups or trial).ab.	1916245	
13	drug therapy.fs.	1728855	
14	or/11-13	3430383	
15	random*.ti,ab.	739136	
16	or/14-15	3575985	
17	and/3-4,10,16	766	
18	exp animals/ not hu- mans.sh.	3974624	
19	17 not 18	719	

20	remove duplicates	713		6
	from 19			

\* Search performed at 02<sup>nd</sup> of February 2015, using the following database in OvidSP: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present

<sup>†</sup> Top-up search in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) at 03<sup>rd</sup> Februari 2015, to retrieve citations not yet indexed in OvidSP MEDLINE databases

# Appendix 2. EMBASE and CENTRAL search strategies

EMBASE*			CENTRAL†			
Search line	Search Terms	No. citations	Search line	Search Terms	No. citations	
1	*Adrenal Cortex Hormones/ or *17-Hydroxy- corticosteroids/ or *11-Hydroxy- corticosteroids/ or *Hydroxycor- ticosteroids/ or *Ketosteroids/ or *17-Ketos-	191907	#1	MeSH descrip- tor: [Adrenal Cortex Hormones] explode all trees	11438	
	teroids/ or *An- drostenedione/ or *Prednisolone/ or *Glucocor-		#2	MeSH descrip- tor: [Prednisolone] explode all trees	3470	
	ticoids/ or *Tri- amcinolone Ace- tonide/ or *Hy- drocortisone/ or *cortisone/		#3	MeSH descriptor: [Hydro- cortisone] explode all trees	4565	
2	(adrenal cortex hormone* or adrenal corti- cal hormone* or adrenal steroid* or adrenocortical hor- mone* or adreno- cortical steroid* or adrenocortical- s- teroid* or adreno-	871195	#4	MeSH descrip- tor: [Triamcinolone Acetonide] explode all trees	603	

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright  $\textcircled{\sc 0}$  2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

corticosteroid cortical ster or cor steroid\* or c coid\* or cort teroid\* or der cortico-steroi or dermoc costeroid\* or  $\operatorname{cocortic}^* \ or$ droxycorticosteroid\* o tosteroid\* or drostenedion steroid or tr cinolone hex tonide or hy cortison\* or p nisolone or F nison\* or c

I* or roid* tico- orti- icos- rmo- d* orti- glu- hy- r ke- * or iam- scace-				
rdro- ored- orti- ''	#5	MeSH descriptor: [Ketos- teroids] explode all trees	962	
	#6	"adrenal cortex hor- mone*" or "adrenal cortical hor- mone*" or "adrenal steroid*" or "adrenocortical hor- mone*" or "adreno- cortical steroid*" or "adrenocorticals- teroid*" or "adreno- corticos- teroid*" or "corti- cal steroid*" or "corti- cal steroid*" or "corti- coid* or corticos- teroid* or corticos- teroid* or "dermo- cortico-steroid*" or dermocorticos- teroid* or glucocor- tic* or hydroxycorti- costeroid* or ketos- teroid* or androstenedion* or steroid or "tri- amcinolone hexac-	33629	

3 4	or/1,2 (intraartic* or in- tra-artic* or in- ject* or infiltra- tion* or infiltrat- ing).mp	874556 1069778	-	etonide" or hydro- cortison* or pred- nisolone or Predni- son* or cortison* or Pregnadiene*		
5	exp osteoarthritis/	92440	#7	#1 or #2 or #3 or # 4 or #5 or #6	35680	
6	(osteoarthriti\$ or osteoarthro\$ or gonarthriti\$ or gonarthro\$ or coxarthriti\$ or coxarthro\$).ti,ab, sh	96428	#8	intraartic* or intra- artic* or inject* or infiltration* or infil- trating	52930	
7	(arthros\$ or arthrot\$).ti,ab.	36551	#9	MeSH descrip- tor: [Osteoarthritis] explode all trees	3605	
8	((knee\$ or hip\$ or joint\$) adj3 (pain\$ or ach\$ or discomfort\$)). ti,ab	29955	#10	(osteoarthritis* or osteoarthro* or gonarthriti* or go- narthro* or coxarthriti* or coxarthro* or arthros* or arthrot* or ((knee* or hip* or joint*) near/3 (pain* or ach* or discomfort*)) or ( (knee* or hip* or joint*) near/3 stiff*) )	12050	
9	((knee\$ or hip\$ or joint\$) adj3 stiff\$).ti,ab.	4364	#11	#9 or #10	12050	
10	or/5-9	160749	#12	#7 and #8 and #11	481	
11	exp clinical trial/ or exp evaluation	1017697	#13	#7 and #8 and #11 [in trials]	264	

	studies/			
12	(clin\$ adj25 trial\$).ti,ab. or ( (singl\$ or doubl\$ or trebl\$ or tripl\$) adj25 (blind\$ or mask\$)).ti,ab. or (placebo\$ or ran- dom\$ or control\$ or prospectiv\$ or volunteer\$).ti,ab	4813156		
13	(randomized con- trolled trial or randomization or double blind procedure or sin- gle blind proce- dure or method- ology or follow up or prospec- tive study or com- parative study or placebo).sh	3749360		
14	or/11-13	7670295		
15	and/3-4,10,14	1364		
16	animals/ not hu- mans/	1206540		
17	15 not 16	1356		
18	remove dupli- cates from 17	1341		

\* Search performed at 03<sup>rd</sup> of February 2015, using the following database in OvidSP: Embase Weekly Alerts 2014/07/28-Present, Embase Classic+Embase 1947 to Present

<sup>†</sup> Search performed at 03<sup>rd</sup> of February 2015, using the Cochrane Library of the publisher Wiley at http://onlinelibrary.wiley.com/ cochranelibrary/search.

Intra-articular corticosteroid for knee osteoarthritis (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### WHAT'S NEW

Last assessed as up-to-date: 3 February 2015.

Date	Event	Description
2 November 2015	Amended	Typo corrected.

# HISTORY

Protocol first published: Issue 1, 1998 Review first published: Issue 2, 2005

Date	Event	Description
2 September 2015	New citation required and conclusions have changed	The review has been updated since last version of 2006.

# CONTRIBUTIONS OF AUTHORS

Protocol completion: Jüni, Rutjes, Reichenbach, da Costa. Acquisition of data: Hari, Rutjes, Fischer, Silletta, da Costa. Analysis and interpretation of data: Jüni, Hari, Reichenbach, da Costa. Manuscript preparation: Jüni, Hari, da Costa. Statistical analysis: Jüni, da Costa.

## DECLARATIONS OF INTEREST

Peter Jüni: none Roman Hari: none Anne WS Rutjes: none Roland Fischer: none Maria G Silletta: none Stephan Reichenbach: none Bruno R da Costa: none

# SOURCES OF SUPPORT

#### Internal sources

• No sources of support supplied

#### **External sources**

• NIHR Cochrane Direct Commmission Incentive Award, UK.

This review was supported by a grant from the NIHR, UK (NIHR Cochrane Direct Commmission Incentive Award)

# DIFFERENCES BETWEEN PROTOCOL AND REVIEW

#### **Types of studies**

In the previous version of this Cochrane Review, only RCTs were eligible for inclusion, while in the present review update both RCTs and quasi-RCTs were eligible.

#### **Types of interventions**

In the previous review version, control interventions were both sham intra-articular corticosteroid and active interventions (joint lavage, intra-articular hyaluronan/hylan, and other intra-articular corticosteroids). In the present review update, the prespecified control interventions were sham intra-articular corticosteroid and no intervention.

#### Types of outcome measures

In the previous review version there were eight outcomes: pain, physical function, patient global assessment, joint imaging, adverse reaction caused by procedure, adverse reaction caused by corticosteroid, adverse reaction caused by toxicity-related withdrawals, total number of withdrawals and dropouts. In the review update, there were two prespecified primary outcomes and six prespecified secondary outcomes. Primary outcomes were pain and physical function, and secondary outcomes were quality of life, joint imaging, and the number of participants who experienced any adverse event, withdrew because of adverse events, and experienced any serious adverse events.

#### Search methods for identification of studies

In the previous review version, the following four databases were searched: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (including PreMEDLINE), EMBASE, and Current Contents. The electronic searches were supplemented by handsearches of bibliographic references and abstracts published in conference proceedings or in special issues of specialised journals, and industry representatives were contacted to request additional studies of their product that could meet eligibility criteria. In the present review update, we searched the following three databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid and PubMed platforms, and EMBASE. The electronic searches were supplemented by handsearches of bibliographic references, abstracts published in conference proceedings, and search of clinical trial registers to identify ongoing or recently concluded trials.

# INDEX TERMS

# Medical Subject Headings (MeSH)

Adrenal Cortex Hormones [\*administration & dosage; adverse effects]; Hyaluronic Acid [adverse effects; analogs & derivatives; therapeutic use]; Injections, Intra-Articular; Osteoarthritis, Knee [\*drug therapy; therapy]; Randomized Controlled Trials as Topic; Therapeutic Irrigation [methods]

#### MeSH check words

Humans